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Abstract 
Diabetes is characterised by increased activation of platelets and coagulation 
factors, contributing to the high risk of cardiovascular disease in these 
individuals. 
Aspirin is a classic antiplatelet agent used for the protection from 
atherothrombotic disease. Clinical evidence suggests the efficacy of this agent 
is reduced in diabetes, by mechanisms that are not entirely clear. I 
hypothesise that the reduced clinical efficacy of aspirin in diabetes is related to 
a compromise in the effects of this agent on both the cellular and fluid phase 
of coagulation, secondary to elevated blood glucose levels. 
 
Using a combination of ex vivo/in vivo aspirin experiments in patients with type 
1 diabetes and healthy controls, I demonstrate reduced platelet inhibition by 
low aspirin concentration in diabetes, which appears to be related to both 
medium term as well as instantaneous hyperglycaemia. This suggests that 
current treatment strategies of administering aspirin once daily in diabetes are 
inadequate. Moreover, I show that the fibrinolytic properties of aspirin are 
reduced in diabetes, which may be related to reduce acetylation of one or 
more plasma protein other than fibrinogen. Finally, I describe a potential 
mechanism for aspirin, related to the effect of this agent on platelet-fibrinogen 
interaction, an effect that is also compromised in patients with diabetes. 
 In conclusion, my data indicate that both medium term and immediate 
hyperglycaemia modulate the effects of aspirin on the cellular and protein arm 
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of coagulation. Future work is required to understand the best glycaemic 
indices that optimise response to aspirin in diabetes. Moreover, additional 
studies are necessary to clarify the role of alternative dosing strategies for 
aspirin in patients with diabetes 
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Chapter 1 
Introduction 
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1.1 Cardiovascular disease  
Cardiovascular disease (CVD) remains a major cause of mortality and morbidity 
worldwide, a trend that is likely to continue in the near future (Franco et al., 
2011). Coronary artery disease (CAD) is predicted to be the most common 
cause of death globally by 2020 (Murray and Lopez, 1997) despite efforts to 
control various risk factors (Padmanabhan et al., 2010).  In the UK, 33% of 
death in 2008 was due to CVD(BHFreport, 2010), with an increased risk in 
some ethnic minorities, including South Asians (Wild and McKeigue, 1997). The 
higher risk in South Asians may be secondary to the higher prevalence of 
insulin resistance and diabetes (Dhawan et al., 1994), which contribute to 
vascular pathology. 
An enhanced thrombotic milieu is associated with increased risk of CVD, and 
this has been the focus of many therapeutic agents aiming to reduce the 
thrombotic environment. This is discussed in details below (1.6). 
1.2 Mechanisms of vascular pathology that enhance thrombosis risk 
1.2.1 Atherosclerotic plaque formation 
Atherosclerosis is an inflammatory disease affecting blood vessels. Endothelial 
denudation was proposed to be the first step in the atherosclerotic process  
(Ross and Glomset, 1973), but more recently endothelial dysfunction was found 
to be the key initial event. Endothelial dysfunction could be caused by a large 
number of factors including hyperglycaemia, elevated LDL, smoking and 
hypertension (Ross and Glomset, 1973, Ross, 1986, Ross, 1981). 
Endothelial dysfunction occurs as a compensatory response to injury in order to 
maintain normal homeostatic properties of the blood vessel (Ross, 1999). With 
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prolonged endothelial dysfunction, cells become less tight, allowing LDL-
cholesterol to diffuse into the vessel wall, which is subsequently transformed 
into atherogenic oxidised LDL (ox-LDL). Endothelial dysfunction also causes the 
expression of adhesion molecules, allowing the attachment of inflammatory 
cells and subsequent migration into the vessel wall. Migrated monocytes 
become macrophages, which take up ox-LDL and are then transformed into 
foam cells. A collection of foam cells forms the fatty streak, the earliest 
abnormality in the atherosclerotic process and which can be found at a very 
early age, as young as children (Stary et al., 1994, Napoli et al., 1997, 
Simionescu et al., 1986, Ajjan and Grant, 2006b). 
The presence of fatty streaks creates an inflammatory reaction with 
inflammatory mediators, vasoactive molecules, cytokines and growth factors 
drawn into the site of lesion. The inflammatory infiltrate further results in 
migration and proliferation of smooth-muscle cells, which contribute to 
narrowing the lumen of the vessel. At this stage, the artery compensates by 
dilation in order to maintain the lumen of the artery and to ensure healthy blood 
flow(Glagov et al., 1987). If the inflammation continues, it increases migration of 
inflammatory cells (Jonasson et al., 1986, van der Wal et al., 1989, Ross, 1999) 
and the fatty streak is gradually transformed into the atherosclerotic plaque 
through the deposition of collagen (Libby, 2009). This results in the 
development of an advanced atherosclerotic lesion that is composed of a lipid 
core and a fibrous cap covering the lesion. In the late stages, the atherosclerotic 
lesion ruptures, exposing a prothrombotic core which activates platelets and 
coagulation factors resulting in the formation of an obstructive thrombus that 
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may block the lumen of the blood vessel, consequently causing organ damage 
(Ross, 1999). 
1.2 Thrombus formation  
Thrombus forms secondary to a complex interaction between the cellular arm of 
coagulation, represented by platelets (A), and the fluid phase of coagulation that 
includes a large number of plasma proteins (B). 
1.2.3 Role of platelets in thrombus formation 
Platelets play a key role in the formation and growth of thrombus. Platelets are 
anucleate cells produced by megakaryocytes in the bone marrow and released 
into the circulating blood at about 85 million cells per day. Around 70% of the 
platelets are present in circulating blood and 30% are stored in the spleen. The 
average size of platelets is 2-3 µm, which makes them the smallest component 
of circulating blood cells, and have a half-life of 7-10 days (150-400)×109/L 
(Wong, 2013, Walsh et al., 2014, Smyth, 2010). 
Platelets activation, adhesion, spreading and degranulation 
The main role of platelet is to prevent bleeding by haemostatic thrombi 
formation. It is very important that a balance is maintained between platelet 
activation and inhibition, as dysregulation of this process may lead to 
inappropriate thrombus formationor conversely it may increase bleeding risk. 
Plateletsin blood arein their resting state and get activated following vascular 
injury (Li et al., 2010). Platelets undergo a very organised series of functional 
response (activation) starting with adhesion to the site of injury followed by 
spreading, release reaction, aggregation, exposure of procoagulant surface, 
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culminating in mature clot formation (Harrison, 2005). Platelet receptor 
glycoprotein GP or integrins such as αIIbβ3 “fibrinogen receptor”, α2β1 “collagen 
receptor” and α5β1 “fibronectin receptor” play key roles in platelet adhesion and 
aggregation (Li et al., 2010). 
Following vascular damage, the subendothelial tissue is exposed which 
contains collagen fibrils (Brass, 2000). Subsequently, collagen comes into 
contact with vWF, which then adheres to platelet glycoprotein receptor GP 
Ib/IX/V complex. As platelet primarily exist in a high shear stress environment 
and need to “settle” at the site of injury, vWF forms the so-called “flex bond” or 
“catch bond” with the receptor Gb Ib-IX (Kim et al., 2010).This slows down 
movement of platelets, allowing them to adhere to the vessel wall. Furthermore, 
platelet receptor GbVI directly binds to collagen leading to cellular activation, 
further ensuring firm adhesion.Also plateletsare activated by thrombin, which 
can maintain platelet activation at low concentrations. Thrombin is generated 
from prothrombin following activation of the coagulation cascade secondary to 
TF release from subendothelial tissue (Ruggeri and Landolfi, 2001).  
During the adhesion step, platelet glycoprotein receptor (GP) interacts with 
extracellular matrix proteins which triggers a complex cascade of signals 
transmitted from platelet membrane into the cytoplasm, consequently leading to 
platelet activation. This process is referred to as outside–in signalling (Jurk and 
Kehrel, 2005). The signalling events occur following interactions between 
collagen and GPVI/GPIbα, Adenosine diphosphate (ADP),  an organic 
molecule that involved in blood  platelet activation and P2Y1/P2Y12, thrombin 
and PAR1/PAR4 and thromboxane A2 TxA2 and thromboxane receptor (TP) 
(Brass, 2010). As a result of activation of receptors GpIIb/IIIa and α2β1 
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(Harrison, 2005) and the presence of other platelet activators such as thrombin, 
ADP and TxA2, activated platelets change their shape secondary to 
conformational alterations of cytoskeleton proteins and the formation of 
pseudopodia in cell membrane, in which new actin filaments are formed 
(Offermanns, 2006, Fox, 1993). This helps the platelets to act as a “plug” at 
sites of injury as further detailed below. 
Platelet adhesion and activation trigger platelet intracellular signalling and 
subsequent degranulation (Harrison, 2005). Platelets secrete granule 
components that modulate the coagulation process through a number of 
mechanisms. The dense granules in activated platelet are responsible for ADP 
production, one of the most important platelet agonist, particularly in the early 
stages of platelet aggregation (Gachet, 2001). Also, dense granules produce 
serotonin (5-hydroxtrryptamine, 5-HT), a vasoconstrictor that works together 
with ADP to increase platelet activation (Jurk and Kehrel, 2005). Furthermore, 
there is a calcium pool in dense tubular system which causes calcium fluxes 
that are necessary for platelet activation and aggregation (Nesbitt et al., 2003). 
The second type of platelet prothrombotic factors are stored in the α-granules 
that contain various proteins including vWF, vitronectin and some coagulation 
factors, including factors V, VII, XI, and XIII as well as protein C and PAI-1. The 
more advanced step in platelet activation is platelet aggregation which occurs 
rapidly and leads to the formation of platelet plug. With platelet receptor 
GPIIb/IIIa (αIIb/β3-integrin) having a key role in this process. Fibrinogen acts as a 
bridge between platelets by interacting with GPIIb/IIIa (αIIbβ3) (Bennett et al., 
2009). In the resting stage, αIIbβ3is not able to bind to soluble ligands such as 
fibrinogen or vWF but following platelet stimulation,αIIbβ3undergoes a 
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conformational change that enable binding to soluble ligands. Platelet-
fibrinogen interaction is further discussed in detail in section 1.2.5 and 1.3.7 
Adhesion and degranulation of platelet result in liberation of ADP, thromboxane, 
serotonin, calcium, which help in starting fibrin network formation by 
immobilising fibrinogen, through interaction via αIIbβ3 and activation of the 
coagulation cascade as detailed below. Finally, the orientation of platelet 
membrane phospholipids changes and negatively charged phospholipids such 
as phosphatidylserine are expressed on the surface of platelets. These 
negatively charged surfaces in turn increase binding activity of plasma 
coagulation factors such as V, VIIIa, IXa and Xa which are essential for 
thrombin production. The various phases of platelet activation are summarised 
in Figure 1.1 
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Figure 1.1 Platelet activation steps. At the beginning adhesion and activation, 
secondary to vascular damage, platelet comes in contact with exposedsubendothelial 
tissue that contains collagen fibrils. Platelet adheres to thevessel wall and 
subsequently spreading occurs together with release of thrombin, ADP, TXA2, vWF. In 
the aggregation step, αIIbβ3undergoes a conformational change that enables binding to 
soluble ligandslike fibrinogenand then binding toanother platelet. Finally, the orientation 
of platelet membrane phospholipids changes and negatively charged phospholipids are 
expressed on the surface of platelets. This in turn increases binding activity of plasma 
coagulation factors such as V, VIIIa, IXa and Xa.  
Platelet and coagulation 
It is well recognised that platelets play a key role in controlling the coagulation 
process by producing two types of proteins:intrinsic platelet coagulation proteins 
and platelet surface-related proteins. As discussed before, platelet α granules 
are the main storage of intrinsic platelet coagulation proteins which are released 
when platelets are activated (Bevers et al., 1991). The formed platelet plug that 
produced in the aggregation stage is unstable until it is enforced by the fibrin 
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strands.  The formation of fibrin depends on the conversion of prothrombin to 
thrombin. 
Platelet signalling 
On platelet membrane, there are different integrins: αIIbβ3 (fibrinogen receptor), 
α2β1 (collagen receptor), and α5β1 (fibronectin receptor). The most important 
integrin in platelet isαIIbβ3 that mediates the aggregation of platelets. The 
formation of stable thrombus is mediated by the process of outside-in and 
inside-out signalling (Ma et al., 2007). Several receptors have different functions 
and signalling pathways. As the platelet integrin αIIbβ3 binds to VWF and 
fibrinogen, an integrin-proximal intracellular signalling process triggers changes 
in extracellular ligand binding domain of the integrin leading to transformation 
from “low-affinity” to “activated” state, which is referred to as inside-out 
signalling (Coller and Shattil, 2008). Meanwhile, after ligand binding to integrin 
αIIbβ3, a ligand–induced conformational change of integrin occurs leading to a 
series of intracellular signalling process which are called “outside-in” signalling 
(Li et al., 2010). 
In what can be called “the intermediate common signalling”, a mixture of soluble 
platelet agonists are liberated from activated platelets such as TXA2, ADP and 
serotonin. (Offermanns, 2006). Platelet stimulation by these agonists occurs by 
binding to G-protein-coupled receptors (GPCRs) in which the signals are 
transmitted from integrin via heterotrimeric G proteins seven transmembrane 
receptors (Li et al., 2010). 
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1.2.4 Fibrin clot formation and lysis 
Fibrin clot formation 
As alluded to earlier, the fibrin network is the skeleton of the blood clot and is 
formed from fibrinogen, an abundant plasma protein. Fibrinogen is a trinodular 
340 KDa glycoprotein, produced by the liver and consists of three pairs of 
polypeptide chains, linked by 29 disulfide bond (Wolberg and Campbell, 2008, 
Guthold et al., 2007). All six polypeptide chains are supercoiled as α-helices 
(Standeven et al., 2005) to form the molecule which consists of central domain 
(E) and two lateral domains (D). N-termini of all six chains end in E domain, 
while C-termini of Bβ and γ chains expand into the lateral 2D domain and C-
termini of Aα chains are extended outside D domain (Wolberg and Campbell, 
2008). The basic structure of fibrinogen is summarised in Figure 1.2 
 
Figure 1.2 Schematic draw of the fibrinogen structure showing the E and D 
domains. Bβ chain is shown in blue, γ chain in red and Aα chain in black. N-termini of 
all six chains end in E domain. Carboxyl end of Bβ and γ chains expand into the lateral 
2D domain.  The arrow indicates the terminal of one of the Aα chains [(adapted from 
(Weisel et al., 1985)]. 
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As a result of plaque rupture, a prothrombotic core is exposed and plasma 
comes in contact with tissue factor (TF). Simultaneously, platelets attach to the 
site of injury and get activated as described above. TF activates FVII and 
activated FVII/TF complexes, then activates FIX and FX, which in turn activate 
FX and FV. Activated FX and FV mediate prothrombin cleavage to produce 
small amount of thrombin sufficient to maintain platelet activation but not 
enough for full activation of the coagulation cascade(Kazama et al., 1995). The 
contact of partially activated platelet with collagen and thrombin leads to full 
activation and degranulation of platelet followed by FV release which is then 
activated by thrombin and FX. Platelet surface FXa/Va complex leads to the 
production of enough amount of thrombin suitable to convert fibrinogen into 
fibrin and form a stable plug (Ajjan and Grant, 2006a, Medved and Weisel, 
2009). 
Thrombin cleaves small fibrinopeptides (A and B), from aminotermini of Aα and 
Bβ chains allowing interaction with cleaved chains from another molecule 
resulting in the formation of insoluble fibrin fibres that further complex together 
to form the cross-linked fibrin network (Ariens et al., 2002). At first,  
Fibrinopeptide A (FpA)  is cleaved and this exposes an N-terminal α-chain motif 
Gly-Pro-Arg (GPR), called knob A (Medved and Weisel, 2009). Knob A is then 
joined with a hole (a) in the γ-chain of an adjacent fibrin molecule. This process 
produces A:a bond which is both strong and stable (Litvinov et al., 2005), and 
regarded as the cornerstone in fibrin polymerization (Weisel and Litvinov, 2013).  
The cleavage of FpB exposes N-terminal β-chain motif Gly-His-Arg-Pro 
(GHRP), called knob B, which binds to hole b in an adjacent fibrinogen β-chain. 
The affinity of knob B is relatively low compared with knob A (Everse et al., 
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1998). However, cleavage of FpA without the cleavage of FpB leads to 
theformation of clots made up of thinner fibres than if it is produced by the 
cleavage of both fibrinopeptides (Weisel and Litvinov, 2013). The binding of 
knob A from fibrin monomer with a hole from another monomer (Knob-hole 
interaction) occurs in a half-staggered manner to hold the two monomers 
together (Weisel and Medved, 2001). 
In addition to knob–hole interaction, there is D-D interface that is similar to end-
to-end junction between monomers (Everse et al., 1998, Zhmurov et al., 2011). 
More fibrin monomers can be added to form a longitudinal chain of oligomers 
and then protofibrils then join with each other side by side (lateral aggregation) 
to increase fibre thickness (Weisel and Litvinov, 2013) 
To stabilise the produced clot, thrombin-activated FXIIIforms several cross-links 
within α and β chain. Furthermore, FXIII-mediated crosslinking of various 
proteins into the clot, such as plasminogen inhibitor, increases the clot strength 
and resistance to fibrinolysis. (Ajjan and Ariens, 2009). 
Fibrin clot lysis 
There is a fine balance between clot formation and breakdown (lysis) in vivo, in 
order to avoid widespread vascular occlusion following an external injury. 
Analogous to thrombin, plasmin is the pivotal enzyme in the fibrinolytic cascade. 
Plasmin is generated following cleavage of plasminogen by a serine protease, 
tissue plasminogen activator (tPA) and this reaction occurs 1000 fold faster in 
the presence of fibrin. Plasmin cleaves arginine and lysine sites on a range of 
molecules and its activity is tightly controlled by plasmin inhibitor (PI) to prevent 
systemic proteolysis (Weisel and Litvinov, 2008). Cleavage of fibrin by plasmin 
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leads to the generation of fibrin degradation products, which can be clinically 
used as an indicator of a thrombotic condition. In addition to PI, other inhibitors 
of this pathway include plasminogen activator inhibitor-1 (PAI-1) and thrombin 
activatable fibrinolysis inhibitor (TAFI). PAI-1 is the fast acting inhibitor of tPA 
and is produced by endothelial cells, platelets and adipose tissue. TAFI is found 
in large quantities in platelets and plasma, is activated by thrombin, a cleavage 
event that is much enhanced when thrombin is bound to thrombomodulin. 
Activated TAFI cleaves the N-terminal lysine residues from degrading fibrin 
fibres to prevent binding of plasminogen and tPA to fibrin which results in 
inhibition of plasmin generation and clot lysis (Antovic, 2003). The main steps in 
clot formation and lysis are summarized in Figure 1.3 
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Figure 1.3 Diagram summarising blood clot formation secondary to activation of 
the cellular and fluid phase of coagulation. Following plaque rupture, platelets 
interact with collagen, which leads to initial and partial platelet activation and 
degranulation, resulting in the secretion of various agonists. These agonists further 
enhance platelet activation and facilitate platelet spreading and platelet fibrinogen-
interaction. Simultaneously, TF release results in activation of the coagulation cascade, 
including FV, FVII, FIX and FX, resulting in thrombin generation and conversion of 
soluble fibrinogen into insoluble fibrin networks. A number of interactions take place 
between coagulation proteins and platelets, which are detailed in the text. EC: 
endothelial cells, ADP: adenosine diphosphate, Plt: platelets, TF: tissue factor, TXA2: 
thromboxane A2, VWF: Von Willebrand factor, FXIII: factor FXIII. 
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1.2.5 Platelet-fibrinogen interaction 
In the platelet aggregation process, fibrinogen binds to platelet glycoprotein IIb-
IIIa (integrin αIIbβ3) complex, which is the most abundant integrin on platelet 
membrane and represents about 50000-80000 copies per platelet (Jennings, 
2009, Kouns et al., 1994).The integrin αIIbβ3 receptor is formed from two 
calcium-dependent heterodimers (Jennings and Phillips, 1982, Wencel-Drake et 
al., 1986). These are encoded on chromosome 17q21.32 (O'Toole et al., 1989, 
Thornton et al., 1999)  leading to the production of two glycoprotein subunits 
GPIIb/GPIIIa (integrin αIIbβ3) that are either transported to the cell surface or 
stored within platelets alpha granules (Phillips and Agin, 1977, Bray et al., 1986, 
Rosa and McEver, 1989). 
Resting platelet integrin αIIbβ3 does not interact with soluble fibrinogen but when 
platelets attach to extracellular wall and get activated, conformational changes 
in αIIbβ3 occur making it able to bind to fibrinogen  (Sims et al., 1991) as well as 
fibrin (Falati et al., 2002, Hayashi et al., 2008, Hechler et al., 2010). The 
connection between fibrinogen and integrins occurs in thecarboxyl-terminus of 
α-chain and carboxyl-terminus on γ-chains (Kloczewiak et al., 1984, Springer, 
2009, Kloczewiak et al., 1989). The initial interaction between fibrinogen and 
αIIbβ3happens in the carboxyl-terminal sequence in γ central domain which is 
highly specific (Springer et al., 2008, Kloczewiak et al., 1984, Kloczewiak et al., 
1989). By means of specific binding sites present in the carboxy terminus of α- 
and γ-chains, one fibrinogen molecule can attach with two αIIbβ3 molecules in 
which each one is located on a different platelet, thereby having a bridging 
effect between the cellular components of thrombosis.Integrins have the affinity 
to adsorb proteins and peptides containing the tetrapeptide sequence Arg-Gly-
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Asp-X (RGD) in which x could be a different residue such as valine, serine, 
phenylalanine or alanine (Pytela et al., 1986). 
The binding between αIIbβ3and fibrinogen is a multi-step process: First, the 
reversible step, within second to minutes, followed by the step where the bound 
ligand is no longer able to dissociate, making the process irreversible 
(Marguerie et al., 1980, Peerschke and Wainer, 1985). αIIbβ3is a receptor that 
requires signalling events to be in the active state. ADP is one of the agonists 
that activate αIIbβ3, which leads to rearrangement of the ligand-binding site, 
transforming the integrin from closed low-affinity conformation to an open high 
affinity conformation (Kamata et al., 2010, Floyd and Ferro, 2012). Savage and 
Ruggeri demonstrated that unstimulated platelets do not attach to 
immobilizedfragment E of fibrinogen, which contains an Arg-Gly-Asp sequence 
at Aα and adhere to fragment D γ-chain. In contrast, activated platelets adhere 
to immobilised fibrinogen and fragments D, and E in time–dependent and 
equivalent manner. Thus unstimulated platelets partially interact with fibrinogen, 
and the initial attachment is followed by spreading and irreversible adhesion 
(Savage and Ruggeri, 1991). Platelet-fibrinogen interaction steps are 
summarised in Figure1.4 
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Figure 1.4 Platelet fibrinogen interaction steps. A. Resting platelets express low 
copies of integrin αIIbβ3 which do not interact with soluble fibrinogen. B. When platelets 
attach to extracellular wall and get activated, conformational changes in αIIbβ3 occur 
making it able to bind to fibrinogen. This active state is a reversible step that extends 
from second to minutes. C. The final and irreversible step in which bound ligand can no 
longer dissociate. 
1.3 Diabetes mellitus  
Diabetes mellitus (DM) is defined by the American Diabetes Association as 
“group of metabolic diseases characterised by hyperglycaemia resulting from 
defects in insulin secretion, insulin action, or both”. Diabetes mellitus is 
becoming the epidemic of the 21st century and the complications associated 
with this condition result in significant personal and financial burden. The 
percentage of diabetes for all age-groups globally was predicted to reach 2.8% 
in 2002 and 4.4% in 2030. The total number people having diabetes worldwide 
were estimated to increase from 171 million in 2000 to 366 million in 2030 (Wild 
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et al., 2004). Diabetes leads to both macrovascular and microvascular 
complications, consequently resulting in high degree of morbidity and mortality. 
Type 1diabetes, evident in around 5% of diabetes patients and previously called 
insulin-dependent diabetes (IDDM), develops as a result of pancreatic β-cells 
destruction secondary to an autoimmune process. In contrast, type 2 diabetes 
(T2DM), previously known as non-insulin dependent diabetes, is far more 
common representing over 90% of patients with diabetes. T2DM develops 
secondary to obesity and insulin resistance, following the failure of the 
pancreatic β-cells to keep up with the increasing demand for insulin secretion as 
a result of resistance to this hormone (NDFS, 2007). There are some rare forms 
of diabetes, including maturity onset diabetes of adults (MODY). This is an 
autosomal dominant condition due to various mutations in transcription factors 
that are involved in glucose haemostasis. Diabetes can also occur secondary to 
pancreatic destruction (due to alcohol excess for example) or rare endocrine 
conditions including acromegaly and Cushing’s syndrome (American Diabetes 
Association, 2004). 
1.3.1 Diabetes and cardiovascular risk 
Despite advances in therapy, cardiovascular disease (CVD) remains the main 
cause of morbidity and mortality in patients with diabetes. Globally, 281 million 
men and 317 million women died of diabetes related complications in 2011, the 
majority from CVD (www.diabetesatlas.org/content).  Patients with DM have 2-4 
times higher mortality than the general population and up to 80% of patients of 
diabetes subjects die secondary to cardiovascular disease (CVD). The risk of 
first ischaemic event in subjects with diabetes and no clinical CVD is similar to 
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the non-diabetic population with a previous history of ischaemic heart disease 
(IHD) (Haffner et al., 1998, Wild et al., 2004). It is not only that diabetes 
increases the risk of first cardiac event, but the prognosis of these patients 
following coronary ischaemia remains poor despite advances in management. 
Our Division investigated the efficacy of modern treatment strategies on clinical 
outcome following acute coronary syndrome (ACS). Comparing 2003 with 1995, 
a 15% reduction in mortality at 18 months was evident in individuals without 
diabetes (p<0.01), but only a non-significant 4% reduction was documented in 
those with diabetes (p=0.71) (Cubbon et al., 2007). It could be argued that 
treatment has further improved over the past decade, and more up-to-date 
strategies may have narrowed the difference between diabetes and non-
diabetes subjects. However, recent work on individuals with myocardial 
infarction (MI), undergoing percutaneous coronary artery intervention, has 
shown higher mortality in patients with diabetes compared to those without 
diabetes at 30 days (7.4% vs 3.8%, respectively; p<0.01), and at 12 months 
(13.9% and 6.5%, respectively; p<0.0001) (Kahn et al., 2012). The same 
applies to individuals treated with coronary artery bypass graft (CABG). In 
10626 patients who have undergone CABG, mortality in individuals with 
diabetes remained significantly higher at 1, 5 and 10 years of follow-up (van 
Straten et al., 2010). A separate study has shown that drug-eluting stents or 
CABG, as a treatment of multi-vessel coronary artery disease in diabetes, do 
not improve clinical outcome after a median follow-up of 5.6 years, indicating 
that type of revascularisation has little effect on longer term prognosis in 
diabetes (Kim et al., 2012). The increase in cardiovascular mortality in patients 
with diabetes is due to a number of factors including more extensive vascular 
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disease and increased thrombosis potential due to changes in clotting factor 
plasma level/activity, impaired fibrinolysis and increased platelet reactivity 
(Alzahrani and Ajjan, 2010, Angiolillo et al., 2005). 
The close link between diabetes and CVD formed the basis for the “common 
soil” hypothesis. This postulates thatDM and CVD share common 
environmental and genetic risk factors that lead to vascular pathology (Ajjan 
and Grant, 2006b). These common risk factors are discussedabove and 
clinically targeted modulation of these risk factors result in asignificant reduction 
in vascular risk (Mccalum and Fisher, 2005). 
Insulin resistance does not only lead to the development of diabetes but is also 
an important factor in the development of vascular disease. Insulin resistance 
results in deranged glucose and lipid metabolism, both of which results in 
endothelial dysfunction, one of the earliest abnormalities in the atherosclerotic 
process as described above. Therefore, insulin resistance provides an 
important link between diabetes and CVD.  
1.3.2 Hypoglycaemia 
In people with T2DM, severe hypoglycaemia is a potential risk factor for 
cardiovascular disease (Zoungas et al., 2010, Duckworth et al., 2011). Intensive 
glucose control was shown to reduce the risk of non-fatal myocardial infarction 
in T2DM (Kelly et al., 2009, Boussageon et al., 2011). However, some studies 
have demonstrated an increase in cardiovascular mortality following 
hypoglycaemia, which is becoming an important clinical topic (Zoungas et al., 
2010). The mechanisms for increased cardiovascular mortality following 
hypoglycaemia may be related to cardiac arrhythmia and/or the predisposition 
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to an inflammatory and thrombotic environment (Stahn et al., 2014). The link 
between hypoglycaemia in cardiovascular disease has been recently 
emphasised in a meta-analysis covering six studies with 903510 participants 
and the authors concluded that avoiding hypoglycaemia may help in preventing 
vascular ischaemia (Goto et al., 2013). 
1.3.3 Diabetes-specific atherothrombotic risk factors and extensive vascular 
pathology 
Diabetes-specific mechanisms for increased atherothrombosis include more 
extensive vascular pathology and an enhanced thrombotic environment. 
Individuals with diabetes display a prothrombotic environment characterised by 
increased prothrombotic coagulation factor level/activity coupled with 
hypofibrinolysis, as well as increased platelet activation. For example, TF 
expression by endothelial cells is upregulated in diabetes resulting in higher 
plasma protein levels (Breitenstein et al., 2010). Furthermore, there is enhanced 
thrombin production in diabetes and elevated levels of fibrinogen, related, at 
least in part, to elevated glucose levels, adding to the prothrombotic milieu 
(Ceriello et al., 2007, Boden et al., 2007, Klein et al., 2003). Hypofibrinolysis is 
documented by increased levels of plasminogen activator inhibitor (PAI)-1 
levels and enhanced incorporation of plasminogen inhibitor into the clot (Dunn 
et al., 2004). 
Medium to long term increased plasma glucose levels result in various protein 
undergoing post-translational modifications, and in the case of coagulation 
proteins, this can increase thrombosis risk as further detailed below (Ajjan et al., 
2013). 
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It is well accepted now that chronic inflammation plays a key role in the 
pathogenesis of vascular pathology. Diabetes is associated with raised plasma 
levels of inflammatory markers including C-reactive protein (CRP) and 
complement C3, both of which have a predictive value for future vascular 
events (Hess et al., 2012). The rise in inflammatory markers is more 
pronounced in patients with type 2 than type 1 diabetes, consistent with earlier 
vascular disease in the former group. This may further explain the reasons 
behindyouth with T2DM having increased damage of the vascular endothelium 
compared with age-matchedT1DM subjects (Ohsugi et al., 2014). 
1.3.4 Role of plateletsin increased thrombosis potential 
The elevated turnover of circulating platelets results in high numbers of young 
platelets which are characterised by increased reactivity compared with the 
older platelet population. These young circulating reticulated platelets are 
increased in patients with acute coronary syndrome and stroke (Lakkis et al., 
2004). Similarly, platelets from patients with diabetes display similar 
characteristics as they are larger in size and hyperactive, thereby increasing 
thrombosis risk (Arjomand et al., 2003).  
A number of mechanisms could be behind the increase in platelet activity in 
diabetes. One is related to non-enzymatic glycation of platelet surface proteins 
that decreases membrane fluidity, which in turn enhances platelet adhesion 
(Winocour et al., 1992). Also in hyperglycaemic environment, there is increased 
platelet-surface expression of αIIbβ3 (GPIIb/IIIa) and GP Ib (Vinik et al., 2001). 
Furthermore, thromboxane A2 (TxA2) production is increased in diabetes due to 
the reduction in theintracellular level of antioxidants such as glutathione 
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(Thomas et al., 1985). Davi and his group have shown that tight metabolic 
control in patients with diabetes result in asignificant decrease in TxA2 
biosenthysis, suggesting that controlling glycaemia reduces thrombosis risk 
(Davi et al., 1990). In addition to various factors that increase platelet activation 
in diabetes, there is a reduction in factors that inhibit the activity of these cells. 
Nitric oxide (NO), produced by endothelial cells, is a potent inhibitor of platelet 
activation. In the setting of endothelial dysfunction, secondary to metabolic 
changes in diabetes, NO production is reduced, thereby liberating the platelets 
from NO-induced inhibition (Queen et al., 2003). Moreover, Li and his group 
have assessed the ability of platelets to release or promote Ca2+ influx. Platelets 
from healthy controls released Ca2+ more effectively than platelets from patients 
with diabetes. In contrast, diabetic platelets showed a more active Ca2+ influx 
process compared with controls (Li et al., 2001). Finally, the P2Y receptor, one 
of ADP agonists receptors, is suggested to be upregulated in platelets of 
patients with diabetes (Yamagishi et al., 2005), further contributing to enhanced 
platelet activation. The main mechanisms leading to increased platelet 
activation in diabetes are summarised in Table 1.1 
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 Effect of diabetes Platelet response 
1 
Non-enzymatic glycation of platelet surface 
(Winocour et al., 1992) 
Reduced membrane 
fluidity and increased 
platelet adhesion 
2 
Increasedplatelet-surface expression of 
αIIbβ3(Vinik et al., 2001) 
Increasedplatelet-
fibrinogen binding 
3 
Reduced intracellular level of antioxidants 
Ex: Glutathione 
(Thomas et al., 1985, Davi et al., 1990) 
 
Increased TXA2 
production and hence 
increased platelet 
activation 
4 
Hyperglycaemia and insulin 
resistance(Queen et al., 2003) 
Reduced Nitric oxide 
production by endothelial 
cells 
5 
Na+/Ca2+ exchange process working in 
reverse mode(Li et al., 2001) 
Increased Ca2+ influx 
6 
P2Y receptor upregulation 
(Yamagishi et al., 2005) 
Increased platelet 
activation to ADP 
Table 1.1 Potential mechanisms that are affecting increased platelet reactivity in 
diabetes. ADP: adenosine diphosphate, TXA2: thromboxane A2, P2Y. 
1.3.5 Role of fibrin structure and fibrinolysis in diabetes 
Studies have shown that both compact fibrin networks and clots that are 
resistant to fibrinolysis are associated with increased risk of CVD. I discuss 
below the changes observed in fibrin network properties in individuals with 
diabetes with special emphasis on the role of glycaemia.  
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Fibrin network structure in diabetes  
A number of studies have shown an increase in fibrin network density in 
diabetes. Jörneskog and colleagues were the first to report changes in the fibrin 
network in individuals with type 1 diabetes (T1DM) (Jorneskog et al., 1996). 
Work from our laboratory further documented that alterations in fibrin network 
structure can occur at a very early age in patients with T1DM (Hess et al., 
2012). The advantage of studying T1DM patients is the ability to address the 
role of glycaemia on fibrin clot structure whilst keeping the effects of 
confounding factors, frequently seen in type 2 diabetes (T2DM) patients, to a 
minimum. Indeed, the relationship between glycaemia and fibrin clot properties 
in T2DM is less clear. One study of 20 T2DM patients and 18 controls did not 
show significant differences in plasma clots comparing the two groups, which 
may be due to the small number of samples studied and the heterogeneity 
observed in T2DM (Pieters et al., 2008). The latter concept is particularly 
important as we have shown that the presence of micro and/or macrovascular 
complications is associated with altered fibrin clot properties in T2DM (Alzahrani 
et al., 2012).  
In order to dissect out the mechanistic pathways, work from our laboratory 
studied the characteristics of clots made from plasma purified fibrinogen of 150 
T2DM patients and 50 healthy controls. Diabetes clots had smaller pore size, 
increased fibre thickness and number of branch points compared with controls, 
indicating that post-translational modifications in fibrinogen are directly 
responsible for altered clot structure in diabetes (Dunn et al., 
2005).Furthermore, HbA1c levels showed a negative correlation with pore size 
and a positive correlation with number of branch points within the clots, 
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suggesting that glycaemic control has an effect on clot structure in this 
population (Dunn et al., 2006). Therefore, current studies indicate the formation 
of more compact fibrin networks in individuals with both T1DM and T2DM. 
Altered clot structure in diabetes is evident from childhood and glycaemic 
control appears to modulate the characteristics of the fibrin network. However, 
there is a great variability in fibrin networks in patients with T2DM with additional 
changes in clot characteristics in the presence of complications. This indicates 
that altered clot structure in diabetes is present at various stages of this 
condition, which may have future clinical implications.  
Fibrinolysis in diabetes  
Several studies have shown impaired clot lysis in diabetes and these included 
patients with both T1DM and T2DM (Hess et al., 2012, Neergaard-Petersen et 
al., 2014b, Alzahrani and Ajjan, 2010). We have shown that fibrinolytic 
alterations in diabetes are detected at a young age and can also be found in 
those with advanced vascular complications (Hess et al., 2012, Alzahrani et al., 
2012, Neergaard-Petersen et al., 2014b). Whilst impaired fibrinolysis is 
generally associated with more compact fibrin networks (Collet et al., 2000), 
other factors also play a role such  as increased incorporation of antifibrinolytic 
proteins into the clot and direct impairment in the fibrinolytic system, which are 
discussed in detail below. 
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1.3.6 Mechanisms for altered clot structure and fibrinolysis in diabetes 
There are a number of factors that affect clot structure and fibrinolytic efficiency 
in diabetes, and these include qualitative and quantitative changes in the 
coagulation proteins. 
Clot structure  
Quantitative changes in coagulation factors modulate the final ultrastructure of 
the clot. Most importantly, increased plasma levels of fibrinogen, commonly 
found in diabetes, result in the formation of more compact clots (Alzahrani and 
Ajjan, 2010). In addition to quantitative changes, qualitative alterations in 
clotting factors can influence the structure of the fibrin network. High plasma 
glucose mediates glycation of fibrinogen (Pieters et al., 2007) and clots made 
from glycated protein are more tightly packed. Moreover, the by-product of 
protein glycation, glycolaldehyde, induces post-translational modifications in 
fibrinogen, which impairs the fibrinolytic process (Andrades et al., 2009). It 
should be remembered that diabetes is also associated with increased oxidative 
stress and fibrinogen oxidation has been shown to modulate clot structure, 
adding another mechanism for altered clot structure in diabetes (Henschen-
Edman, 2001).  
If hyperglycaemia has a deleterious effect on clot structure, then improving 
glycaemic control should result in the production of less compact clots. Initial 
attempts at optimising glucose control with continuous subcutaneous insulin 
infusion (CSII) were associated with increased plasma fibrin gel porosity but, 
unexpectedly, this was not related to improvement in glycaemic control as the 
fall in HbA1c was minor and non-significant (Jorneskog et al., 2003). 
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Subsequent work from our laboratory has shown that a mean drop in HbA1c by 
13 mmol/mol is associated with a decrease in plasma clot final turbidity, 
indicating the formation of less compact clots (Hess et al., 2012).Others have 
demonstrated that improving glycaemic control in 20 T2DM subjects has no 
effect on fibrinogen levels, plasma clot porosity or turbidity curves but it results 
in a small reduction in clot compaction (Pieters et al., 2007). Investigating clots 
made from plasma-purified fibrinogen from the same patients has shown that 
improving glycaemia results in variable changes in clot structure, an effect that 
was more obvious in a small group of 7 individuals with larger drop in fibrinogen 
glycation (Pieters et al., 2008). 
Fibrinolysis  
Changes in fibrinolysis in diabetes can be secondary to: i) Altered clot structure, 
ii) Increased incorporation of antifibrinolytic proteins into the clot and iii) 
Deranged activity of the fibrinolytic system.  
More compact clots display increased resistance to fibrinolysis as previously 
demonstrated (Collet et al., 2000, Collet et al., 2006). Therefore, the changes in 
clot structure outlined above can indirectly affect theefficiency of the fibrinolytic 
process in diabetes. More recently, an additional mechanism has been 
described that is particularly interesting as it may have future therapeutic 
implications. FXIII mediates the cross-linking of various proteins into the clot in 
order to strengthen the fibrin and increase its resistance to fibrinolysis. PI 
represents a classic protein that is cross-linked into the fibrin clot in order to 
make it more resistant to lysis (Schaller and Gerber, 2011). Recent work has 
shown that diabetes clots are characterised by increased PI incorporation into 
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the fibrin network, representing an additional mechanism for impaired clot lysis 
in diabetes (Agren et al., 2014). Another protein that may also be diabetes-
specific is complement C3. Work from our laboratory has shown that 
complement C3 can be detected in the fibrin clot using proteomics techniques 
(Howes et al., 2012, Distelmaier et al., 2009). Interestingly, C3 incorporation 
into the clot impairs the fibrinolytic process, which may be due to the 
mechanical inhibition of clot lysis secondary to presence of C3 but may also be 
related to C3 acting as a substrate for plasmin (Seya et al., 1985). Our studies 
in patients with T1DM have shown increased incorporation of C3 into diabetes 
clots, explaining the exaggerated anti-fibrinolytic response to C3 in this 
population (Hess et al., 2012). Further work in 822 patients with type 2 diabetes 
has shown that C3 plasma are at least as good a predictor of fibrin clot lysis as 
PAI-1 (Hess et al., 2014). Interestingly, there was no correlation between C3 
and PAI-1 plasma levels, consistent with the two proteins affecting different 
pathways in the fibrinolytic system. Increased incorporation of PI and C3 into 
the fibrin clot in diabetes offers the exciting possibility of developing diabetes-
specific therapies that target fibrin-PI or fibrin-C3 interactions as a means of 
improving the fibrinolytic efficiency in this condition, whilst keeping bleeding risk 
to a minimum. 
Finally, diabetes can directly modulate the efficiency of the fibrinolytic system. It 
has been known for a long time that increased plasma levels of PAI-1, a 
characteristic of insulin-resistant states and T2DM, represent a key mechanism 
for impaired fibrin clot lysis in these conditions (Trost et al., 2006). PAI-1 inhibits 
plasmin generation and levels of this protein have been repeatedly used as a 
surrogate marker for fibrinolytic efficiency in various research studies. More 
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recently, however, a new mechanism for impaired fibrin clot lysis in diabetes 
has been described that is related to increased glycation of plasminogen. Nε-
fructosyl-lysine residue on plasminogen from T1DM individuals was increased 
three-fold compared with protein purified from healthy controls, and a 
preferential glycation of lysine 107 and 557 within the protein was 
demonstrated. These sites are believed to be involved in fibrin binding and 
plasmin(ogen) cleavage, offering mechanistic explanations for our findings 
(Ajjan et al., 2013). Indeed, reduced conversion of diabetic plasminogen to 
plasmin together with decreased protein activity were evident, with improvement 
documented following better control of glycaemia. Mechanisms for 
hypofibrinolysis in diabetes are summarised in Figure 1.5 
  
31 
 
Compact fibrin 
networks
Increased anti-fibrinolytic
proteins in fibrin clots Compromised 
fibrinolytic system
Mechanisms for 
hypofibrinolysis in 
diabetes
↑PAI-1 plasma levels
↑Plasminogen glycation
↑PI & complement C3
incorporation into  fibrin
Quantitative & qualitative 
changes in fibrinogen
Figure 1.5 Mechanisms responsible for hypofibrinolysis in diabetes. The three 
main mechanisms responsible for hypofibrinolysis in diabetes include: 1) the formation 
of more compact clots, which increases mechanical resistance to lysis; 2) increased 
incorporation of antifibrinolytic proteins into the fibrin network, including plasmin 
inhibitor and complement C3; and 3) compromised efficacy of the fibrinolytic system 
through increased plasma levels of plasminogen activator inhibitor and compromised 
plasmin production and function secondary to increased protein glycation. 
Abbreviations: PA: Plasminogen activator inhibitor-1, C3: complement 3, PI: plasmin 
inhibitor. 
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1.3.7 Role of fibrinogen-platelet interactions in diabetes 
The stickiness of platelets from both patients with diabetes and healthy 
individuals is increased in the presence of excess glucose (Bridges et al., 
1965). Comparing 41 patients with diabetes (27 type I and 14 type II) and 23 
healthy controls, Tschoepe and his group have shown that the average number 
of glycoproteins per platelet (including αIIbβ3), is significantly increased in 
diabetes.Additionally, they found that there is apositive relationship between 
vWF plasma levels and HbA1c.This may further contribute to increased platelet 
fibrinogen binding capacity (Tschoepe et al., 1990).   
Glycation of the fibrinogen affects both its conformation and function. Due to the 
reaction between the free amino group in the fibrinogen molecule and the 
carbonyl group of a reducing sugar, amadori product is produced, which can 
alter protein conformation (Mirmiranpour et al., 2012). These changes in 
fibrinogen may in turn lead to different interaction with platelets, thereby 
modulating the thrombotic process. However, this concept is not supported by 
other studies, demonstrating that fibrinogen binding to ADP-activated platelets 
from patients with diabetes and healthy control have the same pattern 
(Niewiarowski et al., 1987). 
On the other hand, clinical studies indicate that disrupting platelet-fibrinogen 
interaction, as part of the treatment for unstable coronary artery disease, 
appears to be particularly beneficial in individuals with diabetes. This suggests 
that platelet-fibrinogen interaction may be different in diabetes compared to 
normoglycaemicindividuals, or it may simply indicate that manipulating this 
interaction has a superior role in protecting from thrombotic events in this 
population. 
33 
 
1.3.8 Glycaemia and clinical studies 
Given that high glucose levels have a deleterious effect on clot 
structure/fibrinolysis, it is expected that improving glycaemia reduces the risk of 
atherothrombotic disease. However, this has not been shown in all studies and 
remains an area of constant debate. The Diabetes Control and Complications 
Trial (DCCT) and further extension in the Epidemiology of Diabetes 
Interventions and Complications (EDIC) trial has shown that early glycaemic 
control in type 1 diabetes reduces longer-term atherothrombotic 
complications(Nathan et al., 2005). Largely similar findings were documented in 
the UK Prospective Diabetes Study (UKPDS) with long-term follow-up of 
patients with newly diagnosed type 2 diabetes (Holman et al., 2008). The 
Diabetes mellitus Insulin Glucose infusion in Acute Myocardial Infarction 
(DIGAMI)-1 study demonstrated that improving glycaemic control following a 
cardiac event improves clinical outcome (Malmberg et al., 1996). In contrast, 
the DIGAMI-2 study, investigating the best strategy to lower blood glucose 
levels following MI, failed to show a beneficial effect of tight glycaemic control 
(Malmberg et al., 2005). This was hardly surprising given the similar HbA1c 
values in three study arms and the fact that the study was underpowered. Two 
large studies investigating the medium-term vascular effects of tight glycaemic 
control have shown either an absence of an effect, or quite worryingly, an 
increase in mortality (Patel et al., 2008, Gerstein et al., 2008). There are a 
number of explanations for these contradictory findings when addressing fibrin-
related thrombosis risk. First, the effect of glycaemia on fibrin network structure 
is only apparent with very high glucose levels, and perhaps only a modest 
improvement in glycaemia is required for the reduction of fibrin-related 
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thrombosis risk. Therefore, a drop in HbA1c from 75 to 65 mmol/l will have a 
significant effect on thrombosis risk that is not seen following a reduction in 
HbA1c levels from 65 to 55 mmol/mol. Second, HbA1c is a poor marker of 
acute glycaemia as it fails to take into account fluctuations in glucose levels, 
which can be prothrombotic (Ceriello et al., 2014). Third, several pieces of 
evidence indicate that hypoglycaemia, which HbA1c fails to capture, is 
prothrombotic and may have a role in the adverse clinical outcome in diabetes. 
Previous work has shown that acute hypoglycaemia is associated with a rise in 
PAI-1 levels (Gogitidze Joy et al., 2010) and an increase in factor VIII 
coagulation activity coupled with accelerated thrombin generation (Ibbotson et 
al., 1995). Our ex-vivo studies using hypoglycaemia clamp studies in patients 
with diabetes have shown that low blood glucose levels are associated with 
hypofibrinolysis, measured using the validated turbidimetric assays. Moreover, 
this thrombotic effect of hypoglycaemia can persist for one week following the 
event, adding an important dimension to our understanding of the impact of 
hypoglycemia on thrombosis risk (Kurdee et al., 2014). The above findings may 
explain improved clot porosity after continuous subcutaneous insulin infusion, 
despite no improvement in HbA1c, as this treatment is typically associated with 
less hypoglycaemic episodes (Jorneskog et al., 2003). Therefore, clinical 
studies investigating the effects of glycaemia on cardiovascular event and 
thrombosis risk should not only rely on HbA1c but should take into account 
glucose variability and hypoglycaemia (Ajjan and Owen, 2014), which will only 
be possible using continuous glucose monitoring. With the development of new 
continuous glucose devices, a more sophisticated approach to monitoring 
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glycaemia is now a real possibility that should be explored in future 
cardiovascular studies in diabetes. 
1.4 Ex vivo tests of thrombosis potential (Platelet function tests) 
Assessing bleeding potential is regularly used to tailor therapy in a large 
number of medical conditions. With the same token, assessing thrombosis may 
help to tailor anti-thrombotic therapy according to the need of each individual. 
However, the latter remains largely a research tool and clinical applicability has 
been somewhat limited mainly due to the large variability encountered with 
these tests and the relative inability to define a “normal range”. A number of ex 
vivo tests can be performed to assess thrombosis risk and these are briefly 
described in this section.  
Platelets function tests were mainly used to determine bleeding risk (Peerschke, 
2002) but more recent studies are calling for their use to predict risk of 
thrombosis and to monitor the efficacy of antiplatelet therapy (Paniccia et al., 
2015). One of the earliest platelet function tests is in vivobleeding time that was 
used for decades (Guidelines on platelet function testing (BCSH, 1988)). The 
principle of the test depends on measuring the time between thestart of 
bleeding, after an incision is made in the skin, until the bleeding stops (Harrison, 
2005). The disadvantages of this test are that it is invasive, time-consumingwith 
poor reproducibility (Rodgers and Levin, 1990). Therefore, platelet aggregation 
tests were subsequently developed, which are less invasive and more accurate. 
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1.4.1 Measurement of platelet aggregation (LTA and multiplate) 
Turbidimetric platelet aggregometryor light transmission aggregometry (LTA) is 
the in vitro test for platelet aggregation in response to different agonists such as 
ADP, Collagen and AA using platelet rich plasma (PRP). It is still regarded by 
many as the “gold standard” when assessing platelet reactivity (Seyfert et al., 
2007, Harrison, 2004). However, it has several limitations, including sample 
preparation to obtain platelet rich plasma (PRP), which is both times consuming 
and requires laboratory expertise. Moreover, platelets tested are not in their 
normal physiological environment, casting doubt about the clinical validity of 
such an approach (Valles et al., 1993, Valles et al., 2002).  
Perhaps a more “physiological” test is whole blood impedance aggregometry 
(Cardinal and Flower, 1980). This technique offers several advantages over 
LTA, including: i) only a small blood volume is needed, ii) there is no need for 
samples preparation, iii) platelets are tested in their normal environment (Jarvis, 
2004). 
1.4.2 VerifyNow system 
The verifyNow system (ITC, Edison, NJ, USA) is a technique that assesses 
platelet aggregation using turbidimetric-based optical detection. The system 
uses cartridges that contain fibrinogen-coated beads and different platelet 
agonists. As platelets aggregate upon the fibrinogen-coated beads within the 
assay cartridge, the optical signal increases, which is then measured (Paniccia 
et al., 2015). There is moderate agreement between VerifyNow system and 
other platelet function tests (Paniccia et al., 2015). However, variability remains 
high and the early enthusiasm for the use of this technique has been quickly 
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fading. However, it remains a useful clinical tool to predict the post-operative 
haemorrhage (Rosengart et al., 2013, Yu et al., 2014). 
1.4.3 Platelet function analyser (PFA)-100 
The platelet Function Analyser PFA-100 tests the capacity of platelets to adhere 
under shear stress conditions in response to agonist present in the system. 
Citrated whole blood is flows under high shear stress through a capillary 
containing collagen-coated membrane, treated with either ADP or epinephrine 
(EPI). Once the platelet are activated and clump together, the capillary is 
blocked and blood flow stops, which is then measured as closure time (CT). 
Shorter CT is associated with increased platelet aggregation (Paniccia et al., 
2015). Limitation of this technique includes low platelet count, a decrease in 
haematocrit as well as conditions with inherited platelet dysfunction (Chakroun 
et al., 2004, Mannini et al., 2006). Given these limitations, PFA-100 has fallen 
out of favour and it is now less commonly used to test platelet function.   
In double-blind, placebo-controlled, randomised, three-period cross-over study 
in healthy volunteers, Chen and his group have compared different techniques 
assessing platelet reactivity aggregation using LTA, Multiplate®, Platelet 
function analyser-100®, and VerfyNow®. They have found that any of the 
simple to use technique can reliably test aspirin effect on platelet function (Chen 
et al., 2012). 
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1.4.4 Markers of platelet activation (FACS) 
One of therecent advances is testing platelet activation using flow cytometry. 
Quantitation of glycoprotein receptor density, to diagnose disease like Bernard 
Soulier disease and Glansmann’s thrombosthenia, is one of the most commonly 
used platelets tests (Cohn et al., 1997, Lindahl et al., 1992). A clear advantage 
of this technique is studying the platelets in their natural environment with little 
sample manipulation (Harrison, 2005). The main disadvantage, however, is the 
need for expensive equipment and considerable expertise (Harrison, 2005). 
1.5 Ex vivo tests of thrombosis potential (fibrin structure and fibrinolysis) 
The fibrin network forms the backbone of the fibrin clot and a number of tests 
are routinely used in research studies to investigate structure of the fibrin clot 
and resistance to fibrinolysis.  
1.5.1 Permeation assays 
In fibrin permeation test, plasma samples incubated with human thrombin and 
calcium in an open tube at room temperature for 2 hours, resulting in the 
formation of a fibrin clot. A neutral buffer is then dropped under pressure 
through the fibrin clot and flow rate through the fibrin clots is measured. In this 
technique the Darcy constant Ks or permeation coefficient is calculated, which 
measures the porosity of the clot (less porous clots are more thrombotic) (Mills 
et al., 2002). 
1.5.2 Turbidimetric assays 
In turbidity measurement technique, plasma is incubated with human thrombin 
and calcium in a microtiter plate followed by reading of absorptivity every couple 
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of seconds using spectrophotometric plate reader. In this technique, lag phase 
(the time required for the fibrin clot to start forming) maximum absorbance (a 
measure of clot density and fibre thickness) and lysis time (the time required for 
fibrin clot to be degraded) (Mills et al., 2002, Weisel and Nagaswami, 1992). 
1.5.3 Clot visualisation  
In scanning electron microscopy (SEM),the clot is prepared after the addition of 
thrombin and calcium followed by dehydration and sputter coating before 
visualisation under electron microscopy (Langer et al., 1988). The power of the 
electron microscope (x5000-100000 magnification) allows detailed investigation 
of clot ultrastructure includingfibre thickness and clot pore size. The other 
helpful clot imaging technique is confocal microscopy in which the fibrin clot of 
fluorescently labelled fibrinogen is analysed (Collet et al., 2005). The main 
advantage of confocal microscopy over SEM is visualisation of fully hydrated 
clots and the ability to conduct clot lysis experiments. On the other hand, 
confocal microscopy is unable to provide the resolution necessary to study clot 
ultrastructure. Therefore, the two techniques are complementary. 
1.5.4 Platelet fibrinogen interaction tests 
In order to determine the adhesion of human platelets to fibrinogen and other 
proteins, Bellavite et al 1994 developed a protein-coated microwell system. 
Isolated and washed platelets are added to 96-well microtiter plate coated with 
the fibrinogen. Unbound platelets are washed off  and  acid phosphatase 
activity in adherent platelet is subsequently measured (Bellavite, 1993). Another 
technique to study platelet fibrinogen interaction is flow cytometry, whereby 
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fibrinogen is labelled with fluorescent dye that enables detection of platelet 
binding (Heilmann et al., 1994). This technique has the advantages of being 
sensitive and is able to test interactions in solution without the need to 
immobilise fibrinogen. 
1.6 The role of hypoglycaemic agents in Prevention of thrombus formation and 
thrombosis risk in diabetes 
As mentioned above, type 2 diabetes is a heterogeneous condition with a large 
number of variables that may affect CVD risk. One set of these variables is 
introduced by the type of treatment used to treat hyperglycaemia. Metformin is 
usually used as first-line therapy in subjects with type 2 diabetes and the 
UKPDS demonstrated that use of this agent is associated with reduced risk of 
ischemic heart disease in overweight patients (UK Prospective Diabetes 
Study(UKPDS, 1998)). This is further supported by observational data from the 
REACH registry including a large number of 19,691 patients (Roussel et al., 
2010). The mechanisms for reduced cardiovascular events in metformin users 
may be partly related to the effects of this agent on the fibrin network, reviewed 
elsewhere (Alzahrani and Ajjan, 2010).  
Thiazolidinediones are peroxisome proliferator-activated receptor γ stimulators 
that directly modulate insulin resistance, the key pathogenic mechanism in 
diabetes. Treatment with thiazolidinediones is associated with lower fibrinogen 
and PAI-1 levels, which reduces thrombosis potential and improves fibrinolysis 
(Haffner et al., 2002, Buckingham, 2005, Chen et al., 2010, Perriello et al., 
2007). Furthermore, these agents can delay intra-arterial thrombus formation 
and reduceprogression of atherothrombotic lesions (Li et al., 2005, 
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Mieszczanska et al., 2007, Marx et al., 2005). In the PROactive trial, 
pioglitazone treatment resulted in reduction in the composite end point of all-
cause mortality, nonfatal MI, and stroke (2006, Dormandy et al., 2005). 
However, there was an increase in heart failure making the cardiac protective 
role of this agent debatable. In a controversial meta-analysis, rosiglitazone was 
found to increase the risk of cardiovascular events in diabetes (Nissen and 
Wolski, 2007), which subsequently resulted in withdrawal of this agent from the 
European market. The promising effects of glitazones on various cardiovascular 
risk factors did not translate clinically into meaningful vascular protection and 
the use of rosiglitazone was associated with apparent harm, although the data 
are far from conclusive. This clearly demonstrates that reliance on surrogate 
markers is not enough to assess the clinical efficacy of a drug, for which 
outcome studies are required.  
Gliptins and glucagon-like peptide 1 (GLP-1) analogues are relatively new 
hypoglycemic agents and current evidence suggests that gliptins have a neutral 
effect on cardiovascular risk, whereas studies with GLP-1 analogues are yet to 
be reported (De Caterina et al., 2010, Scirica et al., 2013, White et al., 2013). 
Finally, insulin-treated patients with type 2 diabetes are at greater risk of 
cardiovascular events compared with noninsulin-treated subjects, which may 
simply reflect longer disease duration with a consequent increase in the risk of 
complications (Margolis et al., 2008). 
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1.7 The role of antiplatelet therapy in prevention of thrombus formation in 
diabetes 
Anti-platelet therapy remains a cornerstone of the management of individuals 
with established CVD. Following an acute ischaemic event, dual antiplatelet 
therapy is used to inhibit two pathways of platelet activation usually for one 
year. This is then followed by anti-platelet monotherapy that continues 
indefinitely (Carreras and Mega, 2014). 
1.7.1 P2Y12 receptor blockers 
The receptor P2Y12 plays  an important role in platelet aggregation and 
activation by the agonist ADP (Dorsam and Kunapuli, 2004).  Inhibition of 
P2Y12 reduces platelet aggregation, decreases thrombin production, and 
modulates production of several pro-inflammatory markers such as TNF-α, p-
selectin and CRP (Gurbel et al., 2006)  There are different generations of ADP 
P2Y12 receptor inhibiting drug. The first generation is represented by the 
thienopyridine, ticlopidine. This drug is banned from the market because of 
unfavourable side effect profile. Clopidogrel is the second generation of 
thienopyridines and has been extensively used in the past two decades. 
Prasugrel is the newer version of irreversible P2Y12 inhibitors. Whilst prasugrel 
is largely similar to clopidogrel, a key difference is related to metabolism of the 
active drug that requires a single step, in contrast to clopidogrel that requires 
two steps, a process that may influence its clinical efficacy. The last generation 
of thienopyridines is ticagrelor, which differs from clopidogrel and prasugrel by 
being an active compound (no metabolism is necessary) and characterised by 
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reversibility of action, which may increase safety of this agent (Mega and 
Simon, 2015, Bonaca et al., 2015). 
It is worth noting that platelets are more active in T2DM and have higher 
resistance to P2Y12 inhibitors, which is particularly evident with clopidogrel 
(Angiolillo et al., 2005, Angiolillo et al., 2006, Mangiacapra et al., 2010). 
1.7.2 Inhibitors of platelet-fibrinogen interaction 
As mentioned previously, platelet αIIbβ3 receptor is the receptor that 
bindsfibrinogenthereby forming a bridge between platelets. Integrin 
αIIbβ3inhibitors suppress the aggregation of platelets by preventing fibrinogen 
binding to αIIbβ3receptors. There are three common αIIbβ3inhibitors (Abciximab, 
Tirofiban and Eptifibatide) (Judy W. M. Cheng, 2012). All of these drugs can 
only be used intravenously and therefore they are not suitable for chronic 
therapy (Ajjan and Grant, 2006b). The work of Roffi M and his group, three 
decades ago,  indicated that αIIbβ3 inhibitors are effective in reducing 30 day 
mortality after acute coronary syndromes (ACS), especially in patients with 
diabetes (Roffi et al., 2001). However, theIntracoronary Stenting and 
Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated 
Thrombotic Risk in Diabetics [ISAR-SWEET] trial conducted on 701 patients 
with diabetes and ACS undergoing percutaneous coronary intervention (PCI), 
showed there is no reduction in one year mortality after treatment with 
abciximab and high dose clopidogrel (600mg) compared with clopidogrel alone 
(Mehilli et al., 2004). In addition eptifibatide and tirofiban did not show a 
significant benefit in patients with diabetes (Schneider, 2011). This was not 
gone unchallenged as others have shown that individuals treated with 
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abciximab (both diabetes and non-diabetes subjects) have better clinical 
outcome. The reason for the contradictory results is almost certainly due to the 
heterogeneity of patients with ACS and, therefore, the large number of patients 
required to make concrete conclusions, which would allow subgroup analysis 
(Ndrepepa et al., 2006). 
1.8 Aspirin (the Inhibitor of the thromboxane pathway): the evidence, mode of 
action and role of aspirin  
Aspirin, or acetylsalicylic acid (ASA), is one of the salicylate drugs with a 
formula C9H8O4 (PubChem, 2004) It was first produced by Felix Hoffman in 
1897 as an anti-pyretic and anti-inflammatory and it was not until 1971 that the 
antithrombotic properties of this drug were discovered by Sir John Vane (Tantry 
et al., 2009). Although the role of aspirin for primary CVD prevention is 
questionable, particularly in those with diabetes, it remainsan important agent  
for secondary prevention (Szczeklik et al., 2005). 
1.8.1 Platelet and aspirin 
Aspirin saved the lives of millions of CVD patients(Antithrombotic Trialists' 
Collaboration(ATT, 2002)). ASA acts by acetylation of platelet cyclooxygenase-
1(COX-1) at position serine 529. This chemical modification inactivates the 
enzyme and as a result cyclic endoperoxide (prostaglandin G2 “PGG2” and 
“PGH2”) production from arachidonic acid is reduced. Consequently, this 
reduction in PGG2 and PGH2 leads to reduction of prostanoid thromboxane A2 
(TXA2) synthesis, a potent vasoconstrictor and platelet activator (Roth and 
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Calverley, 1994). The action of aspirin is irreversible and lasts till the end of 
platelet life (Angiolillo and Suryadevara, 2009) 
In addition to this “traditional” mode of action for aspirin, this agent can acetylate 
fibrinogen resulting in the formation of a more porous fibrin network that is 
easier to lyse. Earlier work has shown that acetylation of fibrinogen occursat 
both the D and E domains and on α, β and γ chains where N-acetyl-lysin 
formed (Bjornsson et al., 1989). However, a more recent study suggested that 
acetylation occurs preferentially in the α-chain of fibrinogen (Ajjan et al., 2009). 
Furthermore, aspirin can also affect other coagulation factors resulting in altered 
thrombin generation and FXIII activity (Undas et al., 2007).   
1.8.2 Aspirin and the fibrin clot 
The fibrin clot formed from purified fibrinogen after incubation with aspirin ex 
vivo showed increased gel porosity, making these clots less thrombotic (He et 
al., 2001). In vivo administration of aspirin in healthy controls also resulted in 
altered clot structure, that was particularly noticeable with lower aspirin dose 
(Antovic et al., 2005, Williams et al., 1998). More recent work employed a 
recombinant system to test the effect of aspirin on the fibrinogen molecule. 
Chinese Hamster Ovary (CHO) cells that have been transfected with the three 
chains of fibrinogen were grown in the presence and absence of increasing 
concentrations of aspirin. Fibrinogen was then purified from culture media and 
fibrin clots were made. Clots made from recombinant fibrinogen produced by 
CHO cells in the presence of aspirin showed less compact structure and 
reduced resistance to fibrinolysis, which was due, at least in part, to acetylation 
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of the fibrinogen molecule (Ajjan et al., 2009). The different modes of action of 
aspirin are summarised in Figure 1.6. 
Collagen
TRAP
ADP
TXA2
AA1
cox1
Acetylated       
cox
TXA2
ASA 
Fibrinogen
acetylated 
fibrinogen
Change in clot 
structure and 
enhanced 
fibrinolysis
other  
proposed 
effects of 
ASA
Lower thrombin 
generation – less  
FXIII activity
AA
Figure 1.6 The effects of aspirin on platelet function, coagulation factor activity 
and clot structure/fibrinolysis. When aspirin acetylates cyclo-oxygenase (Cox)-1, the 
production of the platelet agonist thromboxane A2 (TXA2) is diminished, thereby 
inhibiting platelet reactivity. Aspirin acetylates fibrinogen and the resulting fibrin network 
is less compact and easier to lyse. Aspirin has another proposed effect on lowering 
thrombin generation and may also affect FXIII activity. ASA: acetyl salicylic acid, Cox: 
cyclo-oxygenase, TXA2: thromboxane A2, AA: arachidonic acid, TRAP: thrombin 
receptor-activating peptide ADP: adenosine diphosphate, a2B1, 5HT2a,P2Y12: 
Different platelet receptors. 
1.8.3 Diabetes and aspirin treatment  
The term aspirin variable response has recently appeared in the literature and 
generated significant interest. This can be divided into biochemical and clinical 
aspirin resistance. The former is defined as incomplete inhibition of platelet 
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function by aspirin, measured using various platelet function assays (Watala et 
al., 2004). Given the lack of a consensus over the best assay to measure 
biochemical aspirin resistance, the prevalence is hugely variable comparing 
different studies ranging from 5.5-45% (Pamukcu, 2007). Clinical aspirin 
resistance is defined by some as “the occurrence of an arterial thrombotic event 
despite aspirin therapy” (Michelson et al., 2005) However, others argue that 
occurrence of an ischaemic event despite aspirin treatment is perhaps better 
described as aspirin treatment failure. 
The exact cause(s) for aspirin resistance is still not clear but likely to include a 
mixture of environmental and hereditary factors (Watala et al., 2004, Martin and 
Talbert, 2005). For example, cigarette smoking leads to increased platelet 
reactivity and aggregation, which is related, at least in part, to lower platelet NO 
production in long term smokers (Ichiki et al., 1996) secondary to inhibition of 
eNOS mRNA expression (Shimasaki et al., 2007). 
In patients with diabetes, it is now generally accepted that the clinical effects of 
aspirin are compromised (reviewed by (Ferreiro et al., 2010). The exact 
mechanisms for this phenomenon are unknown, but there are a number of 
hypotheses, which are discussed in detail below. 
1.8.4 Aspirin treatment failure 
Early evidence for reduced clinical efficacy of aspirin in diabetes came froma 
meta-analysis including 287 studies (135000 patients). The authorsdocumented 
that antiplatelet treatment (aspirin in most studies) was associated with a 
significant 22% risk reduction in vascular event when used for primary 
prevention, but this figure was much smaller, and non-significant, at 7%, 
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(Antithrombotic Trialists' Collaboration (ATT, 2002)). 
The Primary Prevention Project (PPP) is an early randomised open label trial 
that demonstrated that patients with diabetes do not benefit from aspirin when 
used for primary CVD prevention (Sacco et al., 2003). More recent work by 
Belch and colleagues (POPADAD trial) have also arrived at the same 
conclusions that low daily dose aspirin (100mg/day) fails to provide primary 
CVD protection (Belch et al., 2008). However, this study has been repeatedly 
criticised, mainly due to lack of adequate power and the inclusions of patients 
with evidence of peripheral vascular disease, making it a secondary prevention 
study (Elwood, 2008). Finally, the JPAD study using low-dose aspirin also  
concluded that this agent has little benefit in term of primary CVD prevention, at 
least in Japanese (Ogawa, 2011). Subgroup analysis suggested that some 
groups may benefit, further highlighting the difficulties encountered when 
studying a highly heterogeneous population such as individuals with type 2 
diabetes.  
Ongoing and adequately powered clinical studies such as ASCEND and 
ACCEPT-D,  which will be reporting in the next 2-3 years, should be able to 
shed more light on the role of aspirin in primary prevention in diabetes and 
hopefully will also identify patient subgroup(s) that benefit the most from this 
form of therapy. 
The reduced clinical efficacy of aspirin in diabetes is related to a number of 
factors. Some of these factors are non-specific, related to the general increase 
in thrombosis potential in diabetes, whereas others appear to be specific arising 
secondary to direct interactions between glycaemia and response to aspirin 
therapy.   
49 
 
 
1.8.5 High platelet reactivityrole in aspirin treatment failure  
Even in the absence of vascular injury, platelets of subject with diabetes appear 
to be in a state of constant low-grade activation (Watala, 1991, Winocour, 
1992).  
The non-enzymatic glycation of platelet proteins can alter the physio-chemical 
properties of cell membranes, making platelet more “sticky” (Watala, 1991, 
Watala et al., 1998). Also, patients with diabetes show high platelet Ca2+ influx 
in the resting condition and higher Ca2+ mobilisation secondary to activation 
with ADP or thrombin (Mazzanti et al., 1990, Watala et al., 1998). 
1.8.6 Interaction between glycation and acetylation role in aspirin treatment 
failure  
In diabetes, increased glycation of platelets and coagulation proteins glycation 
may interfere with the acetylation process by aspirin (Rendell et al., 1986, 
Swamy-Mruthinti and Carter, 1999, Watala et al., 2005). Watala and his group 
have shown that in animal models of streptozotocin-induced diabetes platelet 
response to aspirin is blunted compared with non-diabetic animals, likely to be 
related to documented reduced acetylation of platelet protein (Watala et al., 
2006). Given the concept of competition between glycation and acetylation in 
diabetes, it is valuable to analyse whether glycaemic control or increased 
aspirin dose enhance the efficacy of aspirin (Watala et al., 2004, Takahashi et 
al., 2007). Using optical platelet aggregation and platelet function analyzer 
(PFA)-100 techniques, Gum and colleagues found no differences in biochemical 
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aspirin resistance comparing individuals with and without diabetes with higher 
doses of 325 mg/day aspirin (Gum et al., 2001). 
1.8.7 Increased platelet turnover role in aspirin treatment failure  
In patients with diabetes, an increase in platelet turnover is represented by an 
increase in circulating reticulated platelets, which are more sensitive to 
activation (Guthikonda et al., 2008). Pharmacokinetic studies have shown that 
plasma concentration of aspirin after 80 mg/day oral dose reaches 1ug/ml after 
30 minutes and declines rapidly witha terminal half-life of 0.4 hrs. Salicylic acid 
(SA), the aspirin metabolite,forms rapidly and peaks at ~4ug/ml within 
approximately 1hr with a terminal half-life of 2.1 hrs (Benedek et al., 1995). 
Given this relatively short half-life of aspirin and the documented increase in 
platelet turn-over in diabetes, some platelets may “escape” inhibition by aspirin 
over 24 hours. This concept is gaining momentum as a mechanistic explanation 
for the reduced clinical efficacy of aspirin in diabetes (Guthikonda et al., 2007). 
1.8.8 Possible compromised fibrinolytic effects 
As explained above, enhanced fibrinolysis by aspirin represents a non-platelet 
pathway for the antithrombotic action of this agent (He et al., 2001). It is 
possible that interaction between acetylation and glycation impairs the 
fibrinolytic effects of aspirin in diabetes, which may contribute to the reduced 
clinical efficacy. However, there is a lack of studies investigating this possibility.  
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1.9 Hypothesis and Aims  
Although aspirin was previously recommended for primary cardiovascular 
protection in diabetes, this is not the case anymore due to the reasons outlined 
above. However, aspirin remains in use for secondary cardiovascular 
protection, although its efficacy in diabetes is questioned (Cubbon et al., 2008). 
Taken together, the antithrombotic effects of aspirin in diabetes appear to be 
significantly diminished. Several hypotheses have been forward to explain the 
reduced efficacy of this agent in diabetes, but no concrete conclusions have 
been made. Therefore, there is a need to better understand the mechanisms for 
this phenomenon, which will help to clinically tailor therapy thereby maximising 
benefits and reducing the risks associated with antiplatelet therapy.  
Hypothesis 
The reduced clinical efficacy of aspirin in diabetes is related to a compromise in 
the effects of this agent on both the cellular and fluid phase of coagulation, 
secondary to long term hyperglycaemia and increased protein glycation. 
 Aims of the project 
The main aims of the project were to investigate the molecular basis for variable 
response to aspirin treatment failure in diabetes, which will hopefully help to 
identify those at risk and tailor therapy according to the need of each indevidual. 
Therefore, the main aim of this work was to investigate the ex vivo effects of 
aspirin on platelet function and on fibrin clot lysis in individuals with and without 
diabetes in the presence and absence of excess glucose. Secondary aims were 
to: 
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1. Study the in vivo effects of aspirin on platelet function and fibrin clot lysis 
in individuals with and without diabetes. 
2.  Investigate the effects of ex vivo and in vivo aspirin on platelet-fibrinogen 
interaction in individuals with and without diabetes.  
.   
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Chapter 2 
General Methods 
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2.1 Sample collection and preparation 
2.1.1 Patient recruitment 
Blood samples from healthy donors were used to optimise the various 
experiments. Samples were then taken from patients with type 1 diabetes 
(T1DM) and sex/age-matched healthy controls after informed consent, see 
appendix.T1DM patients were chosen for the study rather than T2DM patients 
as the latter group represents a heterogeneous population of patients who are 
likely to be on a number of different treatments, thereby introducing confounding 
factors, making data analysis and interpretation problematic. Our T1DM patients 
were only on insulin treatment. A total of 29 T1DM patients and 29 controls 
were recruited after informed consent. 
Exclusion criteria include: a history of acute coronary syndrome or stroke within 
3 months of enrolment, prior treatment with aspirin, clopidogrel, warfarin or non-
steroidal anti-inflammatory drugs, current treatment with any drug other than 
insulin, a history of deep venous thrombosis or pulmonary embolism, previous 
or current history of upper gastrointestinal pathology, malignancy or coagulation 
disorders.  Any individual with abnormal LFTs (ALT>3 fold upper limit of normal) 
or abnormal TFTs are not included in the study. Finally, patients with 
proteinuria, advanced nephropathy, clinical signs of neuropathy or retinopathy 
(except for those with background changes) are excluded, to minimise the 
effects of confounding factors. 
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2.1.2 Sample collection and preparation 
Blood samples were taken in the morning after a light breakfast, without a 
tourniquet. The first 5 ml of blood sample was used for clinical tests and the rest 
was collected for platelet experiments or to separate plasma samples. Samples 
were collected in tubes contain hirudin anticoagulant (Canyon, USA) for platelet 
aggregation test using platelet rich plasma light transimssionaggregometry and  
hirudin (Multiplate™, Germany) for platelet aggregation test using whole blood. 
For plasma fibrin clot analysis (turbidity analysis, scanning electron microscopy 
and confocal microscopy Images) blood was collected in tubes containing 
sodium citrate (Sigma). For plasma fibrinogen purification, blood samples were 
collected in lithium heparin tubes (Greiner, USA). For platelet fibrinogen 
interaction test, I tested binding of fibrinogen purified from patients and controls 
to platelets of healthy individuals collected in citrated dextrose tubes (Sigma). 
Citrate-based anticoagulants prevent the coagulation of blood by virtue of the 
citrate ion's ability to chelate ionized calcium present in the blood to form a non-
ionized calcium-citrate complex. To investigate the ex vivo effects of glucose 
and aspirin [acetylsalicylic acid (ASA)]on platelet activity, tubes were prepared 
with 0 mg, 1 mg/l and 10 mg/l aspirin in the presence and absence of additional 
20 mmol/l glucose. Samples were then incubated at 37°C for 15 minutes and 
then at RT for 15 minutes followed by the analysis of platelets activity in whole 
blood (Multiplate). For in vivo effect of aspirin on platelet activity using whole 
blood analysis, samples were collected at different visits (A, B, C, D) according 
the treatment plan, which will be discussed later and the test was done in the 
lab immediately after receiving the sample. 
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To investigate the ex vivo effects of glucose and aspirin on fibrin clot, whole 
blood was incubated with different concentration of aspirin (0, 1 and 10 mg/l) 
with and without extra glucose (20 mmol/l) for 30 minutes at 37°C and 30 
minutes at RT, followed by separation of platelet poor plasma (PPP) that was 
aliquoted and stored at -80°C until analysis. To study the in vivo effects of 
aspirin on platelet function and fibrin clot structure, patients were randomised to 
75 mg/d or 300 mg/d ASA for a period of 2 weeks with 3 weeks wash out period 
between the two treatments.Samples were collected at four different visits as 
detailed : In the first visit (visit A), no treatment was given; in the second visit 
(visit B), first half of the patients and controls were given 75 mg/day aspirin and 
the second half were given 300 mg/day aspirin for two weeks followed by three 
weeks wash out and sample collected in the third visit (Visit C). In the fourth 
visit  (visit D), the first half of patients and controls were given 300 mg/day 
aspirin and the second half were given 75 mg/day for two weeks (i.e. cross-over 
study design). For fibrinogen purification, samples were collected in lithium 
heparin, PPP separated and stored at -80°C until analysis Sample collection, 
preparation and analysis is summarised in (Figure 2.1). 
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Figure 2.1 Sample collection, preparation and analysis. For platelet aggregation 
tests using whole blood, samples were collected in hirudin. For ex vivo studies, 
different concentrations of aspirin were added with and without  additional glucose to 
whole blood. Platelet aggregations tests were performed using platelet rich plasma 
(PRP) as well as whole blood. Platelet fibrinogen binding assays, samples were 
collected in lithium heparin followed by fibrinogen purification and incubation with 
different concentrations of aspirin.  In clot structure analysis, samples were collected in 
sodium citrate followed by incubation with different concentration of aspirin with and 
without extra glucose and clots developed from PPP were analysed. In testing the in 
vivo effect of aspirin, samples were collected from different visits (A-D). 
2.1.3 Sample size calculation  
Using previous data on platelet inhibition by aspirin treatment in patients with 
diabetes (Watala 2004 and 2005), a group size of n=26 is sufficient to detect a 
15% difference in platelet activation, following arachidonic acid stimulation, 
comparing diabetes patients with controls, with a power of 80% (at p=0.05). 
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This is based on the assumption that within patient standard deviation of the 
response variable is 13%. This number of individuals is adequate to detect a 
12% difference in turbidity analysis in response to antiplatelet agents with a 
power of 80% at p=0.05, based on the assumption that standard deviation for 
the response variable within patients is 10% as per our own data in 40 patients 
with type 1 diabetes.  This number is also adequate to detect 14% difference in 
clot lysis time given the standard deviation of the response variable at 12% with 
a power of 80% (p<0.05). Power was calculated using approved online software 
(http://hedwig.mgh.harvard.edu/sample_size/js/js_parallel_quant.html) and it 
was double checked by a statistician. This software was developed by David 
Schoenfeld, Ph.D. with support from the MGH Mallinckrodt General Clinical 
Research Centre Massachusetts General Hospital, Boston.  
Given these power calculations, the study is designed to test 30 patients to 
account for a drop out of 15%. Within group analysis will be carried out using 
paired t-test and between group analysis of mean changes in response to 
antiplatelet agents will be done using unpaired t-test for normally distributed 
data and the non-parametric Mann-Whitney test will be used for data that are 
not normally distributed. 
2.2 Platelet aggregation 
2.2.1 Platelet aggregation using light transmission aggregometry (LTA) 
After incubation of blood samples for various time points with aspirin (Sigma), 
hirudin anticoagulated blood tubes were centrifuged for 10minutes at 200 rpm 
and 23⁰C. Platelet rich plasma (PRP) was separated to be tested then the 
remaining red cell layer was centrifuged for 20 minutes at 1500 rpm and 23⁰C. 
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500µl of the upper layer “platelet poor plasma” PPP was pipetted into glass tube 
and set as a baseline for the test. At 37°C, 240 µl of  PRP was pipetted into 
glass tubes containing stir bars where 10 µl of one of the agonists: 10 µmol/l 
and 1 µmol/l ADP (Sigma), 1 mM AA (Chronolog) or 16 ug/ml collagen 
(Nycomed) was added and platelet aggregation recorded using LTAaccording 
to the standard operation protocol. The glass tube sits between a light source 
and a photocell. When an agonist is added the platelets aggregate and absorb 
less light and so the transmission increases and this is detected by the 
photocell and recorded as arbitrary Units (AU). 
2.2.2 Platelet aggregation of blood using Multiplate 
Aggregation of platelet collected in hirudin anticoagulated blood tube was 
performed within 90 mins of blood collection in case of testing the in vivo effects 
of aspirin. For ex vivo experiments, the test was conducted immediately after 
incubation with different concentrations of aspirin for the required period. The 
test was performed using Multiplate™. The response of platelet to different 
agonists was tested by adding 300 µl of pre-warmed 0.9% NaCl solution 
followed by adding 300 µl blood. After 3 minutes incubation time,, 20 µl of one 
of agonists, 6.4 μM ADP, 0.5 mM ASP or 3.2 μg/ml collagen (Multiplate) was 
added. When platelets aggregate, they accumulate on the electrodes and 
change the electrical resistance (or impedance). The change in resistance 
during the analysis is continuously recorded. The Multiplate®-system records a 
double determination that gives the average of two different readings recorded 
in Aggregation Unit (AU) (Figure 2.2) 
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Figure 2.2 Example of the platelet aggregation analysis (Multiplate technique).  I 
demonstrate platelet aggregationtest of one patientin response to aracidonic after in 
vivo treatment with 300 mg/day for two weeks. X axis represents time (S), Y axis 
represents aggregation unit (AU). Two readings are recoreded in the same time, 
redline and blue line. The final reading is the the verage between the two readings. 
2.3 Fibrinogen purification 
Purification of fibrinogen was performed by affinity chromatography using 
calcium-dependent IF-1 monoclonal antibody (Biomedical, Seattle, WA, USA) 
employing an automated chromatography system (Biocad sprint, Applied 
Biosystems Warrington, UK). One ml of heparinised plasma was mixed with 4 
ml of equilibration buffer (0.02 M Tris, 0.3 NaCl and 1 mM CaCl2, pH 7.4) and 
then filtered by a syringe driven filter unit (Millipore, Bedford, MA, USA) prior to 
loading onto the column. After sample application, the column underwent 
washing using 6 column volumes (CV) of 0.02 M Tris,1M NaCl,1 mM CaCl2 pH 
7.4 and 0.05 Na-acetate, 0.3 NaCl,1 mM CaCl2, pH 6. Elution of fibrinogen was 
achieved by adding 6 CV of 20 mmol/LTris, 300 mmol/LNaCl, 5 
mmol/Lethylenediaminetetraacetic acid (EDTA), pH 7.4 to the column. The 
chromatograph produced was used to estimate a peak of fibrinogen eluted. 
Serial tubes of elutant were tested using spectrophotometry by a ND-100 
spectrophotometer (NanoDrop, Wilmington, DE USA), extinction coefficient 
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15.1. All those fragments with a protein concentration >0.05mg/ml were pooled 
and stored at -80°C. 
2.3.1 Fibrinogen concentration 
The eluted fibrinogen was pooled and centrifuged using Amicon Centriplus YM-
100 regenerated cellulose centrifugal devices (Millipore, Bedford, MA, USA) for 
1 hr at 3000 rpm at 25ºC until the volume in the filter reach 1ml. 
2.3.2 Fibrinogen dialysis  
Dialysis tubing (Sigma-Aldrich, St Loius, MO, USA) was prepared by boiling the 
tubing in 1 M EDTA. Pooled fibrinogen was dialysed via dialysis tubing cellulose 
membrane, size 10x6 mm  against 50 mmol-1 Tris, 100 mmol-1 NaClpH 7.4 at 
4ºC for 2 consecutive hrs and overnight with stirring (50rpm). Subsequently, the 
concentration of the protein was adjusted using a ND-1000 spectrophotometer 
and a coefficient ofE = 15.1 
2.3.3 Integrity of fibrinogen samples (SDS page) 
The integrity of all samples was checked using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Each sample (21 μl) was 
mixed with 7 μl 4 x LDS sample buffer (Invitrogen, Carlshad, CA USA) and 3 μl 
10x sample reducing agent (Invitrogen, Carlshad, CA USA). The mixture were 
then reduced at 95ºC for 10 minutes to break the disulphide bonds and ran on a 
4-12% Bis-Tris gradient gel, 1.5 mm x 10 well (Invitrogen, Carlshad, CA USA) 
using 20x MES SDS running buffer (Invitrogen, Carlshad, CA USA). 
Gels were then stained using GelCode blue stain reagent (Pierce, Rockport, IL, 
USA) for 1 hour and subsequently washed with distilled water three times for 2 
62 
 
consecutive hours. and overnight. The gel was visualised using Chemi-imager 
software (Alpha Innotech, San Leandro, CA, USA) using a trans-white light. 
Three bands were expected (for the α, β, and γ chains of fibrinogen), and 
correct sizes verified using an appropriate ladder (66, 65 and 48 KDa 
respectively) as shown in Figure 2.2. Once the integrity and purity of the protein 
had been confirmed, the samples were aliquoted in 50-100 μl aliquots and 
stored at -80°C for further analysis. 
2.4 Fibrinogen acetylation analysis  
2.4.1 Materials  
Buffers and reagents were prepared as follows: 1×TBS buffer was composed of 
25 mM Tris base, 150 mM NaCl, 2 mM KCl at pH 7.4. 1×TBS Tween 20 was 
prepared by mixing 100 ml TBS with 50µl Tween 20.Blocking bufferwas 
prepared by adding 5 g milk powder (Marvel, Republic of Ireland, Dublin). 
Transfer buffer was made by adding 6.06 g Tris, 28.84 g Glycine, 400 ml 
methanol (Sigma) to 2 L distilled H2O and pH 8.1-8.4. The buffer was stored at 
4°c until use. Gels used were 4-12% Bis Tris (Invitrogen), NuPAGE SDS 
running buffer (20x) (Invitrogen). 
2.4.2 Sample preparation 
In order to determine which chain of fibrinogen is acetylated, pooled protein 
from patients or controls were incubated ex vivo with different concentrations of 
aspirin 0, 10 mg/l and samples that blotted using an antibody against 
acetylated-lysine residues (Cell signaling technology). 
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2.4.3 Running the gel  
25 µl samples + 8.3 µl NuPAGE SDS sample buffer (Invitrogen) + 3.4 µl 
NuPAGE sample reducing agent (Invitrogen) were mixed and then heated for 5 
minutes at 95°C. 15 ul of sample was loaded per well to a 4-12% Bis Tris gel 
(Invitrogen) and run for 45 minutes at 200V. Ladder used was low range BioRad 
161-0306. 
After electrophoresis, the gel was removed from the plastic casing and placed in 
transfer buffer until use. An appropriate sized membrane (pore size 0.45uM 
immobilon-P) was cut and activated by soaking in methanol for 15 seconds, 
distilled water for 2 minutes then in transfer buffer until use. The membrane was 
placed directly over the gel inbetween2 pieces of filter paper (pre-soaked in 
transfer buffer) and transferred for 1 hour at 100V.  
The membrane was then removed and blocked for 1 hour at RT on a shaker. 
The blocker was then removed and replaced with primary antibody (for PT 
1:1000 dilution, 10 ml) and then left in thefridge overnight. The primary antibody 
was Acetylated-lysine Antibody (cell Signalling, USA) which detects proteins 
posttranslationally modified by acetylation on the epsilon-amine groups of lysine 
residues. The membrane was then washed in TBS-T, 1x15 minutes and 2x5 
minutes. The secondary antibody was added (anti-mouse IgG 1:4000) and the 
membrane was placed on a shaker for 1hour at room temperature and then 
washed as above. 
2.4.4 Radioactive aspirin and fibrinogen 
This work was led by a member of the team (Dr. Alzahrani), and my main role 
was to help conducting the experiments.  A total of 25 µl of acetyl-1-
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[14C]salicylic acid ([14C]ASA or ([14C]aspirin), specific activity 55 Mci/mmol) 
supplied in from the American Radiolabeled Chemicals, St Louis, USA) was 
added to 25 µl of human purified fibrinogen from diabetes subjects or controls 
(at 0.5mg/ml). Aspirin labelled with 14C at the carboxyl group was used as a 
negative control. The mixture was then incubated overnight in a water bath at 
37°C. Subsequently, radiolabelled fibrinogen was run on NuPage (4-12%) Bis-
Tris Gel (Invitrogen) slowly over 210 minutes to allow enough time for 
separation of fibrinogen chains, which were subsequently cut out separately. 
Gel pieces were then mixed with 12.5 ml of aqueous counting scintillant which 
contains Xylene and methanol (Amersham Bioscience UK). Finally, radioactivity 
was counted in disintegrations per minute using a liquid scintillation analyser 
(Tri-Carb 2800TR). 
2.5 Fibrin structure 
2.5.1 Fibrin clot turbidity and lysis (Clot formation test) 
Clot turbidity measurements were conducted as described by Carter (Carter et 
al., 2007). Briefly, for turbidity measurements, plasma samples were thawed in 
a water bath at a temperature of 37° for 30 minutes. Tubes were vortexed and 
spun down for 30 seconds and then 25 μl of each sample was added to a 96 
well Greiner plate (in duplicate). A total of 75 µl of assay buffer (0.05 mol/lTris-
HCl, 0.1 mol/ NaCl, pH 7.4) was added to each well using multi-channel pipette. 
50 µl of activation mix containing assay buffer, 0.0075 U/ml thrombin 
(Calbiochem) and 7.5 mmol/l CaCl2was added to each well using multi-channel 
pipette at an interval of 10 seconds. The plates were shaken and read at 340 
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nm every 12 sec for 1 hr using ELX-808 IU ultramicroplate reader (BIO-TEK 
Instruments).  
2.5.2 Clot formation and lysis test (turbidity and lysis) 
In clot formation and lysis, plasma samples were thawed in a water bath at a 
temperature of 37° for 30 minutes. Tubes were vortexed and spun down for 30 
seconds. 25 µl of plasma was added in a 96 well clear polystyreneflate bottom 
microplate (Grenier Bio-one, Gloucester, UK). Each sample was tested in 
duplicates, to ensure reproducibility and any variability that exceeds 10% was 
repeated. A total of 75 µl lysis mix (LM) containing (0.05 M Tris and 0.1 M NaCl 
and 2.4 nM tissue plasminogen activator, tPA; Technoclone, Vienna, Austeria) 
was added to each well using multi-channel pipette (Finnpipette Thermo 
scientific) at an interval of 10 seconds. The time of adding the lysis mix was 
recorded to adjust plate reader times to the start of the clot formation. Three 
minutes after adding the lysis mix to the first column, polymerisation and lysis 
were initiated by the addition of 50 µl activation mix, composed of 0.05 M Tris, 
0.1M NaCl, and 0.09U/mlthrombin (Calbiochem, Nottingham, UK) and 22.5 mM 
CaCl2 was then added using multichannel pipette at an interval of 10 seconds 
between each column. The plates were shaken and read in 32°C condition at 
340 nm every 12 sec for 1 hour for clot formation and then every 2 minsfor up to 
9 hrs for lysis time using ELx-808 IU ultramicroplate reader (BIO-TEK 
Instruments INC,Winooski, VT, USA). In analysing the in vivo effect of aspirin 
on plasma clot, a special software application was used that provides several 
clot structure parameters and the following variables that represent the average 
of two readings were recorded (Figure 2.3, 2.4). For purified fibrinogen 
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experiments, data were analysed manually as the software is not designed to 
handle these data.  
 
 
 
Figure 2.3 Different parameters used in the turbidimetric analysis are 
summarised (LTA technique). I represents turbidity analysis, whereas II 
demonstrates turbidity and lyses. A: lag phase.  B: rate of clot formation. C: maximum 
turbidity (absorbance).D: time from clot formation to 50% lysis. E: time from full clot 
formation to 50% lysis. F: rate of clot lysis (Figure kindly provided by my supervisor). 
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Figure 2.4 Example of the turbidimetric analysis of optimisation experiment (LTA 
technique).  I demonstrate turbidity and lyses analysis of experiment that used to 
optimise the effective ex vivo concentration of aspirin 0,1,10,100 mg/l incubated for 30 
minutes. X axis represents time (S), Y axis represents optical density. 
2.5.3 Clot formation and lysis test using purified fibrinogen 
In this assay, turbidity and lysis of fibrin clot developed from a pool of purified 
fibrinogen from subjects with diabetes and a pool of purified fibrinogen from 
control subjects were used. 50 µl of purified fibrinogen at 0.6 mg/ml was mixed 
with 50µl LM, containing 0.2 µM plasminogen (Enzyme Research Laboratories, 
Swansea, UK) in 0.1 M NaCl, 0.05 M Tris, pH 7.4 (permeation buffer [PB]), in a 
Greiner 96 well clear polysteren flat bottom microplate in duplicate. To ensure 
adequate crosslinking, 5µl of FXIII (20µg/ml, 1.56 nM) was added. 
Polymerisation and lysis were initiated by the addition of 50 µl AM containing 
0.37 U/ml thrombin, 3.3 nM tPA and 7.5 mM CaCl2 in 0.1 M NaCl, 0.05 M Tris, 
pH 7.4. Increase in turbidity at 340 nm was continuously monitored every 12 
seconds on ELx-808 IU ultramicroplate reader over a period of 60 minutes.  
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2.6 Clot image analysis by microscopy (laser scanning confocal microscopy, 
LSCM) 
Confocal microscopy was used to visualise the architecture of hydrated clots 
and to study lysis of mature fibrin networks. In contrast to scanning electron 
microscopy, samples do not need fixing and dehydration, and therefore they are 
viewed in a more physiological status.  
2.6.1 Sample preparation for LSCM (plasma fibrin clots) 
For confocal image of plasma fibrin clots, preparation was made as follows: 7.5 
µl of plasma was mixed with 63.2 µl PB (50 mmol/l Tris and 100 mmol-1 NaCl 
and pH 7.4) followed by the addition of 0.036 mg ml-1 fluorescent labelled 
fibrinogen (Alexa 488; Invitrogen, Manchester, UK). Activation mixture (AM), 
containing 0.035 M CaCl2 (final concentration 5 mmol/l), human thrombin 
(Calbiochem, final concentration 0.35 u/ml)and 63.2 µl permeation buffer was 
prepared. 5 µl of this (AM) was added to 30 µl Alexa stained plasma. Then 
immediately, the resulting mixture was pipetted into ibidi slides (Applied 
Biophysics, New York, USA). 
2.6.2 Sample preparations for LSCM (purified fibrinogen clots) 
For confocal image of fibrin clot produced from purified fibrinogen, 19.5 µl of 
control fibrinogen was added to 9.5 µl permeation buffer followed by adding 
0.036mg ml-1fluorescent labelled fibrinogen. Activation mix (AM) was prepared 
by ading4.9µg/mlfactor XIII,5 mmol/l CaCl2 and 0.05 U/ml thrombin to 61.2 µl 
permeation buffer. 5 µl of this (AM) was added to the Alexa stained fibrinogen. 
Then immediately, the fibrinogen pipetted into the Ibidi slides, which was 
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subsequently kept in a humidified environment to preserve the hydrated clot 
until viewing by confocal microscope (LSM 510 META microscope from Carl 
Zeiss; UK) 
2.7 Imaging fluorescent samples 
Images were viewed under 40×/1.3 oil ph3 objective lens. Z-stacks images were 
captured at 20 µm intervals for 10 images (2 µm intervals for each image). The 
scan format was 512×512 pixels and the pinhole set to 90 µm.  
2.7.1 LSCM clot lysis 
To monitor clot lysis, time series function was used with 400 scans with 1 
second between scans. 20 µl of lysis mix, composed of 2 µl tissue plasminogen 
activator (10 µg/ml), 2 µl plasminogen (0.1mg/ml) and  permeation buffer (50 
mmol/l Tris and 100 mmol-1 NaCl and pH 7.4), was added to the edge of the clot 
and the slide tapped gently for 30 seconds to encourage the lysis mix into the 
clot channel. The slide was then left for 3 minutes in a vertical position before 
loading onto the stage and clot visualisation. After 3minutes, lysis was 
monitored and recorded using LSM image browser (Zeiss).      
2.7.2 Scanning electron microscopy 
Although scanning electron microscopy requires clot manipulation (fixing and 
dehydration) it remains the best technique to investigate fibrin network 
ultrastructure.  
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Clot preparation 
A lid from 0.5 ml Eppendorf tube was cut off and pierced with needle several 
times before covering the bottom of the lid with parafilm in order to cover the 
holes. For plasma clots, 50 µl of plasma was diluted 1:2 with PB and 5 µl AM 
(0.05 M CaCl2, 11 U/ml thrombin in PB) added. Thiswas mixed with a 200 µl tip 
that had the end removed to ensure even distribution of the AM. For purified 
fibrinogen clots, 45 µl of fibrinogen (0.5 mg/ml) was mixed with 5 µl of AM 
(0.025 M CaCl2, 5 U/ml thrombin in PB). The clots were left to form in the lid for 
2 hours in a humidified chamber. 
Fixing and dehydration 
After removing the parafilm, the clots were washed by placing the lids 
containing the clots in a beaker of sodium cacodylate buffer (0.078 M Cacodylic 
acid (Sigma), pH 7.4) for 10 minutes, which was then replaced with fresh buffer 
and left for a further 10 minutes. The clots were then fixed by transferring the 
lids to 2% Glutaraldehyde (Sigma) in sodium cacodylate buffer for 30 minutes 
followed by washing steps as above. Once fixed, the clots were dehydrated by 
placing them in acetone at increasing concentrations, 30%, 50%, 70%, 80%, 
90% and 95% for 10 minutes each, after which they were transferred to 100% 
acetone 3 times for 10 minutes. 
Critical point drying  
I was unable to perform critical point drying (CPD) which was carried out by 
Martin Fuller at the University of Leeds using a E3000 critical point dryer 
(Quorum Technologies Ltd, UK). This involves dehydrating the fibrin clot in 
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order for it to be coated with platinum and be detected bythe EM. It is crucial not 
to disturb the surface of the fibrin network during the drying process as EM 
relies on analysing the surface morphology of biological specimens. Air drying 
is, therefore, unsuitable as it may lead to deformation and collapse of protein 
structures as water has high surface tension to air. As liquid in the sample 
evaporates, the specimen is subjected to large forces at the boundary between 
the water in the sample and surrounding air. By replacing the water in the 
sample with liquid CO2, this surface tension is reduced, and the surface tension 
between the liquid in the sample and surrounding air is progressively lowered. 
Liquid CO2 then passes from liquid to gas witoutan abrupt change in state and 
avoids damaging the surface of the sample. 
Sputter coating 
In order to prevent the clots from charging under the electron beam, the 
samples were covered with a thin layer of conducting metal. The clots were 
mountedonto aluminium specimen mounts that were covered in a carbon film. 
They were then coated with a 7 nm thick layer of platinum applied in 208 HR 
high resolution sputter coater (Cressington, UK). 
Sample imaging 
Samples were viewed and photographed using a Quanta 200F FEGESEM field-
emission scanning electron microscope (FEI, Oregon, USA) in 10 different 
areas of each clot, at themagnification (x10000). Images were captured using 
FEI’s own software, designed to run with the EM. Fiber diameters of all clots 
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were determined using image analysis software package ImageJ 1,23y (Ajjan et 
al., 2009). 
2.8 Platelet-fibrinogen interaction studies 
Platelet–fibrinogen interaction measurement was based on the methods for 
measurement of platelet adhesion in microtiter plates technique (Bellavite, 
1993, Oberprieler et al., 2007).  
2.8.1 Static platelet-fibrinogen interaction 
100 µl of 1 mg/ml fibrinogen (Calbiochem) was added to each well of microtiter 
plate (Greiner) for at least 24 hrs at 4°C before performing the test. Ten ml 
blood tube with 10% ACD anticoagulant (113.8 mM D-Glucose, 29.9 mMTris-Na 
citrate, 72.6 mM NaCl, 2.9 citric acid pH 6.4) was centrifuged at 900 rpm at 
20°C for 20 mins. PRP was then transferred into a falcon tube and 50 ng/ml 
final concentration of prostaglandin E1 “PG E1” (Sigma) was added followed by 
centrifugation at 1900 rpm 20°C for 12 minutes. The supernatant consisting of 
PPP was then removed and tube was left to drain. One ml of modified tyrode’s 
buffer MTB which consists of (15 mM NaCl, 5 mM HEPES, 0.55 mM NaH2PO4, 
7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM D-Glucose anhydrous, pH 
7.4) was added to platelet pellet. Manual platelet count “according to manual 
platelet count protocol” was performed and the platelet pellet solution was 
titrated with MTB to reach 1×108 platelet/ml final pellet concentration. Platelet 
suspension was left for 1 hr to be recovered from PGE1 followed by incubation 
with 200 µM RGDS (Tocris) for 20 minutes in 37°C. Meanwhile, fibrinogen was 
washed from the wells by PBS followed by blocking uncovered plastic surface 
with 5% human serum for 30 min at room temperature. After a washing step, 
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100 µl of platelet suspension was added to each well and incubated for 1 hr. 
Wells were washed and 150 µl of citrate buffer added [containing 29 mM citric 
acid, 68 mM sodium citrate dehydrate, 5 mM p-nitrophenyl phosphate (Sigma) 
and 0.1%Triton×100 (Sigma) pH 5.4]. After 1 hr incubation, 100 µl of 2M NaOH 
was added to stop the reaction and wells were read at 405 nm using 
ultramicroplate reader. 
2.8.2 Flow cytometry  
Flow cytometry experiments require fibrinogen to be fluorescently labelled and 
similar concentration used to test for binding to platelets.  
Labelling of fibrinogen 
A buffer free of ammonium ions or primary amines is essential in order to 
successfully undertake the labelling process and to avoid competition with the 
amine groups of the buffer with the reactive dye.  Purified fibrinogen was 
therefore dialysed by slide-A-Lyzer MINI Dialysis Devise (Thermo Scientific, 
Loughborough, UK) in a beaker containing 1 L phosphate-buffered saline 
(PBS). 
After dialysis of fibrinogen, the protein was labelled using Alexa Fluor 647 
monoclonal antibody labelling kit (Invitrogen) as per manufacturer’s instructions. 
Briefly, 1 M solution of sodium bicarbonate (pH 8-9) was prepared by adding 1 
ml of deionised water (dH2O) to the provided vial of sodium bicarbonate. To 
raise the pH of the reaction mixture, 1/10th volume of 1 M sodium bicarbonate 
buffer was added to fibrinogen solution. Subsequently, 100 µl of the fibrinogen 
solution, with concentrations ranging between 0.5-0.6mg/ml was added to the 
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reactive dye then capped and gently inverted a few times to fully dissolve the 
dye. The solution was then incubated for 1 hour at room temperature. The vial 
was gently inverted every 10-15 minutes several times to mix the two reactants 
and increase the labelling efficiency. During the incubation period, the spin 
column for the purification was prepared by stirring the purification resin. One ml 
was addedonto the column and allowed to settle by gravity. More of the 
suspension was added until the resin bed volume reached ~1.5 ml. The column 
buffer was allowed to drain by gravity. To elute first drops of buffer, the spin 
column was put in one of the collection tubes and centrifuged for 3 minutes at 
1100×g. The 100µl reaction solution (labelled fibrinogen after 1hr incubation) 
was loaded drop wise onto the centre of the spin column. The solution was 
allowed to be absorbed into the resin bed. The spin column was then placed 
into empty collection tube and centrifuged for 5 minutes at 1100×g. After 
centrifugation, the collection tube contained labelled fibrinogen in approximately 
100 µl of PBS, pH 7.2 with 2 mM sodium azide. Free dye remained in the 
column bed and was not eluted.  
Measuring fibrinogen concentration 
Protein concentration was estimated three times using the NanoDrop. The 
labelled fibrinogen was then stored at -20° C and protected from light. 
Human blood was taken from healthy volunteers by clean venepuncture into 
acid citrate dextrose (29.9 mM sodium citrate, 113.8 mM glucose, 72.6mM 
sodium chloride and 2.9mM citric acid, pH 6.4) as anticoagulant in a ratio of 1:5 
(vol:vol).In 3 ml tubes, 5 μl of blood from the healthy donor was added to 50 μl 
modified tyrode’s buffer (MTB) which consists of (15 mM NaCl, 5 mM HEPES, 
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0.55 mM NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM D-
glucose anhydrous, pH 7.4) solution containing 50 μg/ml final concentration of 
labelled fibrinogen from each sample (it was prepared according to labelled 
fibrinogen concentration readings, as mentioned in Table 2-1). A total of 2μl of 
FITC mouse CD42b antibodies was added to platelet detection tubes. To stop 
αIIbβ3 receptors from binding to fibrinogen, 2 μl of ethylene glycol tetra-acetic 
acid (EGTA, 100 mM) was added to a tube to provide a negative control for 
fibrinogen binding (final concentration of EGTA was 4mM). The tubes were then 
flicked gently three times and fibrinogen negative control was left for two 
minutes. This was followed by the addition of 5 µl ADP to each tube at a final 
concentration of 4 uM in a timing step. After exactly 10 minutes, the reaction 
was fixed with 0.5 ml of 0.2% formal saline (See table 2-2). The samples were 
then kept at 4°c for 20 minutes before undertaking the analysis.  
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Sample                     
(aspirin/glucose) 
Fibrinogen 
concentration 
(mg/ml) 
Sample 
volume 
to be added 
Permeation 
buffer volume 
Ul 
Control 0.26 9.6 40.4 
Control+aspirin 0.22 11.4 38.6 
Control+glucose 0.22 11.4 38.6 
Control+glucose+aspirin 0.20 12.5 37.5 
Patient+0mg 0.24 10.4 39.6 
Patient+10mg 0.25 10 40 
Patient+glucose 0.24 10.4 39.6 
Patient+g+10 0.24 10.4 39.6 
Control+75mg 0.45 5.6 44.4 
Control+300mg 0.39 6.4 43.6 
Patient+75 0.41 6.1 43.9 
Patient+300 0.53 4.7 45.3 
Table 2.1 Volume of labelled fibrinogen added to MTB solution to achieve a final 
fibrinogen concentration of 50 ug/ml. 
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Fibrinogen      
negative 
Platelet detection 
Sample 
Basal 
With 
ADP 
C/S + labelled 
fibrinogen 
50 ul at 50 ug/ml 
final concentration 
of fibrinogen 
50 ul of c/s only 50 ul 50 ul 
EGTA (100mM) 2 ul ××× ××× ××× 
FITC CD42b ××× 2 ul ×××  
Blood 5 ul 5 ul 5 ul 5 ul 
ADP (100uM) (in 
timing process) 
××× ××× ××× 5ul 
F/Saline (after 10 
min) 
0.5 ml 0.5 ml 0.5 ml 0.5 ml 
Table 2.2 Steps undertaken for conducting flow cytometry experiments of 
labelled fibrinogen. 
Running flowcytometry test 
Measurement of the binding of labelled fibrinogen with platelets was carried out 
by single-colour analysis. Platelets were identified on the basis of their forward 
scatter (FS) and side scatter (SS) and then analysed for binding with APC 
labelled fibrinogen. To exclude readings of platelet-fibrinogen binding using 
receptors other than αIIbβ3, tubes containing blood, fibrinogen and EGTA 
inhibitor αIIbβ3 were run and the population was determined. To exclude false 
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autofluorescence coming from platelets and to determine platelet populations, 
tubes containing blood and CD42b were run and the fluorescence was 
determined. On the plot of FS and SS, a gate was drawn around the platelet 
population. Ten thousand platelet events were collected and a histogram of 
fluorescence gated on the platelet region was drawn. Results are presented as 
percentage of fluorescent platelets as well as median fluorescence for each 
sample. 
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Chapter 3 
Effects of glycation and blood glucose levels on 
platelet response to aspirin therapy 
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3.1 Introduction 
The efficacy of aspirin in diabetes is compromised but the exact mechanisms 
responsible remain largely unclear. The reasons for reduced efficacy of aspirin, 
often termed aspirin variable response, can perhaps be broadly categorised into 
pharmacodynamic and pharmacokinetic factors (Weber et al., 2002). 
Pharmacokinetic causes explore reasons for insufficient blood concentration of 
aspirin whereas, pharmacodynamic factors investigate incomplete suppression 
of platelet activity despite sufficient plasma drug levels (Benedek et al., 1995, 
Cerletti et al., 2003). Benedek et al 1995 have assessed the concentration of 
aspirin after 80 mg/day oral dose of aspirin within 0, 4 and 24 hrs of drug 
administration in healthy controls. The investigators found that plasma aspirin, 
or acetyl salicylic acid (ASA), concentration reached 1ug/ml after 30 minutes of 
drug administration and then started to decline rapidly withthe terminal half-life 
of 0.4 hrs. Salicylic acid (SA), the main ASA metabolite, was rapidly formed to 
reach ~4ug/ml within approximately 1hr and had a terminal half-life of 2.1 hrs. 
An interesting observation in this study was that pharmacokinetic and platelet 
aggregation sensitivity to aspirin showed noticeable intra- and inter-subject 
variability. This heterogeneity in aspirin concentration between different 
individuals, add to the complexity in unravelling the causes for the reduced 
efficacy of aspirin in high-risk vascular patients.  
Concentrating more specifically on patients with diabetes, previous work by 
Watala et al 2005 has shown a potential interaction between glycation and 
acetylation as a cause for the reduced clinical efficacy of aspirin in diabetes 
(Watala et al., 2005). However, this study was conducted in older individuals 
with type 2 diabetes, with various confounding factors, and therefore the 
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observed changes could not be attributed to glycaemia alone. For example, 
some patients were on insulin therapy, whereas others were on 
oralhypoglycaemiatherapy with metformin and/or sulfonylureas. Also, their 
cardiovascular history was unclear and the presence of microvascular 
complications was not documented. 
Therefore, studies that control for confounding factors are needed in order to 
understand the main mechanistic pathways responsible for the reduced efficacy 
of aspirin in diabetes. In order to address pharmacokinetic variability between 
individuals,  potential effects of co-morbidities and various treatments, my aims 
in this chapter were to: i) develop an ex vivo system to enable the analysis of 
similar aspirin concentrations on platelet reactivity in young individuals with type 
1 diabetes, not on any treatment other than replacement doses of insulin, ii)  
analyse the effects of high glucose concentration on platelet response to aspirin 
therapy in both groups, to differentiate between the effects of short and long-
term glycaemia, iii) complement the work with in vivo studies to understand the 
clinical validity of the ex vivo techniques. 
3.2 Materials and Methods 
3.2.1 Patients and controls 
For platelet aggregation experiment, a total of 25 T1DM patients and 26 
controls were collected. I was planning to collect 29 samples from patients and 
29 samples from controls but during the collection period and doing the 
experiment (which extended for two and half years). A total of 4 patients and 3 
controls were lost to follow up due to reasons related to inconvenient timing of 
the samples or pulling out of the study for personal reasons. Therefore, the 
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attrition rate was 13.7% and 10.3% for patients and controls, respectively. 
Patients were recruited from the local diabetes clinic whereas healthy controls 
who were friends of the patients, medical students or University of Leeds 
employees acted as controls. The criteria of patients and controls selection was 
detailed in section 2.1.1 
3.2.2 Sample collection 
Blood samples were taken in the morning after a light breakfast, without a 
tourniquet. The first 5 ml of blood sample was used for clinical tests and the rest 
was collected for platelet experiments or to separate plasma samples. Samples 
were collected in tubes contain hirudin anticoagulant (Canyon, USA) for platelet 
aggregation test using platelet rich plasma light transmission aggregometry, 
which used in optimisation experiments and  hirudin (Multiplate™, Germany) for 
platelet aggregation test using whole blood. 
3.2.3 Sample preparation 
To investigate the ex vivo effects of glucose and aspirin, tubes were prepared 
with 0 mg aspirin, 1 mg/l aspirin and 10 mg/l aspirin in the presence and 
absence of additional 20 mmole/L glucose. Samples were then incubated at 
37°C for 10 minutes and then at RT for 20 minutes before analysis. Analysis of 
platelet aggregation was done within 90 minutes as described previously. 
To investigate the in vivo effect of aspirin, blood samples were collected from 
both patients and healthy controls before giving aspirin (baseline). Then they 
were given 75mg aspirin daily dose for two weeks followed by collection of 
blood as detailed above. After a wash out period of three weeks, patients and 
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controls were given 300mg aspirin daily dose for two weeks followed by sample 
collection (Figure 3.1). 
3.2.4 Assessment of platelet reactivity 
After 30 minutes of incubation with aspirin, platelet aggregation in response to 
three agonists were analysed, which included arachidonic acid (AA), collagen 
and adenosine diphosphate (ADP). Details of the methodology are described in 
Chapter 2. 
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Methods  
Blood samples from diabetes(n=25) and 
healthy control subjects(n=26) 
(Collected in hirudin containing tube)
Platelet function testing in response to
(AA, Collagen, ADP)
Adding aspirin 
(0, 1 & 10 mg/l) 
With and Without excess 
glucose 
(20 mmol/l)  
10 min. incubation at 37°c 
and 20 min. Incubation at 
RT
Collect blood at baseline and 
after giving daily dose of 
75mg/day for two weeks 
and 300mg/day aspirin for 
two weeks
Platelet function testing in response to
(AA, Collagen, ADP)
Ex vivo
In vivo
Figure 3.1 Sample selection and preparation. For ex vivo experiment, blood 
samples from diabetes and controls were collected at baseline. Different 
concentrations of aspirin were then added to whole blood samples (0,1,10 mg/l), with 
and without additional glucose, and incubated for 30 minutes. This was followed by 
testing platelet aggregation in response to arachidonic acid (AA),collagen and ADP. 
For in vivo experiments, blood samples from diabetes and controls were collected 
before and after treatment with aspirin 75mg/day and 300mg/day (two weeks each with 
three weeks wash out period). This was followed by analysing platelet aggregation to 
AA, collagen and ADP was tested. 
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3.3 Results 
3.3.1 Patients and controls characteristics 
Analysis of all patients (n=29) and controls (29) profiles has been done as 
shown in table 3.1 
 Patients (n=29) Controls (n=29) 
Age 24±1.2 25 ± 1.3 
Gender male/female 16/13 15/14 
HbA1c 76 ± 3.6 37.4 ± 3 
systolic blood 
pressure(SBP) 
113 ± 2.4 114 ± 2 
Diastolic blood 
pressure(DBP) 
78 ± 2 76.8 ± 1.8 
Body mass index 
(BMI) 
24.9 ± 0.7 22.5 ± 1.3 
Weight 73.6 ± 1.6 66.8 ± 3.5 
Smokers 2 0 
3.1 patients and controls charectristics  
3.3.1 Optimisation of the ex vivo dose response and incubation time of aspirin 
using PRP (LTA technique) 
In order to optimise the effective concentration of aspirin following 2 hrs 
incubation, aspirin had no significant effect on ADP or collagen-induced platelet 
aggregation, even at high concentrations. In contrast, aspirin resulted in 
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complete inhibition of aggregation to AA at 0.1 mg/l, starting with significant 
inhibition at 0.01 mg/l; p=0.02 (Figure3.2). The readings show the average of 
three repeats of experiment±SEM.  
 
 
Figure 3.2 Aggregation of healthy control platelet in response to different 
agonists after incubation with aspirin using LTA technique. Platelet 
response to ADP (10 µmol/l; white columns), collagen (16 ug/ml; black columns) 
and AA (1 mM, red columns) after incubation with a range of aspirin 
concentrations (0-10 mg/l for 2 hrs. The readings show the mean±SEM of three 
repeat experiments. AU: arbitrary units. 
3.3.2 Optimizing ex vivo time response of aspirin using PRP 
As shorter incubation time is important to avoid platelet damage, time course 
experiments were conducted. Using 0.5 mg/l aspirin, partial inhibition occurred 
after 5 minutes p>0.05 and full inhibition to AA occurred after 30 minutes 
incubation p=0.02 in platelets from healthy volunteers, with no difference 
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observed in ADP or collagen response (Figure 3.3). The readings show the 
average of three repeats of experiment±SEM. 
 
Figure 3.3 Aggregation of healthy control platelets in response to different 
agonists after incubation with aspirin using LTA technique. Platelet 
response to ADP (10 µmol/l; white columns), collagen (16 ug/ml; black columns) 
and AA (1 mM, red columns) after incubation with 0.5 mg/l aspirin for 5, 30, 90, 
120 minutes. The readings show the mean±SEM of three independent 
experiments each conducted in duplicate. AU: arbitrary units. 
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3.3.3 Optimizing ex vivo aspirin concentration using whole blood (Multiplate) 
When compared with LTA test, different concentrations of aspirin were 
necessary when assessing platelet inhibition using whole blood samples. 
Aspirin at 10 mg/l was needed to cause full suppression, which occurred at 30 
mins. Marginal inhibition to aspirin was noted with 1 mg/l. Platelet reactivity to 
ADP was not affected, whereas partial inhibition of platelet respnse to collagen 
was noted at 10 mg/l after 30 mins incubation as shown in Figure 3.4.  
Figure 3.4 Platelet  aggregation using whole blood from of healthy controls in 
response to different agonists after incubation with aspirin using Multiplate 
technique. Platelets response to ADP (white), collagen (black) and AA (red) after 
incubation with different aspirin concentrations 0, 1, 10, 100 mg/l aspirin for  30 
minutes.  The readings show the mean±SEM of three independentexperiments,each 
conducted in duplicate.AU:aggregation unit. 
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3.3.4 Effects of ex vivo aspirin on platelet reactivity in diabetes and control 
subjects 
Given that whole blood represents a more physiological environment to test 
platelet aggregation, further experiments were conducted by adding aspirin, 
with and without additional glucose, to whole blood with platelet function  tested 
after stimulation with arachidonic acid (AA), collagen and ADP. 
Arachidonic acid (AA) 
Given that smoking may affects platelet activity and clot structure, I analysed 
the data of the whole group as well as the group excluding the two 
smokers.Low aspirin concentration at 1 mg/l inhibited AA-stimulated platelet 
aggregation by (12.7%, p=0.01) in patients with diabetes (Figure 3.5A)and by 
(13.1%, p=0.03) in controls (Figure 3.5B). Data were similar when smokers 
were excluded (11.9% inhibition, p<0.05 compared with controls). Interestingly, 
individuals with poor diabetes control (HbA1c≥8.5% or >75 mmol/mol) had no 
response to the inhibitory effects of low concentration of aspirin, suggesting 
interaction between acetylation and glycation (Figure 3.5C). High aspirin 
concentration exerted a more profound inhibitory effect on AA-mediated 
stimulation of platelet aggregation (48%, or 50% after excluding the two 
smokers) and 48% reduction in diabetes and control subjects, respectively, 
p≤0.01 for both) (Figure 3.5 A,B). High aspirin concentration was effective at 
inhibiting AA-mediated stimulation of platelets in subjects with poor diabetes 
control, suggesting that the potential interaction between acetylation and 
glycation can be overcome by increasing aspirin concentrations (Figure 3.5C). 
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Figure 3.5 Ex vivo effect of different concentrations of aspirin on platelet 
aggregation in response to AA using Multiplate. Platelets were stimulated with 
arachidonic acid (AA) in subjects with diabetes (n=25; A), healthy controls (n=26; B), 
subjects with poor diabetes control (n=14; C) and subjects with better diabetes control 
(n=11; D). 
Collagen 
Low aspirin concentration at 1 mg/l inhibited collagen-stimulated platelet 
aggregation by 7.4% (8.3% after excluding the two smokers) in diabetes 
patients (p=0.037) and by 12.4% in controls (p<0.01; Figure 3.6 A, B). 
Interestingly, individuals with poor diabetes control (HbA1c ≥ 8.5%) had no 
response to the inhibitory effects of aspirin, suggesting again interaction 
between acetylation and glycation (Figure 3.6C). High aspirin concentration 
exerted a more profound inhibitory effect on collagen-mediated stimulation of 
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platelet aggregation (30% or 28.6% after excluding the two smokers) and 
32.3%, reduction in diabetes and control subjects, respectively; p<0.01 for 
both). High aspirin concentration was effective at inhibiting collagen mediated 
stimulation of platelets in subjects with poor diabetes control, suggesting that 
the interaction between acetylation and glycation can be overcome by 
increasing aspirin concentrations (Figure 3.6C). 
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Figure 3.6 Ex vivo effect of different concentrations of aspirin on platelet 
aggregation in response to collagen Multiplate. Platelets were stimulated with 
collagen in subjects with diabetes (n=25; A), healthy controls (n=26; B), subjects with 
poor diabetes control (n=14; C) and subjects with better diabetes control (n=11; D). 
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Adenosine diphosphate (ADP) 
Neither low nor high aspirin concentrations had significant inhibitory effects on 
ADP-stimulated platelet aggregation in both patients and controls (figure 3.7A, 
B). There was no difference in ADP response to aspirin treatment comparing 
diabetes patients with poor and good glycaemic control (Figure 3.7C, D). 
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Figure 3.7 Ex vivo effect of different concentrations of aspirin on platelet 
aggregation in response to ADP using Multiplate. Platelets were stimulated with 
ADP in subjects with diabetes (n=25; A), healthy controls (n=26; B), subjects with poor 
diabetes control (n=14; C) and subjects with better diabetes control (n=11; D). 
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3.3.5 Effects of ex vivo aspirin on platelet reactivity in diabetes and control 
subjects in the presence of excess glucose 
Arachidonic acid (AA) 
In individuals with diabetes, the presence of additional glucose (20 mmol/l), 
resulted in reductionin the platelet inhibitory effect of low aspirin concentration 
after AA stimulation of platelet aggregation. 
Low aspirin concentration at 1 mg/l, inhibited AA-stimulated platelet aggregation 
by (7.5% p=0.063, 6.9%, p=0.1after excluding the two smokers) in patients with 
diabetes (Figure 3.8A) and by (7.0%, p=0.074) in controls (Figure 3.8B). 
Individuals with poor diabetes control (HbA1c≥8.5%) had no response to the 
inhibitory effects of aspirin with a trend seen in those with better glycaemic 
control (Figure 3.8C,D). High aspirin concentration was effective in inhibiting 
AA-mediated stimulation of platelets by (56.4%) in subjects with diabetes 
(56.4% in patients after excluding the two smokers) and by (54%) in healthy 
controls. In subjects with poor diabetes control, high aspirin concentration was 
effective in inhibiting AA mediated stimulation of platelet by (59%; Figure 3.8C). 
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Figure 3.8 Ex vivo effect of different concentrations of aspirin, in the presence of 
excess glucose, on platelet aggregation in response to AA using Multiplate.  
Platelets were stimulated with arachidonic acid (AA) in subjects with diabetes (n=25; 
A), healthy controls(n=26; B), subjects with poor diabetes control (n=14; C) and 
subjects with better diabetes control (n=11; D). 
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Collagen 
In the presence of excess glucose, low aspirin concentration at 1 mg/l had no 
effect on inhibiting collagen-stimulated platelet aggregation in patients or 
controls (Figure 3.9A,B). Glycaemic control was not a factor in determining 
platelet responseto collagen stimulation (Figure 3.9C,D). In contrast, high 
aspirin concentration was effective at inhibiting collagen-mediated stimulation of 
platelets by 27.3% (p<0.0001; 23% after excluding the two smokers) in subjects 
with diabetes and by 31.1% (p<0.0001) in healthy controls. Moreover, in 
subjects with poor and better diabetes control, high aspirin concentration 
showed a significant inhibition of collagen mediated stimulation of platelet 
activation by 33.3% (32% after excluding the two smokers) and 22.3%, 
respectively (p<0.002 for both; Figure 3.9C). 
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Figure 3.9 Ex vivo effect of different concentrations of aspirin, in the presence of 
excess glucose, on platelet aggregation in response to collagen using Multiplate.  
Platelets were stimulated with collagen in subjects with diabetes (n=25; A), healthy 
controls (n=26; B), subjects with poor diabetes control (n=14; C) and subjects with 
better diabetes control (n=11; D). 
Adenosine diphosphate (ADP) 
Neither low nor high aspirin concentration had any effect on ADP-mediated 
platelet aggregation in the presence of additional glucose. Results were similar 
in those with poor and better glycaemic control (figure 3.10 A-D). 
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Figure 3.10 Ex vivo effect of different concentrations of aspirin, in the 
presence of excess glucose, on platelet aggregation in response to ADP 
using Multiplate. Platelets were stimulated with ADP in subjects with diabetes 
(n=25; A), healthy controls (n=26; B), subjects with poor diabetes control (n=14; 
C) and subjects with better diabetes control (n=11; D). 
3.3.6 Effects of in vivo aspirin on platelet reactivity in diabetes and control 
subjects 
All samples were taken approximately 2 hours after low (75 mg/day) or high 
(300 mg/day) aspirin ingestion in patients with diabetes and healthy controls. 
Arachidonic acid (AA) 
Low daily dose of aspirin (75 mg/day) inhibited AA-stimulated platelet 
aggregation by 72% in patients with diabetes (70% after excluding the two 
smokers) (p<0.0001; Figure 3.11A) and by 72% in controls (p<0.0007; Figure 
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3.11B). Nearly the same observation was found in individuals with poor and 
good diabetes control with reductions of 69% (68% after excluding the two 
smokers smoker) and 79%, respectively (p<0.0001 for both). High aspirin daily 
dose (300mg/day) exerted a more profound inhibitory effect on AA-mediated 
stimulation of platelet aggregation at 75% (76%after excluding the two smokers) 
(p<0.0001) and 82% p<0.0008 in patients with diabetes and controls. In those 
with poor glycaemic control, inhibition was 67% (65%after excluding the two 
smokers) (p<0.003) whereas in those with good diabetes control the inhibition 
was 83% (p<0.0002) (Figure 3.11 A-D).  
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Figure 3.11 In vivo effect of different daily doses of aspirin on platelet 
aggregation in response to AA using Multiplate. Platelet response to arachidonic 
acid (AA) in subjects with diabetes (n=25A), healthy subjects (n=26; B), subjects with 
poor diabetes control (n=14; C) and subjects with better diabetes control (n=11; D). 
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Collagen  
Low daily dose of aspirin (75 mg/day) inhibited collagen-stimulated platelet 
aggregation by 26% (p=0.014) in patients with diabetes  while it failed to show a 
significant effect in healthy controls (Figure 3.12A,B). Higher aspirin dose 
inhibited collagen-mediated platelet aggregation in both diabetes patients and 
controls by 25.2% (p=0.03) and 34.6% (p=0.001), respectively. When patients 
were split into poor and better glycaemic control, the trend was similar but the 
inhibitory effect of aspirin on collagen-mediated platelet aggregation were not 
significant (Figure 3.12C, D).  
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Figure 3.12 In vivo effects of different daily doses of aspirin on platelet 
aggregation in response to collagen using Multiplate. Platelet response to collagen 
in subjects with diabetes (n=25; A), healthy controls (n=26; B), subjects with poor 
diabetes control (n=14, C) and subjects with better diabetes control (n=11; D). 
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Adenosine diphosphate (ADP) 
Aspirin had no significant inhibitory effect on ADP-stimulated platelet 
aggregation in either patients or controls, regardless of the dose of aspirin used 
(Figure 3.13 A,B). 
A B
Figure 3.13 In vivo effects of different daily doses of aspirin on platelet 
aggregation in response to ADP. Platelet response to ADP in subjects with diabetes 
(n=25; A) and healthy controls (n=26; B). 
3.4 Discussion 
In this ChapterI describe optimisation experiments to test for the ex vivo platelet 
inhibitory effects of aspirin in response to AA, collagen and ADP.Following this, 
I assessed the ex vivo inhibitory effect of low and high aspirin concentration on 
platelet aggregation in both patients with diabetes and healthy controls. Also, I 
investigated the ex vivo effect of high glucose concentration on aspirin inhibitory 
capacity of platelet aggregation in response to these agonists.These 
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experiments were complemented by analysing the in vivo effects of low and 
high dose aspirin on platelet aggregation following AA, collagen and ADP 
stimulation in both patients with diabetes and healthy controls. 
There are a number of novel observations emerging from my studies, i) Addition 
of ex vivo aspirin incubated to whole blood for 30 minutes is able to assess 
platelet response to this agent, ii) Although aspirin suppresses AA and collagen-
stimulated platelet reactivity in both diabetes subjects and controls, the efficacy 
of low aspirin concentration appears to be compromised in individuals with 
diabetes and poor glycaemic control, iii) The platelet inhibitory activities of low 
aspirin concentrations are abolished in the presence of excess glucose in both 
diabetes subjects and controls, iv) Low aspirin concentrations fail to inhibit 
collagen-stimulated platelet reactivity in the presence of excess glucose and v) 
in vivo aspirin administration at 75 or 300 mg/day causes suppression of AA-
induced platelet aggregation in samples collected 2 hours following aspirin 
ingestion. As expected, aspirin had no ex vivo or in vivoeffect on ADP-mediated 
platelet stimulation. 
The prostanoid thromboxane A2 (TXA2) is a key platelet activator that can also 
cause vasoconstriction thus stopping bleeding following vessel injury. Activated 
platelets release AA, which is modified by cyclooxygenase (COX)-1, yielding 
cyclic endoperoxides (prostaglandin G2 “PGG2” and “PGH2”), representing the 
main TXA2 substrate. PGH2 and TXA2 bind to thromboxane/prostaglandin (TP) 
platelet receptor (Yan and Phillips, 2005), resulting in platelet activation as 
detailed in Section 1.7.1. 
Aspirin acts by acetylation of platelet cyclooxygenase-1(COX-1) at position 
serine 529. This chemical modification inactivates the enzyme and as a result, 
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cyclic endoperoxides (prostaglandin G2 “PGG2” and “PGH2”) production from 
arachidonic acid is reduced, consequently decreasing TXA2 synthesis, (Roth 
and Calverley, 1994). Hyperglycaemia has been implicated in reduced efficacy 
of aspirin in diabetes (Ajjan et al., 2008). Several mechanisms have been 
proposed for increased platelet reactivity with high plasma glucose, including 
increased expression of platelet αIIbβ3, upregulation of P-selectin expression 
(Keating et al., 2003), increased platelet intracellular calcium secondary to 
glycation of circulating low-density lipoprotein (LDL) (Ferretti et al., 2002). An 
additional key mechanism for hyperglycaemia increasing platelet reactivity is 
non-enzymatic glycation of platelet membrane, resulting in loss of membrane 
fluidity and enhancement of platelet adhesion capacity (Winocour et al., 1992, 
Watala et al., 1998). Therefore, the general increase in platelet reactivity 
secondary to diabetes may be one mechanism for relative aspirin treatment 
failure or, alternatively, direct interaction between acetylation and glycation may 
be the main mechanism responsible. Both mechanisms have been proposed for 
the reduced clinical efficacy of aspirin, but no conclusive evidence is provided to 
fully back either (Rendell et al., 1986, Swamy-Mruthinti and Carter, 1999, 
Watala et al., 2005). 
Even if we accept that hyperglycaemia reduces response to aspirin treatment, it 
remains unclear whether this is due to protein glycation, or it is simply the result 
of high glucose levels interfering with the acetylation process. Understanding 
the exact mechanisms may have important therapeutic implications. For 
example, if high glucose, rather than glycation, is the cause of reduced aspirin 
efficacy, then normalising glucose levels within hours of cardiac ischaemia 
becomes a priority. In contrast, if glycation is more important, then acutely 
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normalising glucose levels following vascular ischaemia becomes less of a 
priority. 
My data show, for the first time, that both glycation and high glucose levels 
interfere with the action of aspirin. Although low aspirin concentration inhibited 
platelet response to AA stimulation, this effect was compromised in patients 
with poor glycaemia control. In contrast, higher aspirin concentrations inhibited 
AA-induced stimulation of platelet aggregation in both diabetes patients and 
controls and were not affected by glycaemic control. Previous work has shown 
that plasma aspirin levels drop relatively quickly following drug administration 
and therefore very low levels are expected 8-12 hours post ingestion (Benedek 
et al., 1995). Given this fact and increased turnover of platelets in diabetes 
(Ajjan and Grant, 2006a, Guthikonda et al., 2007), my results indicate that 
individuals with poor diabetes control may not be covered by aspirin for the 
whole 24 hours. The counter-argument is that in vivo administration of aspirin 
showed good platelet inhibition to AA-stimulation regardless of glycaemic 
control in the patient group. It should be remembered, however, that blood 
samples were taken approximately 2 hours after aspirin administration, when 
plasma levels of this agent are still high. In retrospect, the study design should 
have included an additional blood sampling before aspirin administration.  
Previous work has shown incomplete inhibition of platelet aggregation in 
response to AA in patients with poor glycaemic control when receiving 30mg 
daily dose of aspirin. However, higher dose of aspirin, resulted in improved 
platelet inhibition, further supporting my data(Lemkes et al., 2012). In addition to 
glycation, it appears that high glucose levels can directly compromise the 
efficacy of aspirin. The ex vivo addition of excess glucose (20mmol/l) abolished 
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the inhibitory effect of low concentration of aspirin on platelet aggregation in 
both patients and controls. This indicates that high glucose levels have a direct 
effect on aspirin efficacy, the mechanism of which remains an area for future 
research. 
Collagen is one of the most important componentsthat triggers platelet 
activation following vessel injury (Roberts et al., 2004). It is proposed that there 
are two main receptors involved in platelet-collagen interaction: collagen first 
adheres to α2β1 on platelet surface then reacts with glycoprotein VI (Poole and 
Watson, 1995). Collagen activates platelet aggregation and stimulates the 
release of α granular protein, β-thromboglobulin and production of TXA2 (Valles 
et al., 1991). At high concentration of collagen, platelet activation occurs 
through a process ending with the release of calcium either from the dense 
tubular system (Brass and Joseph, 1985) or by influx from the extracellular 
milieu (Roberts and Bose, 2002). However, at lower collagen concentration, its 
ability to activate platelet is enhanced by the production of TXA2 (Nakano et al., 
1989). Therefore, the addition of aspirin will partially inhibit the ability of collagen 
to enhance platelet aggregation. This explains the inhibition of platelet activation 
by collagen following aspirin treatment ex vivo or in vivo. Moreover, the failure 
of aspirin to exert an effect in those with poorly controlled diabetes indicates 
that suppression of TXA2 production in these patients is compromised. 
Moreover, it is not only long-term glycaemia that is an issue, but high glucose 
levels also play a role. Nearly the sameobservation was found when assessing 
the in vivo effect of aspirin on collagen-mediated platelet response. Although 
low dose aspirin (75 mg/day) showed an effect in both subjects with diabetes 
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and healthy controls, this effect was reduced in those with poor glycaemic 
control.   
A large body of evidence is available in the literature in relation to the effect of 
diabetes on platelet reactivity and decreased response to aspirin treatment 
(Watala et al 2004). However, most of these studies have assessed the in vivo 
effect of diabetes on the effectiveness of aspirin on platelet response to 
agonists. To my knowledge, there is only one study that assessed both the in 
vivo and ex vivo platelet response to aspirin (Watala et al 2004). Although there 
are some similarities compared with my work, there are a number of differences 
that should be highlighted.First, the cohort of patients analysed was different in 
the two pieces of work: I focused on young type1 diabetes patients devoid of 
complications and not on any treatment other than insulin. This allowed me to 
investigate the effect of glycaemia away from confounding factors frequently 
encountered in older type 2 diabetes patients in the study by Watala et al. 
Second, my study investigated the effects of glycation as well as high glucose 
levels on the platelet inhibitory effects of aspirin. Thirdly, I analysed platelet 
response to three agonists to provide a more complete picture of platelet 
reactivity in patients and controls.  
Keating et al 2003 have studied the ex vivo effect of increased concentration of 
glucose or mannitol on platelet reactivity in 14 healthy volunteers and in 
hospitalized patients with (n=14) or without (n=7) type 2 diabetes mellitus.They 
documented increased activation of platelet αIIbβ3 and P-selectin expression 
after 1hour incubation with high concentration of glucose or mannitol. In my 
study, glucose per se had no effect on platelet activation but it reduced the 
platelet inhibitory effects of aspirin. Also, it should be noted that the study by 
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Keating analysed a limited number of samples and again used type 2 diabetes 
patients who have a more variable profile than type 1 diabetes, as discussed 
earlier.  
Although the idea of aspirin resistance was floated more than two decades ago, 
the exact mechanisms for this phenomenon remain elusive (Ajjan et al., 2008). 
There are a large number of factors that may play a role in aspirin resistance in 
patients with diabetes, including decreased endothelial nitric oxide production 
and the general increase in platelet activation. My study further established that 
both long-term glycaemia and high glucose levels can interfere with the action 
of aspirin. Interestingly, however, minor elevation in HbA1c was not associated 
with decreased response to aspirin. This suggests that only individuals with very 
poor diabetes control (HbA1c≥8.5%) have reduced response to aspirin thus 
explaining some of the contradictory data on aspirin resistance. In reality, 
HbA1c cut off that is not associated with impaired response to aspirin is likely to 
be different from patient to patient, but what this study shows is that very tight 
control of blood glucose is not necessary to improve response to aspirin 
therapy. Naturally, future clinical studies are necessary to test this hypothesis, 
which may have important long-term clinical implications.  
A clear strength of my study is the use of type 1 diabetes patients who have no 
other pathology, enabling me to dissect the role of glycaemia in response to 
aspirin treatment using a combination of ex vivo and in vivo experiments. 
However, there are a number of drawbacks including: i) number of patients 
studied remains relatively small and therefore full characterisation of the 
subgroup with reduced response to aspirin was not possible, ii) for the in vivo 
work, an additional blood sample should have collected before aspirin 
107 
 
administration, which would have given us a better understanding of the time 
course of aspirin action in vivo, and iii) the exact pathways responsible for the 
interaction between glycation/high glucose and acetylation are not clarified in 
this study and remain an area for future work. iv) No measurements of 
thromboxane levels have been done in this study which could have further 
helped to assess the effects of aspirin on this pathway, and v) This study is 
limited to type 1 diabetes patients and the results do not necessarily reflect what 
takes place in type 2 diabetes. However, the reason for choosing type 1 
diabetes was to ensure that the effects of glycaemia was studied away from the 
large number of confounding factors often present in patients with type 2 
diabetes. 
In conclusion, my study demonstrates that ex vivo work is a useful tool to 
address specific aspects of reduced efficacy of aspirin in diabetes. Both long-
term and short-term hyperglycaemia are associated with impairment in platelet 
inhibition by aspirin in this condition. It should be noted, however, that aspirin is 
not only an inhibitor of platelet function but can also affect fibrinolytic potential. 
Therefore, to fully understand the mechanisms of aspirin treatment failure in 
diabetes, studies are required to analyse both the cellular and protein arms of 
coagulation.   
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Chapter 4 
Diabetes, blood glucose and  
modulation of the fibrin clot by aspirin 
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 4.1 Introduction 
Fibrin networks with compact structure, containing thin fibrin fibres with small 
pores, are associated with increased risk of thrombosis and cardiovascular 
disease (Fatah et al., 1996b, Collet et al., 2006, Undas et al., 2010b) . 
Fibrinolysis is compromised in tighter clots, offering one mechanism for higher 
thrombosis risk and poor outcome in individuals with this kind of clot structure 
(Collet et al., 2000).  
Ex vivo clots from individuals with diabetes display a compact structure with 
impaired fibrinolysis (Dunn et al., 2006). Improving clot structure and fibrinolytic 
efficiency in diabetes represent one strategy to reduce thrombotic risk in this 
population. 
As discussed before, aspirin is effective at altering fibrin clot structure, related, 
at least in part, to acetylation of fibrinogen (Ajjan et al., 2009, Undas et al., 
2003). However, in patients with diabetes, the acetylation process by aspirin 
may be compromised. One mechanism implicated is related to an interaction 
between glycation and acetylation, secondary to high plasma glucose levels 
(Rendell et al., 1986, Swamy-Mruthinti and Carter, 1999).  
Researchers have investigated the effect of high plasma glucose on fibrin clot 
structure using ex vivo glycated fibrinogen (Ney et al., 1985, Mirshahi et al., 
1987, Brownlee et al., 1983)  or studying samples from patients with diabetes 
(Dunn et al., 2005, Nair et al., 1991b, Lutjens et al., 1988, Jorneskog et al., 
1996, Pieters et al., 2006).  The advantage of ex vivo glycation is the ease of 
obtaining samples with different degrees of specific glucose-related post-
translational modification. The drawback, however, is related to the non-
physiological nature of the process, and therefore not representing the in 
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vivoenvironment. Obtaining samples from diabetes patients is more 
physiological but has the inconvenience of being affected by inter-individual 
variability (genetic and environmental), making data interpretation problematic. 
To further complicate matters, some researchers used plasma samples to 
investigate fibrin networks, a methodology that takes into account the effects of 
various plasma proteins on the clotting process (Nair et al., 1991a, Nair et al., 
1991b, Jorneskog et al., 1996, Pieters et al., 2006).Others employed purified 
fibrinogen in order to dissect out the effect of diabetes on the fibrinogen 
molecule (Dunn et al., 2005, Lutjens et al., 1988, Dunn et al., 2006). 
Although studies have shown potential interaction between glycation and 
acetylation (Rendell et al., 1986, Swamy-Mruthinti and Carter, 1999), this has 
not been appropriately studied using samples from diabetes patients and 
matched controls. Also, a general criticism of studies to date is the failure to 
investigate the role of instantaneous high glucose on clot structure and 
response to aspirin treatment. Therefore, to obtain a comprehensive 
assessment of glucose and glycation on clot structure and response to aspirin 
therapy, I conducted ex vivo studies to analyse the effect of aspirin on the fibrin 
network with and without high glucose level in individuals with diabetes and in 
healthy controls. 
4.2 Materials and methods 
4.2.1 Patients and controls  
Plasma samples were stored from the same patients and controls who gave 
blood samples for the platelet test (section 2.1). Clot structure studies were 
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conducted in this group using plasma samples or plasma-purified fibrinogen. A 
total of 29 patients and 29 healthy controls were studied. 
4.2.2 Sample preparation 
To investigate the ex vivo effects of glucose and aspirin, samples were 
prepared in two ways, using whole blood or plasma-purified fibrinogen (Figure 
4.1). 
Whole blood preparations 
Samples of whole blood were collected in sodium citrate followed by incubation 
with aspirin at 0mg/l, 1mg/l or 10mg/l in the presence and absence of additional 
20µM glucose. Samples were then incubated at 37°C for 10 minutes and then 
on ice for 50 minutes. Blood samples were then centrifuged at 3000 rpm for 20 
minutes and platelet poor plasma was aliquoted (0.5 ml plasma/tube) and 
stored at -80°C for further analysis (Figure 4.1). After collection of all samples, 
turbidimetric assays were conducted on all samples as described in section 2.5.  
Purified fibrinogen 
Samples collected in lithium heparin were centrifuged for 20 minutes at 3000 
rpm and fibrinogen was purified from plasma samples as detailed in section 2.3. 
Pools of plasma purified fibrinogen were then constructed using 12 samples 
from healthy controls, 12 samples from poor diabetes control (HbA1c≥8.5%). To 
these pools of purified fibrinogen, different concentrations of aspirin were added 
at 0mg/l, 1mg/l and 10mg/ in the presence and absence of additional 20 µM 
glucose. Samples were then incubated for 24 hours at 4°C.  
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4.2.3 Assessment of clot structure 
Clot structure and fibrinolysis were assessed using turbidimetric assays, 
confocal microscopy and, electron scanning microscopy as described in 
Chapter 2 (section 2.5 and 2.6). 
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Figure 4.1 Summary of sample selection and preparation. For plasma fibrin clot 
analysis, blood samples from diabetes (n=29) and controls (n=29) were collected at 
baseline in sodium citrate. Different concentrations of aspirin were then added to whole 
blood samples (0, 1, 10 mg/l), with and without additional glucose, and incubated for 60 
minutes. Platelet poor plasma (PPP) was aliquotedand fibrin clot structure was 
analysed using turbidimetric assay in all 29 samples. Confocal microscopy and electron 
microscopy was used to analyse clot structure in pooled control and diabetes samples 
n=12 each. For clots made from purified fibrinogen, blood samples from diabetes and 
controls were collected in lithium heparin. Fibrinogen was then purifiedfrom individual 
samples followed by pooling healthy control and diabetes samples (n=12 each). Pooled 
fibrinogen was incubated for 24 hrs with different concentrations of aspirin (0, 1, 10 
mg/l), with and without additional glucose (20 mmol/l). Fibrin clot properties were 
analysed using turbidimetric assay, confocal and electron microscopy. 
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4.3 Results 
4.3.1 Turbidimetric analysis of plasma clots  
Lag phase  
Low aspirin concentration at 1 mg/l and high concentration at 10 mg/l had no 
effect on lag phase in patients (Figure 4.2A) or controls (Figure 4.2B). The 
same observation was found in individual with poor diabetes control, 
HbA1c≥8.5% and individuals with better diabetes control, HbA1c<8.5 (Figure 
4.2 C, D).  
In the absence of aspirin, lag phase did not show a significant difference 
comparing controls (357±56 sec.) with diabetes individuals (254±49 sec.), but a 
trend was observed with low concentration of aspirin (413±54 sec., 278±56 sec; 
p=0.09) that disappeared with high aspirin concentration (322±61, 241±48 
p=0.3; Figure 4.3). 
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Figure 4.2 Ex vivo effect of different concentration of aspirin on lag phase 
(measured by seconds) of clot formation using turbidity and lysis technique. 
After addition of 0, 1, and 10 mg/l of aspirin into plasma of subjects with diabetes (A; 
n=29), healthy subjects (B; n=29), subjects with poor diabetes control (C; n=15) and 
subjects with better diabetes control (D; n=14), lag phase was measured.The results 
represent the mean±SEM. 
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Figure 4.3 Analysis of the ex vivo effect of different concentration of aspirin on 
lag phase (measured by seconds) of clot formation in patients and controls 
using turbidity and lysis technique. After theaddition of 0, 1, and 10 mg/l of aspirin 
into plasma of subjects with diabetes (n=29) and healthy controls (n=29), lag phase 
was measured. The results represent the mean±SEM. 
Maximum absorbance  
Low aspirin concentration at 1 mg/l and high concentration at 10 mg/l had no 
effect on fibrin clot maximum absorbance in patients (Figure 4.4A) or controls 
(Figure 4.4B). The same observation was found in both individual with poor 
diabetes control (HbA1c≥8.5%) and individuals with better diabetes control 
(HbA1c<8.5; Figure 4.4 C, D).  
Comparing individuals with poor and better diabetes control, maximum 
absorbance was consistently higher in the former group regardless of the 
concentration of aspirin used (Figure 4.5). 
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Figure 4.4 Ex vivo effect of different concentration of aspirin on clot maximum 
absorbance using turbidity and lysis technique. After addition of 0, 1, and 10 mg/l 
of aspirin into blood samples of subjects with diabetes (A; n=29), healthy subjects (B; 
n=29), subjects with poor diabetes control (C; n=15) and subjects with good diabetes 
control (D; n=14), maximum absorbance was measured. The results represent the 
mean±SEM.AU: arbitrary units. 
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Figure 4.5 Analysis the ex vivo effect of different concentration of aspirin on 
maximum absorbance(measured by arbitrary unit) of clots formation in poor and 
good diabetes using turbidity and lysis technique. After addition of 0, 1, and 10 
mg/l of aspirin into plasma of subjects with poor controlled diabetes (n=15) and subject 
with good controlled diabetes (n=14), maximum absorbance was measured. The 
results represent the mean±SEM. AU: arbitrary units. 
Lysis time 
There was no effect of low or high concentration of aspirin in clot lysis time in 
individuals with diabetes (Figure 4.6 A). However, in healthy controls there was 
reduction in lysis time from 600±63.5sec. before aspirin to 475±26.7sec. after 
1mg/l aspirin, although only a trend was evident (p=0.06). Higher concentration 
of aspirin showed a similar pattern with a significantly shorter lysis time 
(489±28.6sec; p=0.04). Both Individuals with poor diabetes control 
(HbA1c≥8.5%) and individuals withgood diabetes control had no fibrinolytic 
response to aspirin (Figure 4.6C, D).  
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Comparing individuals with diabetes and healthy controls, there were significant 
differences in clot lysis time that were exaggerated in the presence of aspirin 
(p<0.05) (Figure 4.7). 
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Figure 4.6 Ex vivo effect of different concentration of aspirin on plasma clots 
lysis time (measured by seconds) using turbidity and lysis technique. After 
addition of 0, 1, and 10 mg/l of aspirin into plasma of subjects with diabetes (A; n=29), 
healthy subjects (B; n=29), subjects with poor diabetes control (C; n=15) and subjects 
with better diabetes control (D; n=14), clot lysis was measured.The results represent 
the mean±SEM.  
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Figure 4.7 Analysis of ex vivo effect of different concentration of aspirin on 
plasma clots lysis time (measured by seconds) in patients and controls using 
turbidity and lysis technique. After addition of 0, 1, and 10 mg/l of aspirin into plasma 
of subjects with diabetes (n=29) and healthy subjects (n=29), clot lysis time was 
measured. The results represent the mean±SEM. 
4.3.2 Scanning confocal microscopy of plasma clots (clot structure and clot 
lysis) 
Fibrin structure before and after aspirin therapy of plasma clots from a pool of 
healthy controls is shown in Figure 4.8 A, B, respectively.  Aspirin made the 
fibrin clots more porous and a similar finding, although to a lesser extent, was 
observed in patients with diabetes (Figure 4.9 C, D). As expected, there were 
differences in patients and controls in relation to plasma clot density (Figure 4.8 
A and 4.9 C, respectively). Fibrinolysis of mature clots was observed in real 
time using laser scanning confocal microscopy. I recorded lysis time in at least 
four independent experiments for each condition. There was a reduction in lysis 
time of pooled plasma clots of healthy controls after incubation with 10mg/l 
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aspirin from 469±35 to 309±71 sec., although this failed to reach statistical 
significant (p=0.2, Figure 4.10). Ex vivo incubation of 10 mg aspirin 
paradoxically increased clot lysis time but the difference did not reach statistical 
significance (428±56 sec. and 526±143 sec. (p=0.7; Figure 4.10). 
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Figure 4.8 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of 
mature fibrinclot of controls. Fibrin clots made from pooled plasma from healthy 
controls (n=12) incubated ex vivo with 0 mg/l (A), 10mg/l aspirin (B)  
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Figure 4.9 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of   
mature fibrin clot of poor diabetes control. Fibrin clots made from pooled plasma 
ofpoor diabetes control (n=12) incubated ex vivo with 0 mg/l (C), 10mg/l aspirin (D). 
124 
 
 
Figure 4.10 Fibrin clot fibrinolysis of mature clots measured usingconfocal 
microscopy of (magnification of 400x). The results represent the 3 repeats 
mean±SEM of 4 independent lysis experiments of clots made from plasma pool of 
healthy controls (n=12) or subjects from poor diabetes control. 
4.3.3 Scanning electron microscopy of plasma clot 
Scanning electron microscopy failed to show a significant difference in fibrin 
fibre thickness of clots made from pooled plasma of healthy controls before and 
after 10 mg/l aspirin therapy (72±2.5 and 76±2 nm, respectively; p=0.9). The 
same was observed in clots made from pooled diabetes plasma (59±1.3 and 
63±1.8, respectively; p=0.07). Fibres of healthy control clots were significantly 
thicker than those of patients with diabetes (72±2.5 and 59±1.3, respectively; 
p=0.0001). The same significant difference was observedin the presence of 
aspirin (p=0.0001; Figure 4.11A). The pore size of clots from the control group 
before and after aspirin treatment was bigger than the pore size in clots made 
from diabetes patients (Figure 4.11 B-D). 
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Figure 4.11 Fibrin clot analysis using electron microscopy (magnification of 
10000x). Fibrin fibre thickness of clots made of pooled plasma of healthy controls or 
poor diabetes patients (n=12 in each pool) before and after 10mg/l aspirin treatment. 
Results represent the mean±SEM of 200 readings from 10different images captured 
from two fibrin clots(A). Clot Images of healthy controls before (B), and after treatment 
with 10mg/l aspirin (C). Clot image of diabetes patients before (D) and after treatment 
with 10mg/l aspirin (E). 
4.3.4 Turbidimetric analysis (maximum absorbance and clot lysis) of clots made 
from purified fibrinogen 
Aspirin addition, at 10 mg/l numerically increased fibrin clot maximum 
absorbance in controls from 0.033±0.002 to 0.037±0.006, but this failed to 
reach statistical significance (p=0.5). As similar pattern was observed in patients 
with poor diabetes controls with final turbidity at 0.05±0.01 and 0.06±0.01 
before and after aspirin, respectively (p=0.2) (Figure 4.12 A). There was no 
significant difference in clot lysis time before and after incubation of purified 
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fibrinogen with aspirin in controls (151±27sec. and 146±17sec, respectively; 
p>0.1) with similar findings in individuals with poor diabetes control (197±31sec 
and 170±15 sec, respectively; p>0.1) (Figure 4.12 B). Although numerically 
longer, there was no significant difference between patients and controls in lysis 
time after the addition of either 0 or 10 mg/l aspirin (p>0.1 for both).  
 
Figure 4.12 Ex vivo effect of different concentration of aspirin on maximum 
absorbance of purified fibrinogen fibrin clot formation and clot lysis time using 
turbidity and lysis. After addition of 0 and 10 mg/l of aspirin intopool of purified 
fibrinogen of subjects with poor diabetes control (n=12), healthy subjects (n=12), 
maximum absorbance was measured.(A). After addition of 0 and 10 mg/l of aspirin 
intopool of purified fibrinogen of subjects with poor diabetes control (n=12), healthy 
subjects (n=12), lysis time was measured (B). The results represent 3 repeats 
mean±SEM. 
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4.3.5 Scanning confocal microscopy of purified fibrinogen clots (fibrin clot 
structure and clot lysis) 
The fibrin network appeared more porous after aspirin therapy using clots made 
from pooled purified fibrinogen from healthy controls (Figure 4.13 A,B), with 
largely similar findings, observed in clots made from pooled purified fibrinogen 
from poor diabetescontrol (Figure 4.14 C, D). The fibrin network was less 
compact comparing controls with diabetes clots (Figure 4.13, 4.14). There was 
no significant difference in lysis time of clots made from purified fibrinogen of 
pooled control samples before and after incubation with aspirin (405±13 and 
466±42 sec., respectively; p>0.1; Figure 4.15 E). Also, there was no difference 
in lysis time of clots made from pooled purified fibrinogen of poor diabetes 
control before and after incubation with aspirin (525±111 and 467±53 sec, 
respectively; p>0.1). The numerical difference in clot lysis time comparing 
healthy control with patients with poor diabetes control samples did not reach 
statistical significance (p>0.2; Figure 4.15).  
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Figure 4.13 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of   
mature fibrin clot of healthy control. Fibrin clot made from pooled fibrinogen from 
subjects from healthy control (n=12) incubated ex vivo with 0 mg/l (A), 10mg/l aspirin 
(B). 
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Figure 4.14 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of   
mature fibrin clot of poor diabetes control. Fibrin clot made from pooled fibrinogen 
from subjects from poor diabetes control (n=12) incubated ex vivo with 0 mg/l (C), 
10mg/l aspirin (D). 
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Figure 4.15 Fibrin clot fibrinolysis of mature clots measured using confocal 
microscopy of (magnification of 400x). The results represent the 3 repeats 
mean±SEM of 4 independent lysis experiments of clots made from fibrinogen pool of 
healthy controls (n=12) or subjects from poor diabetes control (n=12) incubated ex vivo 
with 0mg/l, 10mg/l aspirin.  
4.3.6 Scanning electron microscopy of purified fibrinogen clot 
Scanning electron microscopy showed that fibrin fibre thickness of clots made 
from purified fibrinogen of pooled healthy controls increased from 71.6±1.7 to 
79.6±2.1nm after aspirin therapy (p<0.05). In contrast, aspirin had the opposite 
effect on fibre thickness of patients with diabetes with a reduction from 66±1.9 
to 61±2.3 after aspirin therapy (p<0.05). Fibres of healthy control clots were 
thicker than those of patients with poor diabetes control (71±1.7 and 66±1.9 nm, 
respectively; p<0.05; Figure 4.16 A). 
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The pore size of clot from controls before and after aspirin treatment was bigger 
than the pore size in patients with the same condition (Figure 4.16 B-D). 
Figure 4.16 Fibrin clot analysis using electron microscopy (magnification of 
10000x). Fibrin fibre thickness of clots made of purified fibrinogen from pooled healthy 
controls (n=12) or patients with diabetes (n=12) before and after ex vivo aspirin 
treatment. Results represent the mean±SEM of 200 readings from 10 imagescaptured 
from two fibrin clots. Aspirin resulted in increased fibrin thickness in healthy control with 
the opposite effect observed in clots made from patients with poor diabetes control. 
Fibrin fibres were thicker in healthy control compared with diabetes patients (A). Fibrin 
clots before and after treatment with 10mg/l aspirin in controls (B, C) or patients with 
diabetes D, E). 
  
B C
D E
A
3µm
132 
 
4.3.7 Turbidimetric analysis of plasma clots in the presence of excess glucose 
Lag phase  
Lag phase of plasma samples was not affected by aspirin in the presence of 
excess glucose in controls or patients with diabetes (Figure 4.17 A-D).  
Lag phase in controls (398±56sec) was marginally longer than patients (263±47 
sec; p=0.07) in the absence of aspirin. This difference became non-significant 
after adding 1 mg/l of aspirin to plasma samples (300±58 and 205±48 Sec, 
respectively; p=0.2). However, with higher aspirin concentration of 10 mg/l, the 
difference was significant (368±62 and 186±38, respectively; p=0.02, Figure 
4.18). 
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Figure 4.17 Ex vivo effect of different concentration of aspirin and 20 mmol/l 
glucose on lag phase (measured by seconds) of clot formation using turbidity 
and lysis technique. After addition of glucose, glucose+1mg/l, and glucose+10 mg/l of 
aspirin into plasma of subjects with diabetes (A; n=29), healthy subjects (B; n=29), 
subjects with poor diabetes control (C; n=15) and subjects with better diabetes control 
(D; n=14), lag time was measured.The results represent the mean±SEM. 
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Figure 4.18 Analysis of the ex vivo effect of different concentration of aspirin and 
20 mmol/l on lag phase (measured by seconds) of clot formation for patients and 
conrols using turbidity and lysis. After addition of glucose, glucose+1mg/l, and 
glucose+10 mg/l of aspirin into plasma of subjects with diabetes (n=29) and healthy 
controls (n=29), lag phase was measured. The results represent the mean±SEM. 
Maximum absorbance 
Both low and high aspirin concentrations had no effect on clot maximum 
absorbance in the presence of excess glucose in either patients (Figure 4.19A) 
or controls (Figure 4.19B). Glycaemic control appears to have affected 
response to aspirin therapy in the presence of additional glucose with a 
marginal difference detected between poor and good glycaemic control patients 
with 1 mg/l aspirin at 0.19±0.02 and 0.14±0.02, respectively; p=0.09). A clear 
difference was evident with 10 mg/l aspirin concentration at 0.2±0.01.and 
0.13±0.01, respectively; p=0.01; Figure 4.19C, D and Fig 4.20). 
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Figure 4.19 Ex vivo effect of different concentrations of aspirin in the presence of 
additional glucose on plasma clot maximum absorbance using turbidity and 
lysis technique. After addition of glucose (g), g+1mg/l, and g+10 mg/l of aspirin to 
blood samples of subjects with diabetes (A; n=29), healthy subjects (B; n=29), subjects 
with poor diabetes control (C; n=15) and subjects with better diabetes control (D; 
n=14), maximum absorbance was measured.The results represent the mean±SEM.AU: 
arbitrary units. 
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Figure 4.20 Ex vivo effect of different concentration of aspirin with 20mmol/l 
glucose on clot maximum absorbance using turbidity and lysis technique. After 
addition of glucose, glucose+1, and glucose+10 mg/l of aspirin into plasma of subjects 
with poor diabetes control (n=15) and better diabetes control (n=14), clot lysis time was 
measured. The results represent the mean±SEM.AU: arbitrary units. 
Lysis time 
There was no effect of low or high concentrations of aspirin with additional 
glucose on clot lysis time in individuals with diabetes or in healthy controls 
(Figure 4.21 A, B). Glycaemic control did not affect these results as shown in 
(Figure 4.21 C, D).  
Comparing individuals with diabetes and healthy controls, lysis time was shorter 
in controls regardless of the presence or absence of aspirin (Figure 4.22).  
Addition of glucose had no effect on clot lysis time in controls in the presence or 
absence of aspirin in controls (Figure 4.23).   
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Figure 4.21 Ex vivo effect of different concentration of aspirin and 20 mmol/l 
glucose on plasma clots lysis time (measured by seconds) using turbidity and 
lysis technique. After addition of 0, 1, and 10 mg/l of aspirin into plasma of subjects 
with diabetes (A; n=29), healthy subjects (B; n=29), subjects with poor diabetes control 
(C; n=15) and subjects with better diabetes control (D; n=14), clot lysis time was 
measured.The results represent the mean±SEM. 
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Figure 4.22 Ex vivo effect of different concentrations of aspirin with 20mmol/l 
glucose on clot lysis time (measured by seconds) using turbidity and lysis 
technique. After addition of glucose, glucose+1, and glucose+10 mg/l of aspirin into 
plasma of subjects with diabetes (n=29) and healthy controls (n=29), clot lysis time was 
measured. The results represent the mean±SEM. 
 
Figure 4.23 Ex vivo effect of different concentration of aspirin with 20mmol/l 
glucose on clot lysis time of controls (measured by seconds) using turbidity 
andlysis technique. After addition of glucose, glucose+1, and glucose+10 mg/l of 
aspirin to plasma of subjects with diabetes (n=29), clot lysis time was measured. The 
results represent the mean±SEM. 
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4.3.8 Scanning confocal microscopyplasma (clot image and lysis time) in the 
presence of extra glucoe 
Fibrin structure before and after aspirin therapy of plasma clots from a pool of 
healthy controls is shown in Figure 4.24 A and Figure 4.24 B, respectively. 
There was no effect of aspirin on fibrin clot structure in healthy controls. A 
similar finding was observed in patients with diabetes (Figure 4.25 C and 4.25 
D, before and after aspirin treatment respectively). Fibrinolysis of mature clots 
was assessed using laser scanning confocal microscopy. Lysis time in four 
independent experiments was recorded (Figure 4.26). There was no difference 
in lysis time of plasma pool clot of healthy control before and after incubation 
with 10mg/l aspirin in the presence of additional glucose (448±27, 502±130 sec, 
respectively; p=0.1). Aspirin had no significant effect on clot lysis time of pooled 
plasma frompatients with poor diabetes control subjects (657±30.sec to 
514±106 sec, before and after aspirin; p>0.1). Lysis time in controls was shorter 
than in patients in the presence of additional glucose. However, no difference 
was detected in the presence of both additional glucose and aspirin (Figure 
4.26). 
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Figure 4.24 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of   
mature fibrin clot of healthy control. Fibrin clot made from pooled plasmaof healthy 
control (n=12) incubated ex vivo with 20 mmol/l glucose (A), glucose+10mg/l aspirin 
(B). 
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Figure 4.25 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of   
mature fibrin clot of poor diabetes control. Fibrin clot made from pooled plasmaof 
poor diabetes control (n=12) incubated ex vivo with 20 mmol/l glucose (C), 
glucose+10mg/l aspirin (D). 
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Figure 4.26 Fibrin clot fibrinolysis of mature clots measured using confocal 
microscopy of (magnification of 400x). The results represent the 3 repeats 
mean±SEM of 4 independent lysis experiments of clots made from pooled plasma of 
healthy controls (n=12) or subjects from poor diabetes control (n=12) incubated ex vivo 
with 20 mmol/l glucose, glucose+10mg/l aspirin.  
4.3.9 Scanning electron microscopy of plasma clot after incubation with extra 
glucose 
Scanning electron microscopy showed, both in controls and patients with poor 
diabete control, that aspirin had no effect on fibre thickness in the presence of 
additional glucose (Figure 4.27). 
 
143 
 
B
ED
C
A
3µm
 
Figure 4.27 Fibrin clot analysis using electron microscopy (magnificatin of 
10000x). Fibrin fibre thickness of clots made of pooled plasma of healthy controls or 
patients with poor diabetes control (n=12 in each pool) after incubation with 20mmol/l 
glucose or glucose+10mg/l aspirin treatment. Results represent the mean±SEM of 200 
readings from 12 images (A). Clot Images of healthy controls after treatment with 
glucose(B)or glucose+10mg/l aspirin (C). D, E, representative images of clots from 
patients with additional glucose or glucose+10 mg/l aspirin. 
4.3.10 Turbidimetric analysis of purified fibrinogen clots in the presence of 
excess glucose (Maximum absorbance and lysis time) 
Aspirin failed to exert an effect on maximum absorbance of clots made from 
purified fibrinogen before and after aspirin treatment in the presence of 
additional glucose. This applied to both controls and patients with diabetes 
(Figure 4.28 A). In the presence of extra glucose, there was no difference in 
lysis time after aspirin treatment of clots made from pooled purified fibrinogen of 
control or subjects with diabetes control (Figure 4.28 B). 
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Figure 4.28 Ex vivo effect of different concentration of aspirin with 20mmol/l 
glucose on clot maximum absorbanceand on clot lysis time using turbidity and 
lysis. After addition of glucose and glucose+10 mg/l of aspirin into purified fibrinogen of 
patients with poor diabetes control (n=12) and good diabetes control (n=12), clot 
maximum absorbance was measured (A). After addition of glucose and glucose+10 
mg/l of aspirin into pooled of purified fibrinogen of healthy subjects (n=12) and subjects 
with poor diabetes control (n=12), clot lysis time was measured (B).The readings 
represent the mean ±SEM of 4 repeat experiments. 
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4.3.11 Confocal scanning microscopy (clot image and lysis time) of purified 
fibrinogen clot after incubation with extra glucose 
Fibrin networks appeared more porous in clots made from pooled purified 
fibrinogen of healthy controls after aspirin treatment in the presence of 
additional glucose. No such an effect was observed in individuals with diabetes 
(Figure 4.29, 4.30). Fibrinolysis was observed in real time using laser scanning 
confocal microscopy and the mean of 4 experiments were recorded (Figure 
4.31). In the presence of extra glucose, aspirin had no effect onlysis time of 
clots made form pooled purified fibrinogen of healthy control. Aspirin appeared 
to increase clot lysis time in patients with diabetes, although the difference did 
not reach statistical significance (p=0.3). Clot lysis time of healthy controls was 
significantly shorter than diabetes in the presence of additional glucose and 
aspirin (Figure 4.31).  
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Figure 4.29 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of   
mature fibrin clot of healthy control. Fibrin clot made from pooled fibrinogenof 
healthy control (n=12) incubated ex vivo with 20 mmol/l glucose (A), glucose+10mg/l 
aspirin (B). 
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Figure 4.30 Confocal microscopy of 20 μm Z-stack (magnification of 400x) of   
mature fibrin clot of healthy control. Fibrin clot made from pooled fibrinogenof poor 
diabetes control (n=12) incubated ex vivo with 20 mmol/l glucose (C), glucose+10mg/l 
aspirin (D). 
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Figure 4.31 Fibrin clot fibrinolysis of mature clots measured using confocal 
microscopy of (magnification of 400x). The results represent the 3 repeats 
mean±SEM of 4 independent lysis experiments of clots made from pooled fibrinogen  
of healthy controls (n=12) or poor diabetes control (n=12) incubated ex vivo with 20 
mmol/l glucose, glucose+10mg/l aspirin 
4.3.12 Scanning electron microscopy of purified fibrinogen clot after incubation 
with extra glucose 
Scanning electron microscopy showed that in the presence of extra glucose, 
fibrin fibre thickness of clots made from pooled purified fibrinogen was not 
affected by aspirin treatment in control or diabetes samples. Also, no difference 
in fibre thickness was observed comparing healthy control with poor diabetes 
control samples (Figure 4.32). 
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Figure 4.32 Fibrin clot analysis using electron microscopy (magnification of 
10000x). Fibrin fibre thickness of clots made of pooled purified fibrinogen of healthy 
controls or patients with poor diabetes control (n=12 in each pool) after incubation with 
20mmol/l glucose and glucose+10mg/l aspirin. Results represent the mean±SEM of 
200 readings from 12 images (A). Clot Images of healthy controls after treatment with 
glucose (B), and after treatment with glucose+10mg/l aspirin (C). D, E, representative 
images from patients in the glucose and glucose+10 mg/l aspirin. 
4.3.13 Fibrinogen purification 
Gel electrophoresis of purified fibrinogen, three bands were expected for 
fibrinogen (corresponding to the α, β and γ; Figure 4.33) 
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Figure 4.33 SDS-PAGE gel using electrophoresis technique showing purified 
fibrinogen. Each band of fibrinogen (α, βγ and γ) iswell defined and separated at the 
expected moleculare weight. There is no smearing or any unexpected bands. 
4.3.14 Acetylation of fibrinogen by the ex vivo effect of aspirin 
Western blot analysis was conducted to assess protein acetylation using a 
monoclonal antibody directed against acetylated protein. In the absence of 
aspirin, a faint band, corresponding to α chain of fibrinogen, was detected in 
both controls and diabetes samples indicating low level protein acetylation. This 
band was more obvious in the presence of 1 mg/l aspirin, although it remained 
faint. This band became intense after treating the samples with 10 mg/l aspirin. 
Moreover, with high aspirin concentration, a band of ~54 Kda became apparent, 
corresponding to the β chain of fibrinogen. No acetylation in γ chain was seen. 
The presence of additional glucose did not appear to affect protein acetylation. 
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Acetylation of fibrinogen was not different comparing patients with controls 
(Figure 4.34). 
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Figure 4.34 Western blotting using antibody against acetylated-lysine residues. 
Samples were prepared using pooled purified fibrinogen from healthy controls and 
diabetes patients in the presence and absence of aspirin with and without additional 
glucose (20 mmol/l). C=controls, P=patients, G=glucose, Asp=aspirin. 
4.4 Discussion  
In this Chapter I assessed the ex vivo effect of low and high aspirin 
concentration on fibrin clot formation, structure and fibrinolysis using plasma 
samples or purified fibrinogen. Both healthy controls and patients with diabetes 
were studied. Moreover, I investigated whether high glucose concentration 
modulates the effects of aspirin on clot structure and lysis.  
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There are a number of observations emerging from my studies that can be 
summarised as follows: i) Diabetes patients exhibit more compact clots with 
resistance to fibrinolysis compared with healthy controls, ii) Addition of aspirin to 
whole blood reduced lysis time of plasma clots made from healthy controls but 
not diabetes patients, iii) The fibrinolytic effects of aspirin were abolished in the 
presence of high concentrations of glucose, iv) Neither aspirin, nor glucose had 
an effect on lysis time in clots made from purified fibrinogen, v) background 
acetylation of fibrinogen was detected in patients and controls, which intensified 
after exposure to high aspirin concentration but no difference was seen 
comparing healthy controls with diabetes samples. 
Jorneskog 1996 and colleagues were the first to investigate the effect of 
diabetes on fibrin gel structure. Ten individuals with type 1 diabetes and no 
cardiovascular history were investigated. None of these patients were on any 
treatment other than insulin.Compared with 15 healthy control subjects, plasma 
clots from diabetes patients showed less permeability and more compact 
structure (Jorneskog et al., 1996). These findings support my data as, I found 
that clots made from plasma or purified fibrinogen have a more compact fibrin 
network structure with impaired fibrinolysis compared with controls.  
Clot changes in subject with diabetes have been reported in a number of 
studies (Jorneskog et al., 1996, Dunn et al., 2006, Ajjan and Ariens, 2009, Hess 
et al., 2012). These changes are related, at least in part, to post-translational 
modifications in the fibrinogen molecules (Dunn et al., 2006) caused by non 
enzymatic glycation of the protein(Brownlee et al., 1983). Pieters et al 2008 
have shown that improving glycaemic control in patients with type 2 diabetes 
decreases glycation of fibrinogen and hence improves permeability and lysis 
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rates in clots made from purified fibrinogen. This is consistent with my findings, 
which demonstrate that lower HbA1c is associated with less thrombotic clot 
phenotype(Pieters et al., 2008). 
Work from our laboratory has shown that addition of aspirin to culture media of 
fibrinogen-producing CHO cells, results in fibrinogen acetylation, which in turn 
affects clot structure and lysis (Ajjan et al., 2009). In particular, aspirin treated 
fibrinogen resulted in clots that were more porous and easier to lyse. These 
findings are consistent with my data, which demonstrated that ex vivo addition 
of aspirin to whole blood and facilitated fibrinolysis and affected clot structure, 
mainly with high aspirin concentrations. After incubation of whole blood 
withaspirin, fibrinolysis was significantly shorter with high concentration of 
aspirin. Enhanced lysis by aspirin was also observed using confocal 
microscopy. However no changes in fibrinolysis were observed, after incubation 
of purified fibrinogen with aspirin. These findings suggest that incubation of 
aspirin in whole blood could affect other plasma protein that makes clot 
fibrinolysis easier while this does not occur with purified fibrinogen. My findings 
contradict previous reports using recombinant or purified fibrinogen (He et al., 
2001). This discrepancy is likely to be related to methodological differences. 
Aspirin was added to culture media in the publication by Ajjan et al, and 
therefore exposure of fibrinogen to aspirin was longer. Moreover, it is possible 
that intracellular acetylation of the protein is important to show an effect. On the 
other hand, He et al used a purified system and showed an effect for aspirin 
using a shorter incubation period. The possibility of fibrinogen degradation 
should be borne in mind given the longer incubation time, which is less likely to 
occur under tissue culture conditions. Interestingly, a short incubation period in 
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whole blood was enough to show an effect and in retrospect, I should have had 
identical incubation periods with aspirin in whole blood and purified fibrinogen. 
Further work is warranted using purified fibrinogen at different incubation times 
with aspirin followed by SDS-PAGE analysis to investigate protein integrity and 
repeat turbidimetric analyses. 
I then moved on to study the effects of glucose on response to aspirin 
treatment. Neir et al 1991 have studied the ex vivo effects of glucose on plasma 
clot characteristics in patients with diabetes. They have shown that fibrin clot 
characteristics were altered in both healthy controls and patients with diabetes 
after the addition of high glucose concentrations immediately before the 
experiments.  In healthy control, extra glucose did not affect fibre thickness but 
permeability and compaction were significantly reduced, indicating the networks 
were altered because fibrin fibres become more tightly packed. On the other 
hand, in subjects with uncontrolled diabetes (type of diabetes was unclear), 
fibre thickness and permeability were reduced but compaction remained 
relatively unaltered (Nair et al., 1991b). My work failed to show a clear effect of 
additional glucose on clot structure but I have found that extra glucose can 
impair the fibrinolytic properties of aspirin, when clots were made from plasma 
samples, which has not been documented before.  However, no such effect was 
observed when aspirin was incubated with purified fibrinogen, indicating that 
aspirin affects other components of plasma proteins. However, the failure to 
detect a difference with purified samples may be due to methodological flaws. In 
the purified experiments, I used pooled samples and therefore these may not be 
representative of the diverse population. Also, detection of acetylation of 
fibrinogen using Western blots and radioactive aspirin techniques strongly 
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suggests that acetylation of this protein plays a role in the observed effects of 
aspirin on plasma clot lysis. Future work is required using large number of 
purified fibrinogen samples in order to establish the exact mechanism for the 
effect of aspirin on plasma clot lysis.  
In conclusion, my data show that the effects of aspirin on plasma clots in 
diabetes are compromised, which may be one mechanism for the reduced 
clinical efficacy of this agent in diabetes. The failure to detect an effect for 
aspirin on clots made from fibrinogen indicates that the observed effects in 
plasma are related to proteins other than fibrinogen or it may simply be due to 
poor sensitivity of the experimental conditions given the use of pooled protein. 
Further work is required to fully understand the mechanisms for the reduced 
effects of aspirin on plasma clot properties in diabetes.  
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Chapter 5 
Diabetes and in vivo 
modulation of the fibrin clot by aspirin 
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5.1 Introduction 
As mentioned previously, altered fibrin clot characteristics can predict the future 
development of cardiovascular disease (Fatah et al., 1996a, Fatah et al., 1992, 
Collet et al., 2006, Undas et al., 2010a). Diabetes is characterised by more 
compact fibrin networks and resistance to fibrinolysis, which appear to 
contribute to increased risk of vascular events in this population (Alzahrani and 
Ajjan, 2010). Jorneskog and colleagues were the first to report altered clot 
structure in diabetes. They have demonstrated that ex vivo plasma clots from 
patients with type 1 diabetes are less permeable and have a more compact 
structure, which is not necessarily related to changes in fibrinogen levels or the 
presence of vascular complications (Jorneskog et al., 1996). Similarly, clots 
from subjects with T2DM also display altered characteristics including smaller 
pore size and increased branch points compared with healthy controls (Dunn et 
al., 2005). Moreover, there is a relationship between fibrin clot properties in 
diabetes and the presence of vascular complications (Alzahrani et al., 2012). In 
those with established vascular disease, diabetes has an additional adverse 
effect on fibrin network structure, making individuals with diabetes and vascular 
pathology at a particularly high risk of thrombosis (Neergaard-Petersen et al., 
2014a). Therefore, modulation of fibrin clot structure in diabetes may offer a 
management strategy to reduce cardiovascular risk in this population. 
Addressing vascular risk factors, including glycaemia, smoking and lipid levels, 
improves clot structure properties in diabetes (Alzahrani and Ajjan, 2010, 
Kurdee et al., 2014). However, current therapies do not specifically target the 
fibrin network directly in order to reduce thrombosis risk and perhaps this may 
be one strategy that requires further exploration.  
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Tehrani et al have analysed the effect of low and high dose aspirin on fibrin gel 
porosity in patients with T1DM. They have shown that only high aspirin was 
able to modulate fibrin clot permeability. Unexpectedly, only patients with poor 
glycaemic control showed a significant benefit, whereas in those with good 
glycaemic control the effect was marginal (Tehrani et al., 2012). However, the 
study can be criticised for the lack of a control group and the use of a single 
technique to assess clot structure that is known to have great variability. 
Therefore, this remains an area in need of further clarification in order to 
understand the role of aspirin in modulating fibrin-related thrombosis risk in 
diabetes. 
In this chapter, I have assessed the in vivoeffects of aspirin, using two different 
doses of 75mg/day and 300 mg/dayon fibrin network characteristics in patients 
with type 1 diabetes and age/sex matched healthy controls.  
5.2 Materials and methods 
5.2.1 Patients and controls  
The same patients and controls who gave blood for platelet tests (Chapter 2), 
gave additional blood that was collected in citrated tubes (Sigma), for plasma 
clot analysis, as well as lithium heparin tubes for fibrinogen purification. 
Samples from a total of 29 patients and 29 healthy controls were collected. 
Sample collection and preparation for clots made from plasma samples 
Blood samples were collected from both patients and healthy controls at 
baseline and after 2 weeks treatment with 75mg/day aspirin. This was followed 
by a wash out period, after which individuals were treated with 300 mg/day 
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aspirin for two weeks with samples collected at baseline and end of the two 
week period. Blood samples were then centrifuged at 3000 rpm for 20 minutes, 
platelet poor plasma collected, aliquotedand stored at -80°C until analysis 
(Figure 5.1). 
Sample collection and preparation for clots made from purified fibrinogen 
Samples were collected (baseline, after 75mg/day and after 300mg/day, as 
described previously) in lithium heparin and centrifuged for 20 minutes at 3000 
rpm. Fibrinogen was subsequently purified from plasma samples as detailed in 
Chapter 2. Pools of plasma purified fibrinogen were then constructed using 12 
samples from patients with diabetes (HbA1c≥8.5%) or 12 samples from healthy 
controls (Figure 5.1). 
5.2.3 Assessment of clot structure 
Fibrin clots were made using plasma samples or purified fibrinogen and 
analysed by turbidimetric assays, laser scanning confocal microscopy and 
electron scanning microscopy as described in Chapter 2 
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Methods
Blood samples from
Diabetes and Healthy control subjects
Turbidimetric assays for pool
(assess clot structure  and lysis) 
Confocal microscopy, Electron microscopy 
Centrifuge and store PPP at -80° C
Turbidimetric assays
(assess clot structure and lysis)
Confocal microscopy, Electron microscopy
Pool of 12 samples of purified 
fibrinogen from poor diabetes 
controls  and pool of 12 samples 
from healthy controls before and 
after in vivo treatment with 75 or 
300mg/day aspirin 
Lithium heparin Sodium citrate
Centrifuge  and store PPP at -80° C
Purify fibrinogen using column chromatography
29 samples of patients with 
diabetes and 29 samples of 
healthy control subjects before 
and after of in vivo treatment 
with 75/day, 300mg/day aspirin
Figure 5.1 Summary of sample selection and preparation. Blood samples from 
diabetes and controls were collected before and after treatment with aspirin 75mg/day or 
300mg/day (two weeks each with two weeks wash out period). For plasma fibrin clot 
analysis, samples were collected in sodium citrate, whereas lithium heparin tubes were 
used to collect plasma samples for fibrinogen purification. 
5.3 Results 
5.3.1 Turbidimetric analysis of plasma fibrin clots  
Lag phase  
Low and high daily dose of aspirin (75mg/day and 300mg/l respectively) had no 
effect on lag phase in individuals with diabetes (Figure 5.2A) or in controls 
(Figure 5.2B). Glycaemic control, assessed as HbA1c, did not influence the 
effects of aspirin on lag phase (Figure 5.2 C, D respectively).  
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There was no difference in lag phase between controls and individuals with 
diabetes at baseline (Figure 5.3).No significant changes have been observed 
after excluding the two smokers. 
A
C
B
D
Figure 5.2 Aspirin on plasma clot lag phase using turbidity and lysis technique. 
Effects of different daily dose of aspirin 0, 75, and 300mg/day on lag phase in subjects 
with diabetes (A; n=29), healthy controls (B; n=29), subjects with poor diabetes control 
(C; n=15) and subjects with better diabetes control (D; n=14). Results(measured by 
seconds) are presented as mean±SEM. 
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Figure 5.3 Aspirin on plasma clot lag phase using turbidity and lysis technique. 
Effects of different daily dose of aspirin on lag phase in subjects with diabetes(n=29) 
and healthy controls (n=29). Results(measured by seconds) are presented as 
mean±SEM. Sec: seconds. 
Maximum turbidity  
Low daily dose of aspirin (75 mg/day) and high daily dose (300mg/day) had no 
effect on fibrin clot maximum absorbance in patients (Figure 5.4A) or in controls 
(Figure 5.4B). The same observation was found in both individual with poor 
diabetes control (HbA1c≥8.5%) and individuals with better diabetes control 
(HbA1c<8.5; Figure 5.4 C, D respectively).  
Comparing individuals with diabetes and healthy controls, maximum 
absorbance was higher in the former group only with 300 mg daily dose of 
aspirin (0.21±0.01 and 0.16±0.01 respectively p=0.016, Figure 5.5 A). While 
comparing individuals with poor and better diabetes control, maximum 
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absorbance was higher in the former group only in the absence of aspirin 
(0.22±0.15 and 0.18±0.015 respectively p=0.04, Figure 5.5 B). No significant 
changes have been observed after excluding two smokers. 
A B
DC
Figure 5.4 Aspirin on plasma clot maximum absorbance using turbidity and lysis 
technique. Effects of different daily dose of aspirin 0, 75, and 300mg/day on maximum 
absorbancein subjects with diabetes (A; n=29), healthy controls (B; n=29), subjects 
with poor diabetes control (C; n=15) and subjects with better diabetes control (D; 
n=14). Results are presented as mean±SEM. AU: arbitrary units. 
164 
 
A B
Figure 5.5 Aspirin and plasma clot maximum absorbance using turbidity and 
lysis technique. Effects of different daily dose of aspirin on maximum absorbance in 
(A) plasma of subjects with diabetes (n=29) and healthy controls (n=29), (B) plasma of 
subjects with poor controlled diabetes (n=15) and better controlled diabetes (n=14). 
Results are presented as mean±SEM. 
Lysis time  
There was no effect of low or high daily dose of aspirin on clot lysis time in 
individuals with diabetes (Figure 5.6A). However, in healthy controls, lysis time 
has significantly reduced from 550±26 before treatment with aspirin to 510±16 
after treatment with high dose of aspirin (300mg/day, p=0.02, Figure 5.6B). 
There was no difference in response in those with poor or better diabetes 
control (Figure 5.6 C, D). Comparing diabetes subjects with healthy controls, 
clot lysis time at baseline was longer in the former group compared with the 
latter but failed to be significant (596±32 and 550±26, respectively), with a 
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bigger difference detected following highdose aspirin treatment (602±32 and 
510±16, respectively; p=0.03,Figure 5.7). No significant changes were observed 
after excluding the two smokers. 
BA
DC
 
Figure 5.6 Aspirin on plasma clot lysis time using turbidity and lysis technique. 
Effects of different daily dose of aspirin 0, 75, and 300mg/day on lysis time in subjects 
with diabetes (A; n=29), healthy controls (B; n=29), subjects with poor diabetes control 
(C; n=15) and subjects with good diabetes control (D; n=14). Results (measured by 
seconds) are presented as mean±SEM. 
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Figure 5.7 Aspirin on plasma clot lysis time using turbidity and lysis technique 
for patients and controls. Effects of different daily dose of aspirin on lysis in subjects 
with diabetes (n=29) and healthy control (n=29). Results (measured by seconds) are 
presentedas mean±SEM. 
5.3.2 Scanning confocal microscopy of plasma fibin clots  
Fibrin clot structure  
Fibrin structure before and after aspirin therapy with 75mg/day and 300mg/day 
of plasma clots from a pool of healthy controls is shown in Figure 5.8 A-C 
respectively. Only high dose of aspirin (300mg/day) made the fibrin clots more 
porous in healthy control (Figure 5.8 C). There was no clear difference in poor 
control diabetes and healthy controls in relation to plasma clot density (Figure 
5.8A, Figure 5.9 D, respectively).  
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A
Figure 5.8 Confocal microscopy of 20 μm Z-stack of mature fibrin clot of healthy 
control (magnification of 400x). Fibrin clots were made from pooled plasma of 
healthy controls (n=12) before aspirin treatment (A), after 75 mg/day aspirin treatment 
(B) and after 300 mg/day aspirin treatment (C). 
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Figure 5.9 Confocal microscopy of 20 μm Z-stack of mature fibrin clot of healthy 
control (magnification of 400x). Fibrin clots were made from pooled plasma of poor 
diabetes control (n=12) before aspirin treatment (D), after 75mg/day aspirin treatment 
(E) and 300mg/day aspirin treatment (F). 
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Clot lysis analysis 
Fibrinolysis of mature clots was observed in real time using laser scanning 
confocal microscopy. I recorded lysis time in at least four independent 
experiments for each condition. Low or high dose of aspirin had no effect on clot 
lysis time of pooled plasma from individuals with poor diabetes control at 
baseline, following 75 or 300 mg/day aspirin (507±35 sec, 532±49 sec and 
507±89, respectively; p>0.1, Figure 5.10A). There was a reduction in lysis time 
of pooled plasma clots from healthy controls from 556±103 sec before treatment 
with aspirin to 441±80 sec after treatment with 75mg/day aspirin. (p=0.03, 
Figure 5.10B). There was also a reduction in lysis time with 300mg/day 
aspirinbut this failed to reach statistical significance (Figure 5.10B).  
30 5 7
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B
Figure 5.10 Aspirin and plasma clot lysis (magnification of 400x). The results 
represent the mean±SEM of 4 independent lysis experiments of clots made from 
pooled plasma samples of subject with poor diabetes control (n=12) (A) or healthy 
controls (n=12) (B). Representative figures of clot lysis using healthy control plasma at 
various time points before (C) and after 75 mg/l aspirin treatment (D). 
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5.3.3 Scanning electron microscopy of plasma fibrin clot 
There was no significant effect of aspirin on fibre thickness of clots made from 
patients with diabetes before, after 75 mg/day with a trend observed with 300 
mg/day aspirin (65±1.6 and 68±1.9 and 70±2 nm, respectively; p=0.1 and 
p=0.09, compared with baseline, Figure 5.11A). There was no significant 
difference in clots made from pooled plasma of healthy controls before and after 
aspirin treatment with 75 mg/day (64±1.7nm and 67±3 nm, respectively; p=0.6), 
whereas fibre thickness increased with 300 mg/day aspirin (73±2 nm, p=0.0006 
compared with baseline). Pore size also increased with aspirin treatment in 
healthy controls but not individuals with diabetes (Figure 5.12).
BA
Figure 5.11 The effect of aspirin in fibrin fiber thickness measures (in electron 
microspore images, magnification of 10000x using ImageJ software). In vivo effects 
of different daily dose of aspirin on fibrin fibre thickness in clots made from pooled 
plasma of subjects with poor diabetes control (n=12, A) or healthy controls (n=12, B). 
Results are presentedas mean±SEM. 
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Figure 5.12 Aspirin and fibrin clot ultrastructure using electron microscopy 
(magnification of 10000x). Clot Images of pooled plasma from healthy controls(n=12) 
before (A) and after 75 mg/day or 300 mg/day aspirin (B, C). Clot images of pooled 
plasma from patients with poor diabetes control (n=12) before (D) and after 75 mg/day 
or 300 mg/day aspirin daily dose (E, F). 
5.3.4 Turbidimetric analysis of plasma purified fibrinogen clots 
Maximum absorbance 
No significant effect of low or high daily dose of aspirin on maximum 
absorbance in individuals with diabetes was noted (Figure 5.13A). In contrast, 
aspirin treatment with 75mg/day increased fibrin clot maximum absorbance in 
controls from 0.04±0.004 to 0.05±0.007 (p=0.02) and to 0.06±0.009 (p=0.02) 
after treatment with 300mg/day respectively (Figure 5.13B). 
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Figure 5.13 Aspirin and clot maximum absorbance using purified fibrinogen 
(turbidity and lysis technique). Maximum absorbance was measured after daily 
aspirin administration at 0, 75, and 300mg/day using pooled purified fibrinogen from 
subjects with diabetes (A; n=12) or healthy controls (B; n=12). Results are presentedas 
mean±SEM of three independent experiments each conducted in duplicate. 
Lysis time  
There was no significant difference in lysis time before and after treatment with 
75mg/day or 300mg/day in patients with diabetes or in healthy controls (Figure 
5.14).  
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Figure 5.14 Aspirin and clot lysis time of fibrin clot from purified fibrinogen 
(turbidity and lysis technique). Lysis time was measured after daily aspirin 
administration at 0, 75, and 300mg/day using pooled purified fibrinogen from subjects 
with diabetes (A; n=12) or healthy subjects (B; n=12). Results are presented as 
mean±SEM of three independent experiments each conducted in duplicate. 
5.3.5 Scanning confocal analysis of fibre clot from plasma purified fibrinogen 
clot 
Clot image  
Fibrin structure before and after aspirin therapy with 75mg/day and 300mg/day 
of made from healthy control pooled purified fibrinogen is shown in Figure 
5.15A-C. Only high dose of aspirin (300mg/day) made the fibrin clots more 
porous in healthy controls. A similar finding was detectedin patients with poor 
diabetes control (Figure 5.16 D-F). Without aspirin treatment, there was no clear 
difference between controls and patients in relation to clot density (Figure 5.15 
and 5.16, respectively).  
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Figure 4.15 Confocal microscopy of 20 μm Z-stack of fibrin clots made from 
healthy controls purified fibrinogen. Fibrin clots were made from pooled fibrinogen 
of healthy controls (n=12) before aspirin treatment (A), after 75, 300 mg/day aspirin (B, 
C; respectively).  
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Figure 4.16 Confocal microscopy of 20 μm Z-stack of fibrin clots made from 
patients with poor diabetes control purified fibrinogen. Fibrin clots were made from 
pooled fibrinogen of subjects with poor diabetes control (n=12) before aspirin treatment 
(D) and after 75, 300 mg/day aspirin (E, F; respectively). 
  
176 
 
Clot lysis analysis 
Fibrinolysis observed in real time using laser scanning confocal microscopy. 
Lysis time readings of different four slides for each pool have been recorded 
(Figure 5.17 A, B). There was no significant reductionobserved in lysis of clots 
made from purified fibrinogen of individuals withpooe diabetes control (Figure 
5.17A). In healthy controls,lysis time did not show significant changes following 
aspirin therapy (Figure 5.17B). 
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Figure 5.17 Fibrinolysis of mature clots made from purified fibrinogen. Results 
are presentedas mean±SEM of 4 independent lysis experiments. Clots were made 
from pooled purified fibrinogen of subjects with poor diabetes control (n=12;A) or 
pooled protein from healthy controls (n=12; B). Representative figures of clot lysis 
using control purified fibrinogen at various time points (measured in minutes) before (C) 
and after 300mg/l aspirin treatment (D). 
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5.3.6 Scanning electron microscopy of plasma purified fibrinogen clot 
Fibrin fibre size analysis 
There was no significant effect of aspirin on clots made from patients with poor 
diabetes control before, after 75 mg/day or 300 mg/day aspirin (66±1.8 and 
66±1.9 and 69±1.9 nm, respectively; p=0.6 and p=0.2, Figure 5.18A). 
No significant difference in fibrin fibre thickness of clots made from pooled 
purified fibrinogen from healthy controls before and after aspirin treatment with 
75 mg/day (70±1.9 and 73±1.8nm, respectively; p=0.2) while with 300 mg/day 
aspirin treatment, the fibrin fibre size was significantly increased (77±2.3 nm, 
p=0.02 compared with baseline). Also, larger pore size was detected in healthy 
controls following treatment with 300 mg/day aspirin (Figure 5.18). 
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Figure 5.18 Effect of aspirin in purified fibrin fiber thickness measures (in 
electron microspore images, magnification of 10000x using ImageJ software). 
Clots were madefrom pooled purified fibrinogen of subjects poor diabetes control 
(n=12, A) or healthy controls (n=12, B). Results are presentedas mean±SEM of a total 
of 200 readings. 
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Figure 5.19 Fibrin clot Images using scanning electron microscopy 
(magnification of 10000x). Clots were made from pooled healthy control fibrinogen 
(n=12) before (A) and after 75 mg/day or 300 mg/day aspirin therapy (B, C) or poor 
diabetes control (D, E and F, respectively). 
5.3.7 Acetylation of fibrinogen by radioactive aspirin  
I further assessed acetylation of pooled fibrinogen from diabetes subjects and 
controls (n=12 each) using radioactive techniques. Two different formulations of 
this agent were tested: C14-labelled aspirin at the acetyl group and C14-
labelled aspirin at the carboxyl group, which provided back ground radiation and 
used as a negative control. Experiments were repeated on 3 different occasions 
and mean difference in radioactive counts were calculated for diabetes and 
control fibrinogen. I found incorporation of acetyl C14 into all three chains of 
fibrinogen. There was small decrease of acetyl C14 incorporation into diabetic 
fibrinogen compared with control protein with reduced α chain acetylation by 
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18.3%, β chain by 12.7% and γ chain by 20.6%. Data are summarised in Figure 
5.20.                             
 
Figure 5.20 Acetylation of purifiedfibrinogen from subjects with poor diabetes 
control and healthy controls. Mean percentage of acetylation reduction in the 
different chains of fibrinogen (A) and all chains of fibrinogen (B) from a pool of controls 
and a pool of patients with diabetes (n=12 for each). Data shown represent the 
mean±SEN of a 3 independent experiments. 
5.4 Discussion  
In this Chapter I assessed the in vivo effect of low (75mg/day) and high 
(300mg/day) daily dose of aspirin on fibrin clot formation, structure and 
fibrinolysis using plasma samples and purified fibrinogen. Both healthy controls 
and patients with diabetes were studied. There are a number of observations 
emerging from my studies that can be summarised as follows: i) Diabetes 
patients exhibit more compact clots compared with healthy controls, ii) In 
healthy controls, aspirin administration results in altered plasma clot turbidity 
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and reduced lysis time, an effect that is not found in those with diabetes, iii) 
Aspirin administration to healthy controls alters the structure of clots made from 
purified fibrinogen but has no effect in individuals with diabetes. 
In order to determine whether aspirin and antioxidant therapy, combined or 
alone, are more effective in reducing the development of cardiovascular events 
in patients with diabetes (T1DM or T2DM), a large prospective study found that 
100 mg aspirin daily dose in diabetic patients has no effect in primary 
prevention of cardiovascular events and mortality (Belch et al., 2008). Nearly 
the same observation was recorded by another large prospective study which 
demonstrated that low dose of aspirin (81- 100mg/day) as a primary prevention 
did not reduce the risk of cardiovascular events in patients with T2DM (Ogawa 
et al., 2008). Aspirin is unique amongst antiplatelet agents by modulating both 
platelet function and fibrin clot structure/lysis (Ajjan et al., 2009). The 
mechanisms for clinical aspirin treatment failure in diabetes are not entirely 
clear and it is possible that an interaction between acetylation and glycation at 
the level of fibrinogen could modulate the fibrinolytic properties of aspirin, thus 
contributing to reduced efficacy of this agent in diabetes. 
My data show that high dose of aspirin (300mg/day) facilitates fibrinolysis in 
healthy controlswith no effect observed in patients with diabetes. Interestingly, 
glycaemic control, measured as HbA1c, had no effect on response to treatment 
in the diabetes group. It should be noted, however, that the numbers became 
small once patients were divided into poor and better diabetes control and the 
study was not powered to investigate at subgroups. Therefore, concrete 
conclusions regarding interaction between glycaemic control and response to 
aspirin therapy cannot be made. Interestingly, there was a reduction in 
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acetylation of diabetic fibrinogen using radioactive techniques, although the 
magnitude of the effect was small and it does not necessarily explain the 
difference in plasma clot lysis comparing controls with diabetes patients. 
When comparing data generated using clots made from plasma samples with 
clots made from purified fibrinogen, there were similarities but also notable 
differences. Aspirin affected structure of clots made from plasma as well as 
clots made from plasma-purified fibrinogen. However, aspirin only affected 
plasma clot lysis and had no effect on fibrinolysis in clots made from purified 
fibrinogen. There is a number of explanations for these results. First, it is 
possible that aspirin may have affected plasma proteins other than fibrinogen, 
and therefore it was able to modulate lysis of plasma clots, but not clots made 
from purified fibrinogen. Second, given that pooled samples were used in the 
purified experiments, it is possible that some minor differences were missed 
and ideally the experiments should have been conducted using individual 
purified fibrinogen samples. However, this was not possible given the limited 
yield of fibrinogen and the need to perform several repeat experiments to 
ensure robustness of the data. Third, the failure to detect differences in lysis 
time using clots made from purified fibrinogen may be related to methodological 
issues. Although a standard methodology was used, lysis time was relatively 
short in the purified experiments. In retrospect, I should have experimented with 
different concentrations of plasminogen and tPA and this is perhaps an area for 
future research. My work shows that in vivo aspirin therapy can modulate 
structure/and or lysis of fibrin clots made from plasma or purified fibrinogen of 
healthy controls. In contrast, aspirin treatment has no effect on fibrinolysis in 
individuals with diabetes regardless of glycaemic control. It was interesting to 
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note that only high dose aspirin resulted in changes to clot characteristics in 
healthy controls. Given that aspirin can be used to protect from venous 
thrombosis (Donohoe et al., 2011), regarded as a fibrin rather than a platelet 
clot, future research needs to consider whether 300 mg/day aspirin represents a 
better option in these patients than the standard 75 mg/day dose. 
Data generated in this Chapter using in vivo studies are largely similar to the 
pervious Chapter employing ex vivo work. Therefore, it can be argued that ex 
vivo studies can replace in vivo work for the assessment of aspirin effects on 
the fibrin network. It remains unclear, however, whether the effects of aspirin on 
the fibrin structure are meaningful clinically. There are some cross-sectional 
studies suggesting that this may indeed be the case but prospective longitudinal 
studies are requiredin order to draw definitive conclusions. 
In summary, the current chapter shows that aspirin affects the clot structure in 
healthy controls, although high doses of this agent were required, at 300 
mg/day, to show an effect. The observed alterations in clot properties by aspirin 
in healthy control appear to be due to changes in the fibrinogen molecule, 
although an additional effect on plasma proteins cannot be ruled out. In 
contrast, aspirin fails to modulate clot structure in individuals with diabetes 
regardless of the dose of aspirin used or the level of glycaemic control. My work 
does not rule out, however, that aspirin may be more efficacious in those with 
near normal blood glucose levels as most of the patients studied had poor 
glycaemic control.   
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Chapter 6 
Platelet-fibrinogen interaction 
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6.1 Introduction 
Platelet-fibrinogen interaction is essential for the formation of the intravascular 
thrombus. The interaction of fibrinogen with activated platelets mainly occurs via 
the integrin receptor complex, glycoprotein (GP) IIbIIIa (αIIbβ3) (Nachman et al., 
1984, Phillips et al., 1991). This complex receptor consists of two glycoproteins: 
IIb (integrin αIIb) and IIIa (integrin β3) (Floyd and Ferro, 2012). In a single 
platelet, there are about 80,000 (GPIIbIIIa) complex, making it the most 
predominant  receptor on the platelet surface (Wagner et al., 1996). This 
number could be increased by the internal pool of αIIbβ3 that exist on α-granules 
inside the platelet, that can move to the surface during platelet activation 
(Wencel-Drake et al., 1986). In addition to binding to fibrinogen,αIIbβ3 can bind 
Von Willebrand factor (vWf) which has a significant role in haemostasis, as 
previously described (section 1.1.2.2).  
There are two main sites on fibrinogen that are responsible for binding αIIbβ3 on 
platelets. It has been shown that the mainsequence mediating fibrinogen 
binding to platelet was the carboxy-terminal sequence on the gamma chain, 
γ406-411 (Kloczewiak et al., 1984).Arg-Gly-Asp (RGDsequences) also bind 
platelets and fibrinogen has two of these sequences on each α-chain. The first 
resides close the N-terminus (AA95-97) with the second towards the C-terminus 
(AA572-574) (Doolittle et al., 1979, Rixon et al., 1983, Sadler et al., 1985).Plow 
et al. (1985) have also explored the presence of (RGD) peptide in vWF and 
investigated its contributions to fibrinogen and vWF binding to platelets. They 
found that RGD containing peptides contribute toenhancing fibrinogen and vWF 
binding to platelets (Plow et al., 1985). 
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As platelets fibrinogen binding is an essential process in the construction of 
platelet-mediated thrombus, factors that modulate this interaction would have a 
crucial role in blood thrombus formation. Preliminary work from our laboratory, 
using recombinant techniques, has shown that exposure of fibrinogen to aspirin 
alters platelet binding properties of the protein (unpublished data). Given our 
findings and the general lack of studies adequately addressing platelet-
fibrinogen interaction in diabetes, the aims of this Chapter were to:  
i) Understand the effects of aspirin on platelet-fibrinogen interaction using 
fibrinogen purified from healthy controls. 
ii) Establish the effects of glucose on this interaction.  
iii) Investigate whether post-trasnslational modifications of fibrinogen in diabetes 
alterinteraction with platelets.  
A combination of in vivo and ex vivo experiments were conducted using 
fibrinogen purified from healthy controls and patients with diabetes. 
6.2  Materials and methods 
In order to study platelet-fibrinogen interaction, two techniques were used. We 
developed a method that relies on labelling fibrinogen and studying its binding 
to platelets using flow cytometry.Also, static platelet-fibrinogen binding 
experiment were performed based on the methods for measurement of platelet 
adhesion in microtiter plates technique (Bellavite, 1993). 
6.2.1 Patients and controls  
Plasma samples were stored from the same patients and controls who gave 
blood samples for the platelet test and clot structure (Chapter 2, 3, 4). Platelet 
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fibrinogen binding studies were conducted in this group using purified 
fibrinogen.  
6.2.2 Purified fibrinogen 
Samples collected in lithium heparin for fibrinogen purification as detailed in 
Chapter 2 (section 2.3). Pools of plasma purified fibrinogen were then 
constructed using 6 samples from healthy controls and6 samples from type 1 
diabetes patients with poor glycaemic control (HbA1c≥8.5%). For ex vivo test, 
different concentrations of aspirin 0 and 10mg in the presence and absence of 
additional glucose (20 mM) were added to pools of purified fibrinogen. Samples 
were then incubated for 24 hrs at 4°C.  
For in vivo test, plasma pools of 6 samples from healthy controls and 6 samples 
from type 1 diabetes patients with poor glycaemic control (HbA1c≥8.5%) were 
made before and after treatment of the individuals for 2 weeks with aspirin at 75 
mg/day, or 300 mg/day aspirin. Pools of fibrinogen were used for platelet 
fibrinogen binding using flow cytometry or static platelet experiments. 
6.2.3 Labelling of fibrinogen for flow cytometry experiment 
In order to measure fibrinogen binding with platelets using flow cytometry 
technique, pools of fibrinogen were labelled using Alex Flour 647 Monoclonal 
antibody labelling kit as described in section 2.8.2 
6.2.4 Measuring of labelled fibrinogen concentration for flow cytometry 
experiment 
The labelled fibrinogen was measured as described in section 2.8.2 
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6.2.5 Preparation of platelets and platelets-fibrinogen binding reaction tube  
Platelets were collectedform healthy volunteers and platelet-fibrinogen 
interactions Static experiments were performed in section 2.8.1. Figure 6.1 
summarised the methods. 
Methods  
Blood samples from diabetes and healthy control subjects
(Collected in sodium citrate containing tube)
Add aspirin (0 & 10 mg/l) without or 
with excess glucose (20 mmol/l)  for 
24hrs.
Fibrinogen purification  then pool 
the sample (n=6) 
Testing fibrinogen binding 
with healthy platelets 
collected in (ACD)
Labeling fibrinogen  
Testing fibrinogen binding 
with healthy platelets 
collected in (ACD)
Flowcytometry Static  test
Figure 6.1 Summary of sample selection and preparation. Blood samples from 
diabetes and controls were collected followed by fibrinogen purification from each 
sample. Fibrinogen from 6 healthy controls and 6 patients with diabetes were pooled. 
Pooled fibrinogen samples were then incubated with 0 and 10mg/l of aspirin with and 
without additional glucose for 24 hrs at 4ºc followed by testing platelet-fibrinogen 
interactions using healthy control platelets. ACD: Acid citrate dextrose. 
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6.3 Results 
6.3.1 Optimisations of flow cytometry 
Conditions for fibrinogen concentration, the effects of ADP, tirofiban, using 
washed or whole blood platelets were optimised.  
Measuring of labelled fibrinogen concentration  
There was no significant difference in fibrinogen concentrations between the 
pool of patients and controls (p>0.1; Figure 6.2).   
It is worth noting that the final concentration of fibrinogen using protein exposed 
to aspirin in vivo was higher than the concentration of fibrinogen in samples 
pooled after the in vitro addition of aspirin, which is explained by the dilution 
effect following the addition of aspirin to the samples. Fibrinogen concentrations 
in the experiments were subsequently kept constant using appropriate dilutions 
as detailed in Table 2.1 
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Figure 6.2 Fibrinogen concentration readings using NanoDrop (mg/ml). Readings 
of fibrinogen concentrations using pools of patients and controls before and after 
aspirin treatment ex vivo or in vivo. The effects of additional 20 mmol/l ex vivo glucose 
were also investigated. 
Fibrinogen binding with washed or whole blood platelets and the effect of 
ADP/tirofiban  
A number of experiments were conducted to assess platelet interactions with 
fibrinogen using washed platelets for specific αIIbβ3-fibrinogen investigations or 
platelets in their natural environment (whole blood) to demonstrate physiological 
relevance.  
Using whole blood samples, platelets were identified by their characteristic light 
scattering, and 10,000 events were collected for each sample. In this 
experiment, 50 μg/ml of labelled fibrinogen was used. Also to test effects of 
ADP on fibrinogen platelet binding, basal platelet (without added ADP) and 
activated platelet (after adding 10uM ADP) analyses were conducted in both 
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whole blood and washed platelets. It appeared that washed platelets did indeed 
enhance the fluorescence signal, but that was at the expense of an increased 
background of non-specific binding. The high background was evidenced by a 
detectable signal that was not decreased by the presence of the αIIbβ3 inhibitor 
tirofiban. This non-specific binding was present in both methods but was 
particularly pronounced with washed platelets. ADP treatment resulted in 
enhanced fluorescence signal using washed platelets or whole blood, 
emphasising the sensitivity of this technique (Figure 6.3). 
 
 
Figure 6.3 Mean fluorescence intensity of platelet fibrinogen binding in flow 
cytometry using whole blood and washed platelets. Cells represent platelet 
fluorescence intensity in the absence of fibrinogen. Basal shows fluorescence following 
incubation of platelets with fibrinogen without any agonist added. Fluorescence 
increases in the presence of 10 µM ADP, whereas inhibition is evident after incubation 
with 50 µg/ml Tirofiban, a known αIIbβ3 inhibitor. 
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6.3.2 Optimisation of static platelet fibrinogen binding 
Optimising fibrinogen concentration   
Differentconcentrations of fibrinogen were used for coating the wells followed by 
adding platelets as detailed in section 2.7. Low fibrinogen concentration 0.001 
and 0.01mg/ml did not show enough binding with platelets while there was 
significant binding with 0.1, 0.125, 0.25, 0.5, and 1 mg/ml (Figure 6.4). The 
readings show the mean±SEM of three independent experiments.  
 
 
 
Figure 6.4 Reading of platelet-fibrinogen interaction in static tests. Plates were 
coated with increasing concentrations of fibrinogen ranging from 0.001 to 1mg/ml. The 
readings show the mean±SEM of three repeat experiments.  
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Specificity of platelet binding to fibrinogen 
In order to ensure specific platelet binding to fibrinogen and that binding occurs 
with the integrins αIIbβ3, I used bovine serum albumin (BSA) and C3 as control 
proteins with and without αIIbβ3 inhibitor tirofiban. The concentration of all these 
proteins was 1mg/ml. The binding of platelets with BSA and C3 was very low 
0.1±0.004 and 0.16±0.04 respectively. Binding of platelets to fibrinogen was 
0.65±0.03 and it was inhibited by tirofiban to reach 0.17±0.006 Readings show 
the mean±SEM of three repeat experiments (Figure 6.5).  
 
 
 
Figure 6.5 Platelet interaction with bovine serum albumin (BSA) complement C3 
and fibrinogen. Plates were coated with BSA, C3 or fibrinogen at 1mg/ml. The 
readings show the mean±SEM of three repeat experiments with tirofiban used to test 
for αIIbβ3 specificity. AU: arbitrary units 
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6.3.2 Ex vivo effect of aspirin on platelet fibrinogen binding 
Fluorescence measurement can be expressed either as the percentage of 
positive cells above the threshold set with an appropriate negative control or as 
the mean or median fluorescence intensity (MFI) of a population of cells. The 
median is the most appropriate measure that shows a non-Gaussian or 
heterogeneous distribution on the platelet population.  Percentage positive data 
are used primarily to measure an increase in the percentage of platelets that 
are bound to labelled fibrinogen, whereas MFI is used to quantify the level of 
expression of fibrinogen that is bound to platelets. Thus, measurement of both 
was undertaken to analyse the affinity and avidity of platelet fibrinogen binding 
under these conditions.  
Aspirin and glucose reduce binding affinity of healthy control, but not diabetic 
fibrinogen to platelets in flow cytometry  
The concentration of pooled fibrinogen from different conditions was similar 
ranging between 0.22-0.26 mg/l (Figure 6.6A). Binding of fibrinogen from 
patients with poor diabetes control to platelets was not affected by the presence 
of aspirin and/oradditional glucose compared with baseline. Aspirin-treated 
fibrinogen resulted in a non-significant increase in binding (3.7±4.4% p=0.4) that 
was not affected by the presence of glucose (3.2±4.5%, p=0.5). Glucose alone 
had no effect on fibrinogen binding to platelets (-1.6±2.2%, p=0.4, Figure 6.6B).  
In contrast, aspirin-treated fibrinogen from healthy controls showed decreased 
platelet binding (-13.3%±2.2 p=0.019) compared with untreated protein, with a 
further inhibition in the presence of additional glucose (-15.9±2% p=0.0006). 
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Interestingly, glucose alone also showed an inhibitory effect at10.1±1.5% 
(p=0.001; Figure 6.6C). 
A
B C
Figure 6.6 The effects of ex vivo aspirin treatment on fibrinogen-platelet 
interactions assessed as percentage of platelet binding. A. Fibrinogen 
concentration was kept constant in the various experiments. B, C. Percentage of 
platelets bound topooled purified fibrinogen from patients with poor diabetes control (P, 
n=6) or healthy controls (Cont., n=6). Purified fibrinogen was incubated without or with 
10 mg/l aspirin (asp), 20 mmol/l glucose (glucose) or both (g+asp). The results 
represent the percentage of cells binding fibrinogen (Fg) corrected for baseline 
(mean±SEM) of 6 independent experiments. 
Aspirin and glucose reduce binding avidity of healthy control, but not diabetic 
fibrinogen to platelets 
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Fluorescence intensity of bound fibrinogen was used as an index to estimate 
the amount of fibrinogen bound per platelet and thereby show binding avidity. 
Similar to results for the binding affinity, platelet-fibrinogen fluorescence 
intensity using fibrinogen from diabetes patients was not affected by aspirin 
and/or glucose therapy compared with baseline. Aspirin-treated fibrinogen from 
patients with poor diabete controlresulted in a non-significant decrease in 
fluorescence intensity (-4376±1108, p=0.1) that was not affected by the 
presence of glucose (2125±697, p=0.09). Glucose alone had no effect on 
theflorescence intensity of fibrinogen binding to platelets (-702±878% p=0.1, 
Figure 6.7 A).  
In contrast, aspirin-treated fibrinogen from healthy controls showed decreased 
fluorescence intensity (-4515±1401, p=0.02) compared with untreated protein, 
with a possible further inhibition in the presence of additional glucose 
(4941±1375 p=0.016). Glucose alone also showed a significant inhibitory effect 
(-3625±979 p=0.012) (Figure 6.7 B).  
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Figure 6.7 Platelet-fibrinogen interaction studies and median fluorescence 
intensity. Platelet binding of pooled purified fibrinogen was tested in the presence of 
10 mg/l aspirin, 20 mmol/l excess glucose or both using protein from patients withpoor 
diabetes control (A) or healthy controls (B). The results represent the mean±SEM of 6 
independent experiments. 
Ex vivo aspirin and glucose fail to show an effect on platelet binding to 
fibrinogen in static tests 
Binding of fibrinogen from patients with poor diabetes control to platelets was 
not affected by the presence of aspirin and/oradditional glucose compared with 
baseline (A). The same observation was shown in controls (Figure 6.8 A, B). 
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A B
Figure 6.8 Static Platelet-fibrinogen interactions. Platelet binding of pooled purified 
fibrinogen was tested in the presence of 10 mg/l aspirin (asp), 20 mmol/l excess 
glucose (Glucose) or both (g+asp) using protein from patients with poor diabetes 
control (A) or healthy controls (B). The results represent the mean±SEM of 6 
independent experiments. 
6.3.3 The effects of in vivo aspirin administration on platelet fibrinogen binding 
In vivo aspirin treatment reduces binding of healthy control, but not diabetic 
fibrinogen to platelets 
The concentration of pooled fibrinogen ranged between 0.4 and 0.5 mg/l and 
there were no differences between different pools (Figure 6.9 A). Low daily 
dose of aspirin (75mg/day) did not inhibit the ability of fibrinogen pooled from 
patients with poor diabetes control to bind platelets. A non-significant increase 
in fibrinogen binding to platelets was observed after in vivo treatment with 75 
mg/day of aspirin (3.9±2.9% p=0.2, Figure 6.9 B). However, 300 mg/day of 
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aspirin showed a significant increase in binding to platelets (10±3.9% p=0.03, 
Figure 6.11 B).  
In contrast, fibrinogen from healthy controls showed a reduction in binding after 
in vivo treatment with 75 mg/day of aspirin (-12.8±4.9% p= 0.048) but not with 
higher aspirin dose (-2.6±2.9%, Figure 6.8 C). 
A
CB
Figure 6.9 The effects of in vivo aspirin treatment on fibrinogen-platelet 
interactions assessed as percentage of platelet binding.  A. Comparison of the 
amount fibrinogen pooled separately from controls and patients with poor diabetes 
control after treatment with 75 or 300 mg/day with aspirin for two weeks. B. Percentage 
of platelets bound to purified fibrinogen pooled from individuals with diabetes (n=6) 
following low and high dose aspirin therapy corrected for baseline. C. Percentage of 
platelets bound to purified fibrinogen pooled from healthy controls (n=6) following low 
and high dose aspirin therapy corrected for baseline. The results represent the 
mean±SEM of 6 independent experiments. 
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Fluorescence intensity 
In patients with poor diabetes control, treated with 75 mg/day, there was an 
increase in fluorescence intensity, indicating higher binding (2874±917 
p=0.026). Treatment with 300mg/day also resulted in a significant increase in 
fluorescence intensity (4129±766 p=0.003) (Figure 6.10A). In contrast, 
75mg/day aspirin treatment in controls showed a non-significant decrease in 
fluorescence intensity (-5245±3193; p=0.3) with no effect observed following 
treatment with 300mg/day (-1161±1351; p=0.7; Figure 6.10B).  
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A B
Figure 6.10 The effects of in vivo aspirin treatment on fibrinogen-platelet 
interactions assessed as fluorescent intensity. A. Median fluorescence intensity of 
platelets bound to purified fibrinogen from pooled patients with poor diabetes control 
samples (n=6) after aspirin treatment, corrected for baseline. B. Median fluorescence 
intensity of platelets bound to purified fibrinogen from pooled healthy controls (n=6) 
after aspirin treatment,corrected for baseline. The results represent the mean±SEM of 
6 independent experiments. 
 
In vivo aspirin fails to show an effect on platelet binding to fibrinogen in static 
tests 
Low daily dose of aspirin (75 mg/day) and high daily dose (300 mg/day) did not 
significantly inhibit the ability of fibrinogen pooled from patients with poor 
diabetes dibete control to bind platelets (Figure 6.13 A) with similar data 
produced when healthy control fibrinogen was investigated (Figure 6.13 B). 
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A B
Figure 6.11 The effects of in vivo aspirin treatment on static fibrinogen-platelet 
interactions assessed as aggregation unite (AU).  A. Platelets bound with purified 
fibrinogen pooled from individuals with poor diabetes control (n=6) following low and 
high dose aspirin therapy [P (75) and P (300), respectively], corrected for baseline. B. 
Platelets bound with purified fibrinogen pooled from healthy controls (n=6) following low 
and high dose aspirin therapy [Cont (75) and Cont (300), respectively], corrected for 
baseline. The results represent the mean±SEM of 6 independent experiments. 
6.4 Discussion  
In this Chapter, I investigated, for the first time, the effect of ex vivo aspirin and 
glucose on platelet fibrinogen interactions using protein purified from patients 
with diabetes and from healthy controls. Moreover, I investigated whether high 
glucose concentration modulates the effects of aspirin on platelets fibrinogen 
binding. This was complemented by in vivostudies investigating the effects of 
low and high daily dose of aspirin (75mg/day and 300mg/day) aspirin on 
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modulation of fibrinogen-platelet interaction.  Platelets used were always from 
healthy controls and therefore this was kept constant. 
This part of the work required significant amount of purified fibrinogen and 
therefore the number of samples were limited. Given the exploratory nature of 
these experiments, and lack of previous data, formal power calculation was not 
possible. Therefore, the results of these experiments must be regarded as 
preliminary and concrete conclusions cannot be made other than confirming the 
feasibility of this new methodology. Future work will be needed, using more 
samples, to confirm the findings and probe into mechanistic explanations for the 
observed differences.  
There are a number of observations emerging from my studies that can be 
summarised as follows: i) Ex vivo aspirin treatment of healthy control fibrinogen 
reduces platelet binding ii) Ex vivo addition of glucose to healthy control 
fibrinogen reduces platelet binding. iii) Neither aspirin, nor glucose had an effect 
on binding of fibrinogen from patients with diabetes to platelets iv) In vivo 
treatment with aspirin results in reduced binding of fibrinogen from healthy 
controls to platelets while this effect of aspirin is abolished in patients with 
diabetes.v) In contrast to flow cytometry studies, static platelet adhesion tests 
failed to show an effect for aspirin and/or glucose on fibrinogen binding to 
platelets.     
Free amino groups on lysine in the fibrinogen molecule can participate in 
various reactions such as crosslinking of fibrin fibres or proteins into the clot by 
factor XIII (Bjornsson et al., 1989). 
Aspirin acetylated fibrinogen forms ε-N-acetyl-lysine in vitro (Bjornsson et al., 
1989, Pinckard et al., 1968). Based on SDS-PAGE gels, using [14C], it has been 
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demonstrated that about 50% of the acetylation occur in the E domain with each 
of the D domains having about 25%. One third of the total acetyl substitution 
occur in each of the individual α, β and γ chain (Bjornsson et al., 1989), 
whereas others have shown this to be slightly different between chains at 41%, 
35% and 24% respectively (Svensson et al., 2012). 
Lysine residues constitute 7% of the 2964 amino acids of fibrinogen and 
therefore acetylation of these residues may have an important role in protein 
function (Bjornsson et al., 1989). Lysine residues involves in acetylation include: 
αK191, αK208, αK224 aK429, αK457, αK539, αK562, in the α-chain, βK233 in 
the β-chain and γ K170 and γ K273 in the γ-chain (Svensson et al., 2012). 
Interestingly, Sevensen and his group reported that glycation occurred at lysine 
residuse on βK133 and γK75, alternatively γK85, ruling out interaction between 
acetylation and glycation. However, in vitro glycation is always a challenging 
technique and the authors should have used samples from diabetes patients, 
which would have better presented the relevant glycation sites. Indeed others 
that studied in vivo glycation of fibrinogen documented additional glycation in 
the three chains of fibrinogen (Dunn et al., 2005).  
Using flow cytometry I showed that ex vivo treatment of samples as well as in 
vivo aspirin therapy is associated with reduced platelet binding to fibrinogen 
using protein from healthy controls. This suggests that fibrinogen acetylation 
reduces interaction with platelet, highlighting a new mechanism of action for 
aspirin that has not been described before. However, there are a number of 
inconsistencies that should be acknowledged. Following high dose in vivo 
treatment with aspirin, there was no reduction in platelet fibrinogen interaction in 
control. This was unexpected given the consistent results with low aspirin dose. 
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Given time restrictions, I was unable to repeat the test using different pool of 
samples, which would have helped to clarify this point. An alternative 
explanation is individuals not complying with higher dose of aspirin due to side 
effects. Another concern was the inability to reproduce the data using static 
fibrinogen-platelet binding tests. Thisis most likely related to the inferior 
sensitivity of this method and the inability to detect small differences that are 
more readily picked up by flow cytometry. In contrast, using fibrinogen from 
patients with diabetes failed to show an effect of aspirin on platelet binding. If 
anything there was a small increase compared with baseline by mechanisms 
that are unclear.This strongly suggests that the effects of aspirin on platelet 
fibrinogen interaction are blunted or reversed in diabetes possibly due to post-
translational modifications of the protein, most probably glycation. It should be 
noted, however, that these experiments can only be described as preliminary at 
this stage and more work is needed using larger number of samples from a 
variety of diabetes patients before concrete conclusions can be made. 
Another observation was the effects of glucose on platelet-fibrinogenbinding 
that was evident in controls but not patients with diabetes. As the glucose 
incubation time was short, fibrinogen glycation is unlikely to account for these 
changes. One of thepossible reasons include alteration in fibrin(ogen) 
conformation resulting from the effect of osmotic changes making the protein 
less amenable to interact with platelets (Rand, 2004). This was not seen in 
those with diabetes who already had elevated levels of glucose in their blood. 
One caveat of the study is the use of platelets from healthy controls. This was 
necessary to keep variables to a minimum but in real life healthy control 
platelets will not encounter diabetic fibrinogen and, therefore, the system used 
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is artificial. There are precedents to this, however, as complement C3 from 
healthy volunteers was used to assess the effect of this molecule on fibrin clot 
lysis using fibrinogen from patients with diabetes and controls (Hess, 
Diabetologia 2012). Further experiments will be required comparing fibrinogen-
platelet interactions in diabetes and healthy controls using cells and proteins 
from the same individuals.     
In conclusion, these preliminary results suggest that ex vivo aspirin treatment of 
fibrinogen reduces platelet-fibrinogen interaction in healthy controls but not in 
patients with diabetes. It shows that the in vivo data largely mirror my ex vivo 
findings except for the high dose aspirin. Reason for the latter are not entirely 
clear (discussed above) and will require further investigation.  
The effects of glucose on platelet fibrinogen interaction in controls but not in 
patients with diabetes indicates that instantaneous high glucose is not 
necessarily prothrombotic and it is long-term hyperglycaemia, leading to post-
translational protein modifications, which is the main culprit for increased 
thrombosis risk in diabetes. 
Finally, it remains unclear whether the observed differences in platelet 
fibrinogen interactions comparing healthy controls with diabetes patients are 
clinically significant and further studies are needed to address this point.  
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Conclusions and future work 
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Cardiovascular disease (CVD) remains a major cause of mortality and morbidity 
worldwide, a trend that is likely to continue in the near future (Franco et al., 
2011), despite efforts to control various risk factors (Padmanabhan et al., 2010). 
One of the most important risk factors of CVD is diabetes mellitus which is 
becoming the epidemic of the 21st with an increasing number of individuals 
diagnosed with this condition.  
Patients with diabetes have 2-4 times higher cardiovascular mortality compared 
with the general population, which is due to a number of factors including more 
extensive vascular disease and increased thrombosis potential. The latter 
occurs secondary to changes in clotting factor plasma level/activity, impaired 
fibrinolysis and increased platelet reactivity (Alzahrani and Ajjan, 2010, 
Angiolillo et al., 2005).  
Anti-platelet therapy remains a cornerstone in the management of individuals 
with established CVD. Aspirin was the first anti-platelet agent used for the 
management of atherothrombotic events. This agent does not only affect 
platelet function, by reducing thromboxane A2 synthesis, but can also acetylate 
fibrinogen resulting in the formation of a more porous fibrin network that is 
easier to lyse.   
The reduced clinical and/or clinical efficacy of aspirin is more commonly 
documented in patients with diabetes (Ferreiro et al., 2010). The exact 
mechanisms for this phenomenon are unknown but there are a number of 
hypotheses that were put forward, related to a compromise in the effects of this 
agent on both the cellular and fluid phase of coagulation, secondary to long-
term hyperglycaemia. 
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The main aim of my work was to investigate the molecular basis for aspirin 
treatment failure in diabetes and the main findings are discussed below.  
1. Effects of glycation and blood glucose levels on platelet response to aspirin 
therapy  
The reasons for aspirin resistance can perhaps be broadly categorised into 
pharmacokinetic (insufficient blood concentration of aspirin) 
andpharmacodynamic factors (incomplete suppression of platelet activity 
despite sufficient plasma drug levels (Benedek et al., 1995, Cerletti et al., 2003), 
(Weber et al., 2002). Inter-individual variability, secondary to co-morbidities, 
various treatment and other unmodifiable factors, is likely to play a role in the 
heterogeneous response to aspirin treatment. In order to address 
pharmacokinetic change and limit inter-individual variability, I have developed 
an ex vivo system to dissect out the role of medium term and instantaneous 
hyperglycaemia on response to aspirin. This is why I concentrated on type 1 
diabetes patients, not on any treatment other than replacement doses of insulin 
and conducted a series of ex vivo and in vivo studies.   
My data show, for the first time, that both glycation and high glucose levels 
interfere with the action of aspirin. Although low aspirin concentration inhibited 
platelet response to AA stimulation, this effect was compromised in patients 
with poor glycaemia control. In contrast, higher aspirin concentrations inhibited 
AA-induced stimulation of platelet aggregation in both diabetes patients and 
controls and were not affected by glycaemic control. This fits nicely with the 
recent hypothesis that the effects of aspirin do not last 24 hours in diabetes 
High aspirin concentration, achieved early following aspirin administration, 
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overcomes the effects of protein glycation and results in good suppression of 
platelet reactivity. However, as the day progresses and given the short half-life 
of aspirin, newly synthesised platelets escape the inhibitory response of low 
aspirin concentration, creating a thrombotic environment.  
Moreover, modulation of response to aspirin by high glucose levels indicates 
that early control of diabetes following an ischaemic event is important to 
optimise response to aspirin therapy.  
Interestingly, minor elevation in HbA1c was not associated with decreased 
response to aspirin. This suggests that only individuals with very poor diabetes 
control (HbA1c≥8.5%) have reduced response to aspirin thus further explaining 
some of the contradictory data on aspirin resistance.  
Future work is required to establish the optimum glycaemic control following 
acute vascular ischaemia. To complicate matters, hypoglycaemia (resulting 
from over-treatment of hyperglycaemia) is in itself prothrombotic and therefore 
developing appropriate glucose monitoring strategies is paramount in order to 
fully understand the role of glycaemia in response to aspirin therapy. This is 
made possible with recently approved new glucose monitoring devices, such as 
Libre (Abbott), and studies in this area are awaited with interest. Also, studies 
assessing biochemical effects of aspirin should not only concentrate on 
obtaining samples at peak aspirin concentration but also at trough drug levels, 
which would give a better indication of platelet suppression over 24 hours. 
2. Diabetes, blood glucose and modulation of the fibrin clot by aspirin  
Clot changes in subject with diabetes have been reported in a number of 
studies (Jorneskog et al., 1996, Dunn et al., 2006, Ajjan and Ariens, 2009, Hess 
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et al., 2012). These changes are related, at least in part, to post-translational 
modifications in the fibrinogen molecules (Dunn et al., 2006) caused by non-
enzymatic glycation of the protein(Brownlee et al., 1983). Work from our 
laboratory has shown that theaddition of aspirin to culture media of fibrinogen-
producing CHO cells, results in fibrinogen acetylation, which in turn affects clot 
structure and lysis (Ajjan et al., 2009). These findings are consistent with my 
data, which demonstrated that ex vivo addition of aspirin to whole blood 
facilitated fibrinolysis in plasma system. However, aspirin had little effect when 
purified fibrinogen was used. These findings suggest that incubation of aspirin 
in whole blood could affect other plasma protein that alter fibrinolysis while this 
does not occur with purified fibrinogen.  Interestingly, a short incubation period 
in whole blood was enough to show an effect and in retrospect, I should have 
had identical incubation periods with aspirin in whole blood and purified 
fibrinogen. In other words, the longer incubation period with fibrinogen may 
have induced some protein degradation and therefore failing to show an effect 
for aspirin on clot lysis. Alternatively, it is possible that the conditions used for 
the turbidimetric experiments were not sensitive enough to detect changes in 
fibrinolysis by aspirin and perhaps a series of experiments are needed using 
decreasing concentrations of tPA and/or plasminogen in order to detect a 
difference. 
My work failed to show a clear effect of additional glucose on clot structure but I 
have found that extra glucose can impair the fibrinolytic properties of aspirin, 
when clots were made from plasma samples, an observation that has not been 
documented before.  However, no such effect was observed when aspirin was 
incubated with purified fibrinogen, indicating, yet again, that aspirin affects other 
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components of plasma proteins. However, the failure to detect a difference with 
purified samples may be due to methodological flaws mentioned above.  
Having an in vitro system mimicking the in vivo situation would help to further 
study interactions between glycation and acetylation in relation to the effects on 
fibrinogen. I considered growing CHO cells with different glucose concentrations 
in the presence and absence of aspirin to further investigate interactions 
between fibrinogen glycation/acetylation. However, preliminary experiments 
indicated that CHO cell growth is compromised in the presence of low glucose 
concentration (these cells are usually grown in the presence of >16 mmol/l 
glucose) and therefore I did not pursue this avenue. 
Further work is required incubating aspirin with whole blood and purified 
fibrinogen for identical periods of time before concluding that in such a system 
the fibrinolytic effects of aspirin are related to an effect on plasma proteins other 
than fibrinogen. Also, further work is warranted using purified fibrinogen at 
different incubation times with aspirin followed by SDS-PAGE analysis to 
investigate changes in protein integrity. 
3. Diabetes, blood glycation and in vivo modulation of platelet function and fibrin 
clot by aspirin 
Given that samples were taken within two hours of aspirin administration, there 
was no difference in platelet inhibition comparing control and diabetes group. 
This is consistent with my ex vivo data showing that high aspirin concentration 
causes similar inhibition of platelet function in control and diabetes subjects. In 
retrospect, I should have arranged for an extra sample to be taken before 
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aspirin dose to investigate platelet inhibition with low aspirin concentration and 
this remains an area for future research as detailed above.  
My data also show that high dose of aspirin (300 mg/day) facilitates fibrinolysis 
in healthy controls with no effect observed in patients with diabetes. 
Interestingly, glycaemic control had no effect on response to treatment in the 
diabetes group. It should be noted, however, that the numbers became small 
once patients were divided into poor and better diabetes control and the study 
was not powered for subgroup analysis. Therefore, concrete conclusions 
regarding interaction between glycaemic control and response to aspirin 
therapy cannot be made. Most importantly, however, data from in vivo work 
largely mirror my ex vivo findings opening the door for further ex vivo 
experiments aiming to identify those with reduced response to aspirin therapy.   
When comparing data generated using clots made from plasma samples with 
clots made from purified fibrinogen, there were similarities but also notable 
differences. It is possible that aspirin may have affected plasma proteins other 
than fibrinogen, consistent with the explanations given for the ex vivo studies 
above. Alternatively, given that pooled samples were used in the purified 
experiments, it is possible that some minor differences were missed. Although a 
standard methodology was used, lysis time was relatively short in the purified 
experiments.In retrospect, I should have experimented with different 
concentrations of plasminogen and tPA, and this is perhaps an area for future 
research.  
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4. Platelet-fibrinogen interaction  
As platelet fibrinogen binding is an essential process in the construction of 
platelet-mediated thrombus, factors that modulate this interaction would have a 
crucial role in blood thrombus formation. Preliminary work from our laboratory, 
using recombinant techniques, has shown that exposure of fibrinogen to aspirin 
alters platelet binding properties of the protein (unpublished data). Given our 
findings and the general lack of studies adequately addressing platelet-
fibrinogen interaction in diabetes, I investigated, for the first time, the effect of ex 
vivo aspirin and glucose on platelet fibrinogen interactions using protein purified 
from patients with diabetes and from healthy controls. Moreover, I investigated 
whether high glucose concentration modulates the effects of aspirin on platelets 
fibrinogen binding. This was complemented by in vivo studies investigating the 
effects of low and high daily dose of aspirin (75 mg/day and 300 mg/day) aspirin 
on modulation of fibrinogen-platelet interaction.  Platelets used were always 
from healthy controls and therefore this was kept constant. 
The preliminary findings using flow cytometry, showed that ex vivo treatment of 
samples as well as in vivo aspirin therapy is associated with reduced platelet 
binding to fibrinogen using protein from healthy controls. This suggests that 
fibrinogen acetylation reduces interaction with platelet, highlighting a new 
mechanism of action for aspirin that has neverbeen described before. In 
contrast, aspirin failed to reduce binding of diabetic fibrinogen to healthy 
platelets. This strongly suggests that the effects of aspirin on platelet fibrinogen 
interaction are blunted or even reversed in diabetes due to post-translational 
modifications of the protein, most probably glycation. Naturally, further 
experiments are needed using different pools and also individual fibrinogen 
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samples from a variety of diabetes patients and different controls before 
concrete conclusions can be made. Nevertheless, these findings provide a 
potential third mode of action for aspirin, which is compromised in diabetes, and 
indicates that studying biochemical efficacy of this agent by monitoring platelet 
function (usually at a single time point) is both inadequate and misleading. 
Another observation was the effects of glucose on platelet-fibrinogen binding 
that was evident in controls but not patients with diabetes. As the glucose 
incubation time was short, fibrinogen glycation is unlikely to account for these 
changes. One possible reasonincludes alteration in fibrin(ogen) conformation 
resulting from the effect of osmotic changes making the protein less amenable 
to interact with platelets (Rand, 2004). The counter-argument, however, is that 
this was not seenin diabetes samples whichhave already been exposed to 
elevated levels of glucose. It should be noted that these are just a preliminary 
findings and future work warranted using higher number of samples to.  
To minimise confounding factors, I always used platelets from healthy donors in 
my experiments. This can be criticised as “diabetic” fibrinogen will not encounter 
“healthy” platelets in vivo. Therefore, further experiments will be required 
comparing fibrinogen-platelet interactions in diabetes and healthy controls using 
cells and proteins from the same individuals. 
In summary, my studies answer questions but equally generate a number of 
interesting questions. In particular, further studies are needed to study the 
cellular and protein arm of coagulation at trough levels of aspirin. Also, more 
work is needed to investigate a potential third mode of action of aspirin, 
affecting platelet-fibrinogen interactions, and further work is required to 
understand whether this pathway is affected in diabetes. Finally, appropriately 
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designed glycaemic studies are required to understand glucose levels at which 
aspirin can have optimal effects in individuals with diabetes. 
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